WO2003085118A1 - Procede de production de composition anticorps - Google Patents
Procede de production de composition anticorps Download PDFInfo
- Publication number
- WO2003085118A1 WO2003085118A1 PCT/JP2003/004502 JP0304502W WO03085118A1 WO 2003085118 A1 WO2003085118 A1 WO 2003085118A1 JP 0304502 W JP0304502 W JP 0304502W WO 03085118 A1 WO03085118 A1 WO 03085118A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- protein
- sequence represented
- dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Definitions
- the present invention relates to a method for producing an antibody composition and cells used for producing the antibody composition.
- CDR as a human-complementarity determining region produced in Chinese hamster ovary cells (CH0 cells) or NS0 cells derived from mouse myeloma cells.
- the transplanted antibody CAMPATH-1H (human IgGl subclass) is treated with various glycolytic enzymes, and the antibody-dependent cytotoxicity of sugar chains (hereinafter referred to as ADCC activity) and the complement-dependent cytotoxicity (hereinafter referred to as ADCC activity).
- ADCC activity antibody-dependent cytotoxicity of sugar chains
- ADCC activity complement-dependent cytotoxicity
- many humanized antibodies that are considered to be applied to medicines are produced using genetic recombination technology, and are used to produce animal cells, such as CH0 cells derived from Chinese hamster ovary tissue and NS0 cells derived from mouse myeloma cells. Etc. are used as host cells.
- animal cells such as CH0 cells derived from Chinese hamster ovary tissue and NS0 cells derived from mouse myeloma cells. Etc. are used as host cells.
- the sugar chain structure is extremely important for the effector function of an antibody. It plays an important role, and differences in the sugar chain structure of the glycoprotein expressed by the host cell are observed, so that host cells capable of producing antibodies with higher effector functions are identified. Development is desired.
- One method to modulate the sugar chain structure of glycoproteins produced by regulating the activity of the enzymes involved in glycosylation of host cells is to apply inhibitors of the enzymes involved in glycosylation. Have been.
- Inhibitors of enzymes involved in sugar chain modification include the ability to selectively inhibit the formation of GlcNAc-P-P-Dol, the first step in the formation of core oligosaccharides, precursors of N-glycoside-linked sugar chains
- core oligosaccharides precursors of N-glycoside-linked sugar chains
- glycosyltransferases As specific inhibitors of glycosyltransferases, deoxy derivatives of substrates for N-acetyltylcorsamine transferase V (GnTV) and the like are being developed (Glycobiology series 2-Fate of sugar chains in cells ( Kodansha Sanentifi) Katsutaka Nagai, Senichiro Hakomori, Yoyo Kohata (1993)). It is known that 1-deoxynojirimycin suppresses the synthesis of complex type sugar chains and increases the ratio of high mannose type ⁇ ⁇ hybrid type sugar chains.
- inhibitors such as stannospermine, N-methyl-11-deoxynojirimycin, swansonine or tsuyu forcemycin alters the sugar chain structure of IgG produced by hybridomas.
- inhibitors such as stannospermine, N-methyl-11-deoxynojirimycin, swansonine or tsuyu forcemycin alters the sugar chain structure of IgG produced by hybridomas.
- the antigen binding property and the ADCC activity are changed (Molecular. Immunol., 26, 1113, (1989)).
- the specificity of these inhibitors is weak and it is difficult to sufficiently inhibit the target enzyme, it is difficult to reliably control the sugar chain structure of the produced antibody.
- a glycoprotein having an altered sugar chain structure can be produced by using a mutant having an altered activity of an enzyme gene involved in sugar chain modification as a host cell. Specifically, it has been known that an antibody having a high mannose-type sugar chain structure can be produced using a CH0 cell mutant deficient in N-acetyldarcosamine transferase I (GnTI) activity.
- GnTI N-acetyldarcosamine transferase I
- the present invention relates to the following (1) to (81).
- a sugar chain structure in which the 6-position of N-acetyldarcosamine at the reducing end of N-daricoside-linked complex type sugar chain and the 1-position of fucose is a-linked is recognized.
- a method for producing an antibody composition, comprising using a cell having resistance to a lectin to be expressed.
- the cell is a cell in which the activity of a protein selected from the group consisting of the following (a), (b) and (c) is reduced or deleted.
- N- glycoside-linked complex type sugar chain of N- ⁇ cetyl Darco enzyme protein alpha 1 to Sa 1-position of fucose to 6-position of the Min is involved in sugar chain modification to bind alpha, is a 6- Fukoshirutora Nsufueraze , (2).
- the 1,6-fucosyltransferase is selected from a protein encoded by a DNA selected from the group consisting of the following (a) to (h) or a group consisting of the following (i;) to (n): The method according to any one of (3) to (5), which is a protein.
- (k) a protein consisting of the amino acid sequence represented by SEQ ID NO: 91 with one or more amino acids deleted, substituted, inserted and / or added, and having ⁇ 1,6-fucosyltransferase activity;
- one or more amino acids consist of an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted and / or added, and have an al, 6-fucosyltransferase activity. protein;
- (m) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 91 and having 1,6-fucosyltransferase activity;
- (n) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 92, and having 1,6-fucosyltransferase activity;
- the RNAi method comprises an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RA, and the amount of ⁇ ⁇ , 6-fucosyltransferase mRNA:
- the method according to (5) or (6) which comprises introducing or expressing a double-stranded RNA capable of reducing the intracellular expression in a cell.
- RNA corresponding to DNA consisting of a nucleotide sequence represented by 10 to 30 consecutive nucleotide sequences in the nucleotide sequence represented by SEQ ID NO: 79;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 80;
- RNA RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA into cells: it is, alpha 1, 6 - fucosyltransferase reduced m RNA of glycosyltransferases, N - glycans Darikoshido binding complex type sugar chain of N- ⁇ cetyl Darco 6-position of Sa Min and 1-position of fucose is bound a (7)
- the method according to (7) which has resistance to a lectin that recognizes a structure.
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83;
- RNA having an RNAi activity substantially the same as that of SEQ ID NO: 83 comprising a nucleotide sequence in which one or several bases have been deleted or added in the nucleotide sequence represented by SEQ ID NO: 83;
- RNA having the same RNAi activity as SEQ ID NO: 84 consisting of the nucleotide sequence of SEQ ID NO: 84 with one or several bases deleted or added.
- An antibody composition having a high antibody-dependent cytotoxicity activity is obtained by combining N-acetyl darcosamine at the reducing end of the sugar chain among all N-daricoside-linked complex-type sugar chains that bind to the Fc region contained in the antibody composition.
- the method according to (14), wherein the ratio of sugar chains to which fucose is not bound is higher than that of the antibody composition produced by the parent cell line.
- the proportion of sugar chains in which fucose is not bound to N-acetyltyldarcosamine at the reducing end of sugar chains is the percentage of all N-glycoside-linked complex sugar chains that bind to the Fc region contained in the antibody composition.
- the sugar chain to which fucose is not bonded is a sugar chain in which the 1-position of the fucose is not bonded to the 6-position of N-acetyldarcosamine at the reducing end of an N-glycoside-linked complex type sugar chain, The method according to (15) or (16).
- mice myeloma cells are NS0 cells or SP2 / 0-Agl4 cells.
- (22) N-Dalicoside-linked complex-type sugar chain into which a gene encoding an antibody molecule has been introduced
- Cells that are resistant to (23) The cell according to (22), wherein the cell is a cell in which the activity of a protein selected from the group consisting of the following (a), (b) and (c) is lower or deleted than that of the parent cell: cell.
- N- glycoside-linked complex type sugar chain of N- ⁇ cetyl Darco enzyme protein alpha 1 to Sa 1-position of fucose to 6-position of the Min is involved in sugar chain modification to bind alpha, is a 6- Fukoshirutora Nsufuweraze The cell according to (23).
- the ⁇ 1,6-fucosyltransferase is selected from a protein encoded by a DNA selected from the group consisting of the following (a) to (h), or a group consisting of the following (i) to (n):
- (k) a protein consisting of the amino acid sequence represented by SEQ ID NO: 91 with one or more amino acids deleted, substituted, inserted and / or added, and having 1,6-fucosyltransferase activity ;
- amino acid sequence represented by SEQ ID NO: 92 one or more amino acids have a deletion, substitution, insertion, or addition of an amino acid sequence, and (3 ⁇ 41,6-fucosyltransferase activity is A protein having;
- (m) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 91 and having ⁇ 1,6-fucosyltransferase activity;
- ( ⁇ ) A protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 92, and having 1,6-fucosyltransferase activity.
- the RNAi method comprises an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA, and the mRNA amount of 1,6-fucosyltransferase
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 79;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 80;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 81;
- a double-stranded RNA composed of an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA By introducing or expressing in a cell a double-stranded RNA composed of an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA:
- the N-glycoside-linked complex-type sugar chain reduced the mRNA amount of ⁇ 1,6-fucosyltransferase and reduced the amount of N-acetyldarcosamine at the reducing end.
- the cell according to (28) which has resistance to a lectin that is recognized.
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83;
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 84;
- RNA having an RNAi activity substantially the same as that of SEQ ID NO: 83 comprising a nucleotide sequence in which one or several bases have been deleted or added in the nucleotide sequence represented by SEQ ID NO: 83;
- RNA having the same RNAi activity as SEQ ID NO: 84 consisting of the nucleotide sequence of SEQ ID NO: 84 with one or several bases deleted or added.
- a fusion protein comprising the Fc region of (a) or (b).
- the antibody-dependent cytotoxic activity is high, and the antibody composition is an N-acetase at the reducing end of the sugar chain among all N-glycoside-linked complex-type sugar chains that bind to the Fc region contained in the antibody composition.
- the proportion of sugar chains in which fucose is not bound to N-acetyldarcosamine at the sugar chain reducing end is the proportion of all N-glycoside-linked complex sugar chains that bind to the Fc region contained in the antibody composition.
- the sugar chain to which fucose is not bound is a sugar chain in which the 1-position of the fucose is not a-linked to the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain.
- the cell according to (35) is a sugar chain in which the 1-position of the fucose is not a-linked to the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain.
- mice myeloma cells are NS0 cells or SP2 / 0-Agl4 cells.
- a method for producing an antibody composition comprising:
- the antibody composition having a high antibody-dependent cytotoxicity is one of the N-acetones at the reducing end of the sugar chain among all N-daricoside-linked complex-type sugar chains that bind to the Fc region contained in the antibody composition. (43) The method according to (43), wherein the ratio of sugar chains in which fucose is not bound to tildarcosamine is higher than that of the antibody composition produced by the parent cell line.
- the proportion of sugar chains in which fucose is not bound to N-acetyltyldarcosamine at the reducing end of sugar chains is the percentage of all N-glycoside-linked sugar chains that bind to the Fc region contained in the antibody composition.
- the sugar chain to which fucose is not bound is a sugar chain in which the 1-position of the fucose is not linked to the 6-position of N-acetyldarcosamine at the reducing end of an N-glycoside-linked complex type sugar chain.
- a 1, 6-fucosyltransferase is an enzyme protein involved in glycosylation in which the 1-position of fucose is ⁇ - linked to the 6-position of ⁇ ⁇ -acetylglycosamine at the reducing end of ⁇ -glycoside-linked complex type glycan (48)
- ⁇ 1,6-fucosyltransferase is a DNA encoded by a DNA selected from the group consisting of the following (a) to (h), or a protein selected from the group consisting of the following (i) to (n) (49)
- one or more amino acids consist of an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, Z or added, and the ⁇ 1,6-fucosyltransferase activity ⁇ 3 ⁇ 4 A protein having;
- (m) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 91 and having ⁇ 1,6-fucosyltransferase activity;
- ( ⁇ ) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 92, and having ⁇ 1,6-fucosyltransferase activity;
- the RNAi method comprises an RNA selected from the group consisting of the following (a), (b), (c), and (d) and its complementary RNA, and the CK 1,6-fucosyltransferase A method characterized in that a double-stranded RNA capable of reducing the amount of mRNA is introduced or expressed in a cell.
- RNA corresponding to DNA consisting of a nucleotide sequence represented by 10 to 30 consecutive nucleotide sequences in the nucleotide sequence represented by SEQ ID NO: 79;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 80;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 81;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 82.
- a double-stranded RNA consisting of a DNA corresponding to an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA is intracellularly
- the amount of mRNA for ot1,6-fucosyltransferase was reduced, and the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain and the 1-position of fucose were ⁇ .
- the myeloma cell according to (51) which has resistance to a lectin that recognizes a linked sugar chain structure.
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83;
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 84;
- RNA having an RNAi activity substantially the same as that of SEQ ID NO: 83 comprising a nucleotide sequence in which one or several bases have been deleted or added in the nucleotide sequence represented by SEQ ID NO: 83;
- RNA having the same RNAi activity as SEQ ID NO: 84 consisting of the nucleotide sequence of SEQ ID NO: 84 with one or several bases deleted or added.
- mice myeloma cell according to any one of (47) to (5 ⁇ ), wherein the mouse myeloma cell is a cell selected from the following ( a ) and (b):
- mouse myeloma cell is a cell into which a gene encoding an antibody molecule has been introduced.
- the antibody-dependent cytotoxic activity is high, and the antibody composition is one of all N-glycoside-linked complex-type sugar chains that bind to the Fc region contained in the antibody composition.
- (61) The cell according to (61), wherein the proportion of a sugar chain in which fucose is not bound to tildarcosamine is higher than the antibody composition produced by the parent cell line.
- the proportion of sugar chains in which fucose is not bound to N-acetyltyldarcosamine at the sugar chain reducing end is the proportion of all N-glycoside-linked complex sugar chains that bind to the Fc region contained in the antibody composition.
- the 1-position of the fucose is an N-glycoside bond and the sugar chain is not ⁇ -linked to the 6-position of N-acetyldarcosamine at the reducing end of the complex type sugar chain.
- a method for producing an antibody composition comprising:
- the proportion of sugar chains in which fucose is not bound to N-acetyltyldarcosamine at the reducing end of sugar chains is the percentage of all N-glycoside-linked sugar chains that bind to the Fc region contained in the antibody composition.
- the sugar chain to which no fucose is bound is a sugar chain in which the 1-position of the fucose is not linked to the 6-position of N-acetyldarcosamine at the reducing end of an N-glycoside-linked complex type sugar chain.
- a medicament comprising the antibody composition according to any one of (0) to (72) as an active ingredient.
- the drug is a diagnostic, prophylactic or prophylactic agent for a disease associated with JK ulcer, a disease associated with allergy, a disease associated with inflammation, an autoimmune disease, a cardiovascular disease, a disease associated with a viral infection or a disease associated with a bacterial infection.
- a double-stranded RNA comprising an RNA selected from the group consisting of the following (a), (b), (c) and (d) and its complementary RNA.
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83;
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 84;
- RNA having an RNAi activity substantially the same as that of SEQ ID NO: 83 comprising a nucleotide sequence in which one or several bases have been deleted or added in the nucleotide sequence represented by SEQ ID NO: 83;
- RNA having the same RNAi activity as SEQ ID NO: 84 consisting of the nucleotide sequence of SEQ ID NO: 84 with one or several bases deleted or added.
- Methods for producing an antibody composition using the cells of the present invention include a method for producing a monoclonal antibody using hybridoma cells, a human antibody and a humanized antibody using a host cell into which an antibody gene has been introduced. After transplanting embryonic stem cells or fertilized egg cells of a non-human animal into which an antibody gene has been introduced into an early embryo of a non-human animal, producing a human antibody using the transgenic non-human animal generated And the like.
- cells resistant to lectin recognizing a sugar chain structure in which the 6-position of N-glycidol-linked glucosamine and the 1-position of fucose in the N-glycoside-linked complex bran chain reducing terminal are ⁇ - linked are as follows:
- Cells capable of producing an antibody composition such as yeast, animal cells, insect cells, plant cells, etc., which are 6-position of ⁇ -glycidyl-linked glycan-reducing terminal ⁇ -acetyldarcosamine and 1-position of fucose Any cell may be used as long as it has resistance to a lectin that recognizes an ⁇ - linked sugar chain structure.
- N-glycoside-linked complex type sugar chain reducing terminal N-acetyldarcosamine Produces hybridoma cells, host cells for the production of human antibodies and humanized antibodies, and human antibodies that are resistant to lectins that recognize an ⁇ -linked sugar chain structure at position 1 and fucose.
- Birth Embryonic stem cells and fertilized egg cells for producing transgenic non-human animals, plant callus cells, myeloma cells, and transgenes for producing transgenic plants for producing human antibodies
- Myeloma cells can be used as fusion cells when producing hybridoma cells.
- the transgenic non-human animal can be immunized with an antigen, and the spleen cells of the animal can be taken out and used to produce hybridoma cells.
- Lectin-resistant cells are cells whose growth is not inhibited even when cell culture is performed with an effective concentration of lectin in the culture medium.
- the effective lectin concentration at which growth is not inhibited may be appropriately determined depending on the cell line, but is usually 10 ⁇ / 1111 to 10. preferably 0.5 to 2. Omg / ml.
- the effective concentration of lectin when a mutation is introduced into the parent cell line is not less than the concentration at which the parent cell cannot grow normally, preferably the same concentration as that at which the parent cell cannot grow normally, more preferably 2 to 5 times. More preferably, the concentration is 10 times, most preferably 20 times or more.
- the parent cell is a cell before any treatment, that is, a cell before performing the step of selecting the lectin-resistant cell used in the present invention, and a genetic engineering treatment for reducing or deleting the above-mentioned enzyme activity. Refers to cells before performing.
- the parent cell is not particularly limited, but specific examples of the parent cell of various cell lines are shown below.
- NS0 cells examples include BIO / TECHNOLOGY, 10, 169 (1992), and Biotechnol. Bioeng., 73, 261, (2001). NS0 cells. Also, there are the NS0 cell line (RCB0213) registered with the RIKEN Cell Development Bank, or a substrain obtained by adapting these strains to a growth medium.
- the parental cells of SP2 / 0-Agl4 cells include, for example, Journal of Immunology (J. Immunol.), 126, 317, (1981), Nature, 276, 269, (1978), and Huyman's SP2 / 0-Agl4 cells described in the literature such as Anti-Ibodies and Hybridoraas, 3, 129, (1992).
- SP2 / 0-Agl4 cells registered with the ATCC (ATCC CRL-1581) or a substrain (ATCC CRL-158.1) obtained by adapting these strains to a medium in which they can grow can also be mentioned.
- CH0 cells derived from Chinese hamster ovary tissue include Journal of Experimental Medicine, 108, 945 (1958), Proc. Natl. Acad. Sci. USA, 60, 1275 (1968), Genetics, 55, 513 (1968). Chromosoma, 41, 129 (1973), Methods in Cell Science, 18, 115 (1996), Radiation Research, 148, 260 (1997), Proc. Natl. Acad. Sci. USA, 77, 4216 (1980), Proc. Natl. Acad. Sci. 60, 1275 (1968), Cell, 6, 121 (1975), Molecular Cell Genetics, Appendix I, II (p883-900). .
- CH0-K1 strain ATCC CCL-61
- DUXB11 strain ATCC CRL-9096
- Pro-5 strain ATCC CRL-1781 registered with ATCC
- commercially available CH0-S strain (Lifetechnologies) Cat # 11619), or a substrain obtained by subjecting these strains to a growth medium.
- the parent cell of the rat myeloma cell line YB2 / 3HL. P2. Gil. 16Ag. 20 cells includes cell lines established from Y3 / Agl. 2.3 cells (ATCC CRL-1631). Specific examples thereof include YB2 / 3HL. P2. Gil. 16Ag. 20 described in the literature such as J. Cell. Biol. 93, 576 (1982) and Methods Enzymol. 73B, 1 (1981). Cells. Also, there are YB2 / 3HL. P2. G11. 16Ag. 20 cells (ATCC CRL-1662) registered with the ATCC, or substrains obtained by adapting these strains to a medium capable of growing.
- a lectin that recognizes a sugar chain structure in which the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain and the 1-position of fucose is a lectin that can recognize the sugar chain structure If present, any lectin is included. Specific examples include lentil lectin LCA (Lentil Agglutinin from Lens Culinaris), endo-pea lectin PSA (Pe Lectin from Pi sum sativum), fava bean lectin VFA (Agglutinin from Vicia faba), and Hylochawanta lectin AAL ( Lectin from Aleuria aurantia) and the like.
- lentil lectin LCA Lientil Agglutinin from Lens Culinaris
- endo-pea lectin PSA Pe Lectin from Pi sum sativum
- fava bean lectin VFA Agglutinin from Vicia faba
- the lectin-resistant cell may be any cell as long as its growth is not inhibited in the presence of a certain effective concentration of lectin.
- the activity of at least one of the following proteins is higher than that of the parent cell.
- Such cells include cells that have been reduced or deleted.
- GDP-fucose synthase an enzyme protein involved in the synthesis of intracellular sugar nucleotide GDP-fucose (hereinafter referred to as "GDP-fucose synthase");
- GDP-fucose transport protein Intracellular sugar nucleotide A protein involved in the transport of GDP-fucose to the Golgi apparatus
- the GDP-fucose synthase includes any enzyme involved in the synthesis of sugar nucleotide GDP-fucose, which is the source of fucose to sugar chains in the cell. Enzymes that affect lipase.
- the intracellular sugar nucleotide GDP-fucose is supplied by the de novo synthesis pathway or the Salvage synthesis pathway. Therefore, all enzymes involved in these synthetic pathways are included in GDP-fucose synthase.
- the GDP-fucose synthase involved in the de novo synthesis pathway includes GDP-mannose 4-dehydratase (GDP-mannose 4-dehydratase; hereinafter referred to as GMD), GDP-ket ⁇ -6-deoxymanno se 3 , 5-epimerase, 4-reductase (GDP-keto-teoxymannose 3,5-epimerase, 4-reductase; hereinafter, referred to as Fx).
- GMD GDP-mannose 4-dehydratase
- Fx 4-reductase
- GDP-fucose pyrophosphorylase GDP-beta-L-fucose-pyrophosphodilase; hereinafter referred to as GFPP
- Fucokinase Fucokinase
- GMD includes:
- the DNA encoding the amino acid sequence of GMD includes a DNA having the nucleotide sequence represented by SEQ ID NO: 85, a DNA having the nucleotide sequence represented by SEQ ID NO: 85, which is hybridized under stringent conditions, and DNA encoding an amino acid sequence having an activity is exemplified.
- the DNA encoding the amino acid sequence of Fx includes a DNA having the nucleotide sequence represented by SEQ ID NO: 87, a DNA having the nucleotide sequence represented by SEQ ID NO: 87, which hybridizes under stringent conditions, and Examples include DNA encoding an amino acid sequence having activity.
- GFPP includes:
- a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, or inserted in the amino acid sequence represented by SEQ ID NO: 90, Z or added, and which has GFPP activity.
- the DNA encoding the amino acid sequence of GFPP includes a DNA having the nucleotide sequence represented by SEQ ID NO: 89, a DNA having the nucleotide sequence represented by SEQ ID NO: 89, hybridizing under stringent conditions, and Fx DNA encoding an amino acid sequence having an activity is exemplified.
- any enzyme can be used as long as it is an enzyme involved in the ⁇ -bond between the 6-position of N-glycidyl-linked glycan at the reducing end of N-glycoside-linked complex type sugar chain and the 1-position of fucose. Included.
- the enzyme involved in the reaction in which the 6-position of ⁇ ⁇ -glycoside-linked complex type sugar chain reducing terminal and the 1-position of fucose are ⁇ -linked is the ⁇ -glycoside-linked complex type sugar chain reducing terminal. Any enzyme that affects the reaction of ⁇ - linkage between position 6 of acetyltilcosamine and position 1 of fucose is included. Specifically, al, 6-fucosyltransferase ⁇ ⁇ -L-fucosidase and the like can be mentioned.
- the enzyme that influences the ⁇ - bonding reaction between the 6-position of ⁇ ⁇ -acetyldarcosamine and the 1-position of fucose at the reducing end of ⁇ -glycoside-linked complex-type sugar chain includes the above-mentioned ⁇ -daricoside-linked complex-type sugar.
- An enzyme that affects the activity of an enzyme involved in the reaction in which the 1-position of fucose is ⁇ -linked to the 6-position of ⁇ ⁇ -acetyldarcosamine at the chain reducing end, or that affects the structure of a substance that is a substrate of the enzyme are also included.
- al, 6-fucosyltransferase includes:
- a protein comprising an amino acid sequence represented by SEQ ID NO: 92 in which one or more amino acids have been deleted, substituted, inserted and / or added, and which has ct1,6-fucosyltransferase activity
- (m) a protein consisting of an amino acid sequence having at least 80% homology with the amino acid sequence represented by SEQ ID NO: 91, and having ⁇ 1,6-fucosyltransferase activity
- a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 92 and having ⁇ 1,6-fucosyltransferase activity.
- Examples of the DNA encoding the amino acid sequence of al, 6-fucosyltransferase include a DNA having a base sequence represented by SEQ ID NO: 79, 80, 81 or 82, and a DNA represented by SEQ ID NO: 79, 80, 81 or 82. And a DNA encoding an amino acid sequence having a 1,6-fucosyltransferase activity that hybridizes with a DNA having a base sequence to be stringent under stringent conditions.
- the GDP-fucose transport protein includes any protein that is involved in the transport of the intracellular sugar nucleotide GDP-fucose to the Golgi apparatus, and specifically includes the GDP-fucose transporter.
- Examples of the GDP-fucose transporter of the present invention include proteins encoded by DNA selected from the group consisting of the following (a) to (h).
- the GDP-fucose transporter of the present invention includes a protein selected from the group consisting of the following (i) to (t).
- a protein comprising an amino acid sequence represented by SEQ ID NO: 94 in which one or more amino acids have been deleted, substituted, inserted, or Z-added, and having GDP-fucose transporter activity;
- a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 96, and having a GDP-fucose transporter activity;
- (0) a protein consisting of the amino acid sequence represented by SEQ ID NO: 99 with one or more amino acids deleted, substituted, inserted and / or added, and having GDP-fucose transporter activity;
- (P) a protein comprising an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, and Z- or added in the amino acid sequence represented by SEQ ID NO: 100, and which has a GDP-fucose transporter activity;
- (q) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 94 and having GDP-fucose transporter activity;
- proteins that influence the reaction of transporting the intracellular sugar nucleotide GDP-fucose into the Golgi are also included in the GDP-fucose transport protein, and specifically, the above-mentioned intracellular sugar nucleotide GDP-fucose is transported to the Golgi apparatus. And proteins that affect the activity of the proteins involved in the expression or the expression.
- DNA that hybridizes under stringent conditions refers to, for example, a colony using, as a probe, DNA such as DNA having a base sequence represented by any of the above SEQ ID NOs or a fragment thereof.
- Hybridization method, plaque ⁇ DNA obtained by using the hybridization method, Southern blot hybridization method, etc. specifically, fixation of DNA derived from colonies or plaques
- the SSC solution with a concentration of 0 :! The composition of the SSC solution is composed of 150 mM sodium chloride and 15 mM sodium citrate), and DNA that can be identified by washing the filter at 65 ° C is used. I can give it.
- a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted and / or added in the amino acid sequence represented by any one of the above SEQ ID NOs, and having the above-mentioned activity is a molecular 'Cloning 2nd Edition, Rental Protocols.In' Molecular Molecular Science, Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci., USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad.
- a site-directed mutagenesis method for example, by adding a site to a DNA encoding a protein having an amino acid sequence represented by any of the above SEQ ID NOs. It can be obtained by introducing a specific mutation.
- the number of amino acids to be deleted, substituted, inserted, and added or added is one or more, and the number is not particularly limited. The number is such that it can be added, for example, 1 to several tens, preferably 1 to 20, more preferably 1 to 10, and still more preferably 1 to 5.
- any method can be used as long as it can select the lectin-resistant cells of the present invention.
- Specific examples include a method for reducing or deleting the activity of the above-mentioned protein.
- Techniques for reducing or deleting the activity of the above-mentioned proteins include:
- the antibody composition refers to a composition comprising an antibody molecule having an N-glycoside-linked complex type sugar chain in the Fc region.
- Antibodies are tetramers in which two types of polypeptide chains, a heavy chain and a light chain (hereinafter, referred to as “H chain” and “L chain”, respectively), are associated with each other by two molecules. About one-quarter of the N-terminal side of the H chain and about one-half of the N-terminal side of the L chain (each more than 100 amino acids) are called variable regions (hereinafter referred to as “V regions”). Rich in sex, directly involved in antigen binding. Most of the part other than the V region is called the constant region (hereinafter referred to as “C region”). Antibody molecules are classified into IgG, IgM, IgA, IgD, and IgE classes according to the homology of the C region. The IgG class is further classified into IgGl to: EgG4 subclasses based on the homology of the C region.
- the H chain is divided into four immunoglobulin domains, VH, CH1, CH2, and CH3, from the N-terminal side.There is a highly mobile peptide region called the hinge region between CH1 and CH2, and CH1 and CH2 And are separated.
- the structural unit consisting of CH2 and CH3 after the hinge region is called Fc region, and has N-glycoside-linked sugar chains attached. This region is where the Fc receptor, complement, etc. bind, (Immunology Illustrated Original 5th Edition, published February 10, 2000, Nankodo Edition, Introduction to Antibody Engineering, January 25, 1994) The first edition of the day, Jinjinkan).
- sugar chains of glycoproteins such as antibodies can be linked to asparagine (N-glycoside-linked sugar chains) and sugar chains linked to serine, threonine, etc. (0-glycosyl-linked sugars) depending on the mode of binding to the protein part. Chains).
- N-glycoside-linked sugar chains have a common basic core structure represented by the following structural formula (I) [Biochemical Experimental Method 23—Glycoprotein Sugar Chain Research Method (JSPS) Reiko Takahashi (eds. 1989) )].
- the N-glycoside-linked sugar chain may be any as long as it has the core structure of the above structural formula (I), but a high mannose type core structure in which only mannose is bonded to the non-reducing end of the core structure.
- Examples include a complex type (complex type) having a structure such as N-acetylethyl dalcosamine of sexting, and a hybrid type having both high mannose type and complex type branches on the non-reducing end side of the core structure.
- complex type complex type having a structure such as N-acetylethyl dalcosamine of sexting
- hybrid type having both high mannose type and complex type branches on the non-reducing end side of the core structure.
- the Fc region of the antibody molecule has a region in which N-glycoside-linked sugar chains bind one by one, two sugar chains are bound per antibody molecule.
- N- binds to antibody molecule
- the darcoside-linked sugar chain includes any sugar chain containing the core structure represented by the structural formula (I), a large number of sugar chains are included in the two N-darcoside-linked sugar chains that bind to the antibody. Will exist.
- the antibody composition produced using the lectin-resistant cell of the present invention is composed of an antibody molecule having a single sugar chain structure as long as the effect of the present invention can be obtained. Or may be composed of antibody molecules having a plurality of different sugar chain structures.
- the ratio of sugar chains in which fucose is not linked to N-acetyltilcosamine at the reducing end of the sugar chain is as follows: With respect to the total number of all N-glycoside-linked complex-type sugar chains that bind to the Fc region contained in the composition, the number of bracken chains in which fucose is not bound to N-acetyltylcolasamine at the reducing end of the sugar chain is determined. The ratio of the number.
- a sugar chain in which fucose is not bonded to N-acetyldarcosamine at the reducing end of N_glycoside-linked complex type sugar chain is defined as fucose that is linked to N-acetyldarcosamine at the reducing end of N-glycoside-linked complex type sugar chain.
- a refers to unlinked sugar chains. Specifically, a sugar chain in which the 1-position of fucose is not a-linked to the 6-position of N-acetyldarcosamine of the N-glycoside-linked complex-type sugar chain is exemplified.
- the proportion of sugar chains in which fucose is not linked to N-acetyldarcosamine at the reducing end of the sugar chain is high.
- fucose binds to N-acetylacetylchocosamine at the reducing end of the sugar chain among all N-dalicoside-linked complex type sugar chains that bind to the Fc region contained in the antibody composition.
- the ratio of unreacted sugar chains is preferably 20% or more, more preferably 30% or more, further preferably 40% or more, particularly preferably 50% or more, and most preferably 100%.
- the present invention also relates to a method for producing an antibody composition having higher ADCC activity than an antibody composition produced by a parent cell line.
- the percentage of glycans in which fucose is not bound to the N-acetyl-darcosamine at the reducing end of the glycan is the antibody produced by the parent cell line
- it has higher ADCC activity than the antibody composition produced by the parent cell line.
- Examples of a method for producing an antibody composition having higher ADCC activity than the parent cell line include a method for producing an antibody composition using the above lectin-resistant strain.
- ADCC activity means that in vivo, an antibody that binds to a cell surface antigen such as a tumor cell activates effector cells through the binding between the antibody Fc region and the Fc receptor present on the effector cell surface.
- Monoclonal Antibodies Principles and Applications;, Wiley-Liss, Inc., Capter 2.1 (1995). Examples of cells include killer cells, natural killer cells, activated macrophages, and the like.
- the ratio of sugar chains in which fucose is not bound to N-acetyltyldarcosamine at the sugar chain reducing end contained in a composition comprising an antibody molecule having an N-daricoside-linked complex type sugar chain in the Fc region is determined by the ratio of the antibody Using known methods such as hydrazinolysis and enzymatic digestion from molecules [Biological Chemistry Experimental Method 23-Glycoprotein Sugar Chain Research Method (Society Press Center), edited by Reiko Takahashi (1989)], release sugar chains and release them.
- the sugar chain thus obtained can be determined by labeling the sugar chain with a fluorescent label or an isotope and separating the labeled sugar chain by a chromatography method.
- the released sugar chains can also be determined by analyzing the released sugar chains by the HPAED-PAD method [Journal of Liquid Chromatography (J. Liq. Chromatogr.), 6, 1577 (1983)].
- the antibody molecule includes any molecule that contains the Fc region of the antibody. Specific examples include an antibody, an antibody fragment, and a fusion protein containing an Fc region.
- Antibodies include antibodies secreted by hybridoma cells produced from spleen cells of immunized animals by immunizing animals with antigens, antibodies produced by genetic recombination technology, that is, antibody expression incorporating antibody genes Examples include an antibody obtained by introducing a vector into a host cell. Specific examples include antibodies produced by hybridomas, humanized antibodies, and human antibodies.
- a hybridoma is a monoclonal antibody having a desired antigen-specific production obtained by cell fusion of B cells obtained by immunizing a non-human mammal with an antigen and myeloma cells derived from mice, rats, etc. Refers to cells that produce antibodies.
- the humanized antibody examples include a human chimeric antibody and a human CDR-grafted antibody.
- the human chimeric antibody is composed of a non-human animal H chain V region (hereinafter also referred to as HV or VH) and an antibody L chain V region (hereinafter also referred to as LV or VL) and a human antibody H chain C region. (Hereinafter, also referred to as CH) and an L chain C region (hereinafter, also referred to as CL) of a human antibody.
- HV or VH non-human animal H chain V region
- LV or VL antibody L chain V region
- CH human antibody H chain C region
- CL L chain C region
- any animal can be used as long as a hybridoma can be produced, such as a mouse, a rat, a hamster, and a rabbit.
- the human chimeric antibody obtains cDNAs encoding VH and VL from a hybridoma producing a monoclonal antibody, and expresses them for host cells having genes encoding human antibody CH and human antibody CL.
- a human chimeric antibody expression vector can be constructed by introducing each of the vectors into a vector, and can be expressed and produced by introducing the vector into a host cell.
- the CH of the human chimeric antibody may be any CH as long as it belongs to human immunoglobulin (hereinafter referred to as hlg), but is preferably of the hlgG class, and furthermore, hIgGl and hIgG2 belonging to the hlgG class. Any of the subclasses hIgG3, hIgG4 can be used.
- the CL of the human chimeric antibody may be any CL as long as it belongs to hlg, and a ⁇ class or L class can be used.
- the human CDR-grafted antibody refers to an antibody obtained by grafting the VH and VL CDR amino acid sequences of an antibody of a non-human animal to an appropriate position of the human antibody VH and VL.
- a human CDR-grafted antibody is prepared by constructing a cDNA encoding a V region obtained by grafting the VH and VL CDR sequences of an antibody from a non-human animal to the VH and VL CDR sequences of any human antibody.
- a human-type CDR-grafted antibody expression vector is constructed by inserting each into a host cell expression vector having genes encoding the antibody CH and the human antibody CL, and the expression vector is introduced into the host cell. As a result, a human CDR-grafted antibody can be expressed and produced.
- any CH may be used as long as it belongs to hlg, but the hlgG class is preferable. Can be.
- the CL of the human CDR-grafted antibody may be any CL as long as it belongs to hlg, and a ⁇ class or a L class can be used.
- a human antibody originally refers to an antibody that is naturally present in a human body. However, if a human antibody phage library has been produced by recent advances in genetic, cell engineering, and developmental engineering techniques, a human antibody phage library can be used. Also included are antibodies obtained from human antibody transgenic non-human animals or human antibody transgenic plants. Antibodies present in the human body can be obtained, for example, by isolating human peripheral blood lymphocytes, infecting EB virus and the like, immortalizing them, and cloning the cells to produce the antibody-producing lymphocytes. Antibodies can be collected.
- the human antibody phage library 1 is a library in which antibody fragments such as Fab and single chain antibodies are expressed on the phage surface by introducing an antibody gene prepared from human B cells into a phage gene. Phage expressing an antibody fragment having the desired antigen-binding activity can be recovered from the library using the binding activity to the substrate on which the antigen is immobilized as an index. The antibody fragment can be further converted to a human antibody molecule consisting of two complete H chains and two complete L chains by genetic engineering techniques.
- a human antibody transgenic non-human animal refers to an animal in which a human antibody gene has been integrated into cells.
- a human antibody transgenic non-human animal can be produced by introducing a mouse antibody gene from a mouse embryonic stem cell, transplanting the embryonic stem cell into an early embryo of another mouse, and then developing the embryo.
- a human antibody transgenic non-human animal can be produced by introducing a human antibody gene into a fertilized egg of an animal and generating the fertilized egg.
- Human antibodies can be prepared from non-human transgenic non-human animals by obtaining human antibody hybridomas according to the normal hybridoma production method used in mammals other than humans, and culturing them. Human antibodies can accumulate in it.
- transgenic non-human animals examples include porcupines, sheep, goats, stags, pomas, mice, rats, chickens, monkeys, and egrets.
- the antibody may be an antibody that recognizes a tumor-associated antigen, an antibody that recognizes an antigen that is associated with allergy or inflammation, an antibody that recognizes an antigen that is associated with a circulatory disease, or an antigen that is associated with an autoimmune disease.
- the antibody is an antibody that recognizes an antigen, or an antibody that recognizes an antigen associated with a virus or bacterial infection.
- the antibody class is preferably IgG.
- the antibody fragment refers to a fragment containing at least a part of the Fc region of the antibody.
- the Fc region means a C-terminal region of the H chain of an antibody, a CH2 region and a CH3 region, and includes a natural type and a mutant type thereof. At least a part of the Fc region preferably refers to a fragment containing the CH2 region, more preferably a region containing the first aspartic acid present in the CH2 region.
- the Fc region of the IgG class is described in the EU Index by Kabat et al. Bok (Sequences of Proteins of Immunological Interest) , 5 th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. C -terminal with Na Nparingu from 226 th Cys of (1991)] or 230 th C from Pro, Means to the end. Examples of antibody fragments include H chain monomers and H chain dimers.
- a fusion protein having a part of the Fc region is a substance obtained by fusing an antibody or a fragment of an antibody containing a part of the Fc region of an antibody with a protein such as an enzyme or cytokin (hereinafter referred to as Fc Fusion protein).
- Cells used for producing the antibody composition of the present invention include yeast, animal cells, insect cells, plant cells, and the like.
- the cell used for producing the antibody composition of the present invention is a lectin that recognizes a sugar chain structure in which the 6-position of the N-glycoside-linked complex type sugar chain reducing terminal N-acetyldarcosamine is linked to the 1-position of fucose. It can be prepared by using a technique for selecting cells that are resistant to chromosomes. Alternatively, from a transformant in which a gene encoding an antibody molecule has been introduced into cells in advance, a saccharide in which position 6 of N-acetyldarcosamine at the reducing end of N-glycoside-linked complex type sugar chain and position 1 of fucose are linked. The cells of the present invention can be produced by selecting a transformant that is resistant to a lectin that recognizes a chain structure.
- a method for selecting cells that are resistant to lectins that recognize a sugar chain structure in which the N-glycidol-linked complex type sugar chain reducing terminal N-acetylacetylcosamine at position 6 and fucose at position 1 are linked is as follows. For example, there is a method of selecting using a lectin described in Somatake 'Cell and' Molecular. Genetics., 12, 51, (1986).
- any lectin can be used as long as it recognizes a sugar chain structure in which the 6-position of N-acetyldarcosamine at the reducing end of the N-dalicoside-linked complex type sugar chain and the 1-position of fucose are linked.
- Specific examples thereof include lentil bean lectin LCA (Lentil Agglutinin from Lens Culinaris) endumamelectin PSA (Pe sum Lactin from Pi sum sativum), fava bean lectin VFA (Agglutinin from Vicia faba), and Hylochawanta lectin ML (Aleuria aurantia-derived Lectin).
- Cells that are resistant to lectins that recognize an ⁇ -linked sugar chain structure at the 6-position of N-acetyltilcosamine at the reducing end of the complex type sugar chain and the 1-position of fucose can be selected.
- any method for selecting a cell that is resistant to lectin such as a method for selecting a resistant strain generated by mutagenizing a cell and a method for selecting a naturally occurring resistant strain may be used.
- any treatment can be used as long as it induces a point mutation, a deletion or a frame shift mutation in the DNA of the cells of the parent strain.
- Specific examples include treatment with ethyl nitrosodiarea, nitrosoguanidine, benzopyrene, and acridine dye, and irradiation with radiation.
- various alkylating agents and carcinogens can also be used as mutagens. Examples of the method of causing a mutagen to act on cells include, for example, the third edition of tissue culture technology (Asakura Shoten), edited by The Japanese Society for Tissue Culture (1996), Nature Genet., 24, 314, ( 2000) and the like.
- the naturally occurring resistant strains include cell strains that originally exist as resistant strains in nature and spontaneous development by continuing subculture under normal cell culture conditions without special mutagenesis treatment. Mutants which occur naturally.
- the cells of the present invention target a gene encoding GDP-fucose synthase, ⁇ ; 1,6-fucose modifying enzyme, or fucose transport protein, introduce a gene disruption method, and introduce a dominant negative body. And methods for suppressing transcription or translation.
- any method can be used as long as it can disrupt the gene of the target enzyme.
- Specific examples thereof include: Examples include the homologous recombination method, the RA-DNA oligonucleotide (RD0) method, a method using a retrovirus, a method using a transposon, an antisense method, a ribozyme method, and an RA interference (R Ai) method.
- RD0 RA-DNA oligonucleotide
- R Ai RA interference
- the cells of the present invention target the above-mentioned genes, and are described in Cell Engineering, 239, (1993), Bio / Technology (BI0 / TECH 0L0GY), 17, 1097, (1999), Human 'Molecular' Genetics (Hum. Mol. Genet.), 5, 1083, (1995), Cell Engineering, ⁇ , 255, (1994), Proceedings.
- an antisense gene or ribozyme construct of an appropriate length including a translated region, untranslated region or intron portion of the target gene is designed.
- a recombinant vector is prepared by inserting the prepared DNA fragment or full length downstream of the promoter of an appropriate expression vector.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- the cells of the present invention can be obtained by selecting a transformant using the activity of the protein encoded by the target gene as an indicator.
- the cells of the present invention can also be obtained by selecting a transformant using the sugar chain structure of the glycoprotein on the cell membrane or the sugar chain structure of the produced antibody molecule as an index.
- any cell having a target gene such as yeast, animal cells, insect cells, and plant cells
- yeast, animal cells, insect cells, and plant cells can be used.
- specific examples include the host cells described in 3. below.
- the expression vector those which can replicate autonomously in the above-mentioned host cells or can be integrated into the chromosome, and which contain a designed antisense gene or a promoter containing a promoter at a position where the ribozyme can be transcribed are used.
- Specific examples include the expression vectors described in 3. below.
- Methods for introducing a gene into various host cells the method for introducing a recombinant vector suitable for various host cells described in 3. below can be used.
- Methods for obtaining cDNA and genomic DNA of the target gene include, for example, the methods described below.
- a cDNA library is prepared from the prepared total RNA or mRNA.
- a degenerate primer is prepared, and the prepared cDNA library is used as a type III gene by PCR. To get.
- the cDNA library of the target gene can be obtained by screening the cDNA library using the obtained gene fragment as a probe.
- mRNA of various host cells commercially available mRNA (for example, Clontech) may be used, or may be prepared from various host cells as follows. Methods for preparing total RNA from various host cells include the guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymology, 154, 3 (1987)], and acid thiocyanate. Guanidine 'phenol' black-mouthed form (AGPC) method [Analytical Biochemistry, 162, 156 (1987); Experimental Medicine, 9, 1937 (1991)].
- AGPC Guanidine 'phenol' black-mouthed form
- mRNA as a method for preparing mRNA as poly (a) + RNA from total RNA, an oligo (dT) -immobilized cellulose column method (Molecular Cloning 2nd edition) and the like can be mentioned.
- mRNA can be prepared by using a kit such as Fast Track mRNA Isolation Kit (Invitrogen) and Quick Prep mRNA Purification Kit (Pharmacia).
- a cDNA library is prepared from the prepared various host cell mRNAs.
- One method for preparing a cDNA library is described in Molecular 'Cloning 2nd Edition, Current' Protocols 'in' Molecular Biology, or a commercially available kit, for example, Superscript Plasmid System for cDNA Synthesis and Plasmid. Methods using Cloning (Life Technologies) and ZAP-cDNA Synthesis Kit (STRATAGENE).
- any phage vector, plasmid vector, or the like can be used as long as it can autonomously replicate in E. coli K12 strain.
- ZAP Express [STRATAGENE, (Strategies), 5, 58 (1992)], pBluescript II SK (+) [Nucleic Acids Research, 17, 9494 (1989)], Lambda ZAP II (STRATAGENE), G tlO, Lgtll [DNA cloning, A Practical Approach], 1, 49 (1985)], ⁇ TriplEx (Clontech),!
- Escherichia coli is preferably used. Specifically, Escherichia coli XLl-Blue MRF, [STRATAGENE, Strategies, 5, 81 (1992)], Escherichia coli C600 [Genetics, 39, 440 (1954)], Escherichia coli Y1088 [Science, 222, 778 (1983)], Escherichia coli Y1090 [Science, 222, 778 (1983)], Escherichia coli NM522 [Jan. Mol. Biol. ), 166, 1 (1983)], Escherichia coli K802 [Journal of J. Mol.
- This cDNA library may be used as is for subsequent analyses, but in order to reduce the proportion of incomplete-length cDNAs and obtain full-length cDNAs as efficiently as possible, the oligocap method developed by Sugano et al.
- a diene-generating primer specific to the nucleotide sequence at the 5 'end and 3' end of the nucleotide sequence predicted to encode the amino acid sequence was prepared.
- Amplification of DNA using PCR method [PCR Protocols, Academic Press (1990)] using the prepared cDNA library as type II to obtain a gene fragment of the target gene Can be.
- the fact that the obtained gene fragment is a target gene can be determined by a commonly used nucleotide sequence analysis method, for example, the dideoxy method of Sanger et al. [Proceedings 'ob'] The 'National' Academy Academy of Sciences (Proc. Natl. Acad. Sci. USA),
- cDNA or cDNA library synthesized from mRNA contained in various host cells is subjected to colony hybridization and plaque hybridization (molecular cloning second edition).
- cDNA of the target gene can be obtained.
- a cDNA library synthesized from mRNA contained in each type of host cell was screened using the cDNA library as a type I PCR. By doing so, the cDNA of the target gene can also be obtained.
- the nucleotide sequence of the obtained target gene cDNA can be analyzed from the end by a commonly used nucleotide sequence analysis method, for example, the dideoxy method of Sanger et al. [Proceedings of 'the' National 'Academy of Sciences (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)] or a base sequence analyzer such as ABIPRISM377 DNA Sequencer (manufactured by PE Biosystems) to determine the base sequence of the DNA. .
- a commonly used nucleotide sequence analysis method for example, the dideoxy method of Sanger et al. [Proceedings of 'the' National 'Academy of Sciences (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)] or a base sequence analyzer such as ABIPRISM377 DNA Sequencer (manufactured by PE Biosystems) to determine the base sequence of the DNA. .
- a base sequence database such as GenBank, EMBL, and DDBJ is searched using a homology search program such as BLAST, so that the target gene can be coded among the genes in the database. It is also possible to determine a gene encoding a protein having a function similar to that of the protein to be expressed.
- Methods for preparing genomic DNA of the target gene include, for example, the methods described below. How to prepare genomic DNA
- genomic DNA library screening system Genomic Systems
- Universal GenomeWalker TM Kits CLONTECH
- Methods for selecting a transformant using the activity of the protein encoded by the target gene as an index include, for example, the following methods. How to select transformants
- Methods for selecting cells based on changes in traits resulting from reduced activity of the protein encoded by the target gene include, for example, selecting transformants using the sugar chain structure of the produced antibody molecule as an index, and selecting a transformant.
- a method of selecting a transformant using the sugar chain structure of a glycoprotein on the cell surface as an index is exemplified.
- Methods for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include the method described in 5. below.
- the above-mentioned position 6 of N-acetyltylcolasamine and one of fucose at the reducing end of the N-glycoside-linked sugar chain are used.
- a method for selecting a strain that is resistant to a lectin recognizing a sugar chain structure having an ⁇ - linked position can be mentioned. Specific examples thereof include a method using a lectin described in Somatic Cell Mol. Genet., 12, 51, (1986) and the like.
- the cells of the present invention can also be obtained by directly introducing an antisense oligonucleotide or ribozyme designed based on the base sequence of a target gene without using an expression vector into a host cell.
- the antisense oligonucleotide or ribozyme can be prepared by a conventional method or by using a DNA synthesizer. Specifically, the target gene cDNA and Based on the sequence information of an oligonucleotide having a sequence corresponding to 5 to 150 bases, preferably 5 to 60 bases, more preferably 10 to 40 bases in the base sequence of the genomic DNA, it is complementary to the oligonucleotide. It can be prepared by synthesizing an oligonucleotide corresponding to the sequence (antisense oligonucleotide) or a ribozyme containing the sequence of the oligonucleotide.
- Oligonucleotides include oligo RNA and derivatives of the oligonucleotide (hereinafter referred to as oligonucleotide derivatives) and the like.
- Oligonucleotide derivatives include oligonucleotide derivatives in which the phosphodiester bond in the oligonucleotide has been converted to a phosphorothioate bond, and phosphodiester bonds in the oligonucleotide in which the N3, -P5 'phosphoramidate bond has been converted.
- the cell of the present invention targets a gene encoding GDP-fucose synthase, a 1,6-fucose modifying enzyme, or a fucose transport protein, and modifies the target gene on the chromosome by homologous recombination. Can be made.
- the modification of the target gene on the chromosome can be performed by the Manipulating the Mouse Embryo A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994) (hereinafter ⁇ Manipulating the Mouse Embryo 'A' Laboratory 'Ma-Yuanore' '' Abbreviation), Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Bio Manual Series 8 Gene Targeting
- the target gene to be modified (for example, a structural gene of a GDP-fucose synthase, a 1,6-fucose modifying enzyme, or a fucose transport protein, or a promoter gene) is homologously recombined.
- a target vector for a GDP-fucose synthase, a 1,6-fucose modifying enzyme, or a fucose transport protein, or a promoter gene is homologously recombined.
- the cells of the present invention can be prepared by introducing the prepared target vector into host cells and selecting cells in which homologous recombination has occurred between the target gene and the target vector.
- any of yeast, animal cells, insect cells, plant cells, and the like that have the target gene can be used. Specific examples include the host cells described in 3. below.
- Target vectors for homologous recombination of the target gene are as follows: Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), No Manual Series 8 Gene Targeting, Generation of Mutant Mice Using ES Cells (Sheep (1995) and the like.
- the target vector can be used in any of a replacement type, an insertion type, and a gene trap type.
- the method for introducing a recombinant vector suitable for various host cells described in 3 below can be used.
- Methods for efficiently selecting homologous recombinants include, for example, Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Neu-Shi Manual Manual 8 Gene Targeting, Mutant Mouse Using ES Cells
- methods such as positive selection, promoter selection, negative selection, and poly A selection described in Production (Yodosha) (1995) can be used.
- Methods for selecting the desired homologous recombinants from the selected cell lines include the Southern hybridization method (molecular 'cloning 2nd edition) for genomic DNA and the PCR method [PCR Protocols (PCR Protocols). ), Academic Press (1990) 1 etc. (3) Preparation of the cells of the present invention by the RDO method
- the cell of the present invention targets a gene encoding GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or fucose transport protein, and uses the RDO (RNA-DNA oligonucleotide) method, for example. It can be manufactured as follows.
- RD0 construct of appropriate length, including the translated region, untranslated region and intron portion of the target gene.
- the cell of the present invention can be produced by introducing the synthesized RD0 into a host cell and selecting a transformant in which the target protein has a mutation.
- any of yeast, animal cells, insect cells, plant cells, and the like that have the target gene can be used. Specific examples include the host cells described in 3. below.
- RD0 For the introduction of RD0 into various host cells, the method for introducing a recombinant vector suitable for various host cells described in 3. below can be used.
- Examples of a method for preparing genomic DNA of the target gene include the “method for preparing genomic DNA” described in 1 (1) above.
- the nucleotide sequence of the DNA is digested with an appropriate restriction enzyme or the like, cloned into a plasmid such as pBluescript SK (-) (Stratagene), and analyzed by a commonly used nucleotide sequence analysis method, for example, dideoxy by Sanger et al. Method [Procedings of the National 'Academy of Sciences (Proc. Natl. Acad. Sci., USA), 74, 5463 (1977)], etc.
- the base sequence of the DNA can be determined by analysis using ALF DNA Sequencer (Pharmacia) or the like.
- RD0 can be prepared by a conventional method or by using a DNA synthesizer.
- a method for introducing RD0 into host cells and selecting a target protein includes: Molecular 'Cloning 2nd Edition, Current' Proto A method for directly detecting a mutation in a gene on a chromosome described in Coles in 'Molecular' Bio Mouth et al.
- the method for selecting a transformant using the activity of the protein encoded by the target gene as an index according to the above 1 (1), and the method using the sugar chain structure of a glycoprotein on a cell membrane as an index A method for selection, or a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index described in 5. below, can also be used.
- RD0 The construction of RD0 is described in Science, 273, 1386, (1996); Nature Medicine, 4, 285, (1998); Hepatology, 25, 1462, (1997); Gene Therapy, 5, 1960, (1999); Gene Therapy, 5, 1960, (1999); Journal of Molecular Medicine (J. Mol. Med) Proc. Natl. Acad. Sci. USA, 96, 8774, (1999); Procedings' op 'the' Nashinanore 'academi 1 to ob' science (Proc. Natl. Acad. Sci. USA), 96, 8774, (1999); Ding's 'The' National 'Académie'Op'Science (Proc. Natl. Acad. Sci.
- the cell of the present invention targets a gene encoding GDP-fucose synthase, ⁇ , 6-fucose modifying enzyme, or fucose transport protein, and is prepared using the RNAi (RNA interference) method, for example, as follows. can do.
- the RNAi method refers to a method in which double-stranded RNA is introduced into a cell to degrade and destroy mRNA homologous to the RA sequence present in the cell, thereby suppressing gene expression.
- RNAi gene construct of an appropriate length including the translated or untranslated region of the target gene.
- a recombinant vector is prepared by inserting the prepared DNA fragment or its full length downstream of the promoter of an appropriate expression vector.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- the cells of the present invention can be obtained by selecting a transformant based on the activity of the protein encoded by the target gene or the sugar chain structure of the produced antibody molecule or the glycoprotein on the cell surface.
- any of yeast, animal cells, insect cells, plant cells, and the like that have the target gene can be used. Specific examples include the host cells described in 3. below.
- the expression vector those which can replicate autonomously in the above host cells or can be integrated into the chromosome, and which contain a promoter at a position where the designed RNAi gene can be transcribed are used. Specific examples include an expression vector of a type in which transcription is carried out by polymerase II or an expression vector described in 3. below.
- the method for introducing a recombinant vector suitable for various host cells described in 3. below can be used.
- Examples of a method for selecting a transformant using the activity of the protein encoded by the target gene as an index or a method for selecting a transformant using the sugar chain structure of a glycoprotein on a cell membrane as an index include, for example, the method described in the above 1 ( The method described in 1) is mentioned. Examples of a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include the method described in 5. below.
- Examples of a method for preparing cDNA of a protein encoded by the target gene include the “method for preparing cDNA” described in 1 (1) above.
- the cells of the present invention can also be obtained by directly introducing an RNAi gene designed based on the base sequence of a target gene into a host cell without using an expression vector.
- the RNAi gene can be prepared by a conventional method or by using a DNA synthesizer.
- RNAi gene constructs are described in [Nature, 391, 806 (1998); Procedural seeding 'op' the 'nation''a power demi one' ob 'science (Proc. Natl. Acad. Sci. USA ), 95, 15502 (1998); Nature, 395, 854 (1998); Proceedings of the 'National Academy'Op'Science (Proc. Natl. Acad. Sci. USA), 96 , 5049 (1999); Cell, 95, 1017 (1998); Proceedings 'Ob-the-National' Academy (Proc. Natl. Acad. Sci. USA), 96, 1451 (1999); ' ⁇ Op' Science (Proc. Natl. Acad. Sci. USA), 95, 13959 (1998); Nayya's 'Cell' Pyology (Nature Cell Biol.), 2, 70, (2000)] Can be designed.
- RNA used in the RNAi method of the present invention includes:
- RNAs corresponding to DNAs encoding the above Preferably Wahi 1, fucose qualified enzyme 6 is, a 1, RNA corresponding to the DNA is 6-fucosyltransferase is like et be.
- RNA used in the RNAi method of the present invention any double-stranded RNA composed of RNA and its complementary RNA and capable of reducing the amount of ⁇ 1,6-fucosyltransferase mRNA can be used.
- the length of RNA is preferably 1 to 30, more preferably 5 to 29, more preferably 10 to 29, and most preferably 15 to 29 continuous RNA.
- the length of RNA is preferably 1 to 30, more preferably 5 to 29, more preferably 10 to 29, and most preferably 15 to 29 continuous RNA.
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 79;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 80;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 consecutive base sequences in the base sequence represented by SEQ ID NO: 81;
- RNA corresponding to DNA consisting of a base sequence represented by 10 to 30 contiguous base sequences in the base sequence represented by SEQ ID NO: 82;
- RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83 (a) RNA consisting of the nucleotide sequence represented by SEQ ID NO: 83; (b) RNA consisting of the nucleotide sequence represented by SEQ ID NO: 84;
- a base sequence represented by SEQ ID NO: 83 wherein the base sequence has one or several bases deleted or added, and has substantially the same RNAi activity as SEQ ID NO: 83;
- RNA consisting of the nucleotide sequence of SEQ ID NO: 84 with one or several nucleotides deleted or added, and having substantially the same RNAi activity as SEQ ID NO: 84;
- RNAJ having substantially the same RNAi activity as SEQ ID NO: 83 or SEQ ID NO: 84 includes RNA represented by SEQ ID NO: 83 or SEQ ID NO: 84 and RNAi similar to 1,6-fucosyltransferase. Any substance having activity may be used, and quantitative factors such as the length of RNA may be different.
- the nucleotide sequence in which one or several nucleotides are deleted or added is a nucleotide sequence in which one or several nucleotides at both ends of SEQ ID NO: 83 or SEQ ID NO: 84 are deleted and / or added.
- the length of the base sequence is preferably 1 to 30, more preferably 5 to 29, further preferably 10 to 29, and most preferably 15 to 29 continuous RNA.
- DNAs corresponding to these RNAs and their complementary DNAs are also included in the present invention, and specific examples of the DNAs corresponding to the RNA include a DNA consisting of the base sequence represented by SEQ ID NO: 63 or 64.
- a recombinant DNA containing the DNA and its complementary DNA in a vector and a transformant obtained by introducing the recombinant DNA into cells are also encompassed by the present invention, and are used for expressing the double-stranded RA. Can be used.
- the cells of the present invention can be prepared using the transposon system described in Nature Genet., 25, 35, (2000), etc., using GDP-fucose synthase, ⁇ , 6-fucose modifying enzyme, or fucose-modifying enzyme.
- the cells of the present invention can be prepared by selecting mutants based on the activity of the transport protein or the sugar chain structure of the produced antibody molecule or the glycoprotein on the cell membrane.
- the transposon system is a system in which a foreign gene is randomly inserted into a chromosome to induce mutation.
- a foreign gene inserted in a transposon is used as a vector to induce mutation, and this gene is at the same time, a transposase expression vector for random insertion of chromosomes into the chromosome is introduced into cells. Any transposase can be used as long as it is suitable for the sequence of the transposon to be used.
- any gene can be used as long as it can induce mutation in the DNA of the host cell.
- Host cells include yeast, animal cells, insect cells, plant cells, and other target genes (such as genes encoding GDP-fucose synthase, genes encoding 1,6-fucose modifying enzymes, or fucose transport proteins). Any gene can be used as long as it has Specific examples include the host cells described in 3. below.
- target genes such as genes encoding GDP-fucose synthase, genes encoding 1,6-fucose modifying enzymes, or fucose transport proteins.
- Any gene can be used as long as it has Specific examples include the host cells described in 3. below.
- the method for introducing a recombinant vector suitable for various host cells described in 3. below can be used.
- a method for selecting a mutant using the activity of the protein encoded by the target gene as an index or a method for selecting a mutant using the sugar chain structure of a glycoprotein on a cell membrane as an index includes, for example, (1).
- Examples of a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include the method described in 5. below.
- the cells of the present invention target GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or fucose transport protein, and It can be produced by using a method of introducing a dominant negative body.
- a specific example of a dominant negative body is an example of a fucose transport protein.
- Transporters of intracellular sugar nucleotides are known to function by forming dimers on the membranes of the endoplasmic reticulum and the Golgi apparatus [J. Biol. Chem.), 275, 17718, 2000] 0 Also, by forcibly expressing intracellular sugar nucleotide transporter mutants in cells, they form heterodimers with the wild-type transporters, and the formed heterodimers are It has been reported to exhibit inhibitory activity against wild-type homodimers [Journal 'ob' Biological Chemistry (J. Biol. Chem.), 275, 17718, 2000].
- the cells of the present invention were prepared using the dominant negative gene of the target protein prepared as described above, using Molecular 'Cloning 2nd Edition, Current' Protocols ',' Molecularity ⁇ biology, ⁇ According to the method of gene transfer described in Emprio 2nd edition, for example, it can be prepared as follows.
- a DNA fragment of an appropriate length containing a portion encoding the protein is prepared, if necessary.
- a recombinant vector is prepared by inserting the DNA fragment or full-length DNA downstream of a promoter in an appropriate expression vector.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- the host cell of the present invention can be prepared by selecting a transformant based on the activity of the target protein or the sugar chain structure of the produced antibody molecule or the glycoprotein on the cell membrane.
- any of yeast, animal cells, insect cells, plant cells, and the like can be used as long as they have the gene of the target protein. Specific examples include the host cells described in 3. below.
- the expression vector those which can replicate autonomously in the above host cells or can be integrated into the chromosome, and which contain a promoter at a position where the DNA encoding the dominant negative body of interest can be transcribed are used. Specific examples include the expression vector described in 3. below.
- a method for selecting a mutant using the activity of the target protein as an index or a method for selecting a mutant using the sugar chain structure of a glycoprotein on a cell membrane as an index, for example, the method described in the above 1 (1) Method.
- Examples of a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include, for example, the method described in 5. below. 2. Preparation of transgenic non-human animal or plant or progeny thereof for use in the production of the present invention
- the transgenic non-human animal or plant used for the production of the antibody composition of the present invention, or a progeny thereof has an ⁇ -fucose at the 6-position of N-acetyldarcosamine at the reducing end of the N-dalicoside-linked complex type sugar chain, and It is resistant to a lectin recognizing the bound sugar chain structure. It should be prepared from the embryonic stem cell, fertilized egg cell, or plant cell of the present invention prepared using the method described in 1., using a known method. Can be.
- the target non-human animal for example, embryonic stem cells such as a pig, a sheep, a goat, a pig, a pig, a mouse, a rat, a chick, a monkey, a rabbit, etc.
- embryonic stem cells such as a pig, a sheep, a goat, a pig, a pig, a mouse, a rat, a chick, a monkey, a rabbit, etc.
- the method of the present invention which is resistant to a lectin that recognizes a sugar chain modification in which the fucose 1 position is bonded to the 6 position of the ⁇ -acetyl side chain of the ⁇ -glycoside-linked complex type sugar chain by using the method of Embryonic stem cells can be produced.
- a gene encoding an enzyme involved in sugar chain modification in which fucose is alpha- linked to position 6 of N-acetylglucosamine at the reducing end of N-dalicoside-linked complex type sugar chain on the chromosome is known.
- Mutant clones which have been inactivated or replaced with an arbitrary sequence by the method of homologous recombination eg, Nature, 326, 6110, 295 (1987), Cell, 51, 3, 503 (1987)].
- An embryonic stem cell clone and a normal cell are prepared by using the produced embryonic stem cells (for example, the mutant clone) by a technique such as chimera method or injection chimera method of injecting an animal fertilized egg into a blastocyst.
- Chimeric individuals can be prepared.
- whole-body cells recognize the glycosylation in which the 1-position of fucose is linked to the 6-position of N-acetyldarcosamine at the reducing end of the N-daricoside-linked complex type sugar chain.
- transgenic non-human animals that are resistant to the lectins of interest can be obtained.
- the target vector for homologous recombination of the target gene should be prepared according to the method described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Production of Mutant Mouse Using ES Itoda Can be.
- As the target vector any of a replacement type, an insertion type, and a gene trap type can be used.
- any method for introducing DNA into animal cells can be used.
- electoporation [Cytotechnology, 3, 133 ( 1990)]
- calcium phosphate method Japanese Unexamined Patent Publication No. 2-227075
- lipofection method [procedures 'ob' the 'na' Shonanore 'Academy'Op'Science (Proc. Natl. Acad. Sci. USA), 84> 7413 (1987)]
- Injection method manipulating, mouse 'employ 2nd edition
- particle gun gene gun
- Methods for efficiently selecting homologous recombinants include, for example, positive selection and promoter described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), production of mutant mice using ES Itoda vesicle, etc. Methods such as selection, negative selection, and poly A selection can be used. Specifically, in the case of a target vector containing the hprt gene, after introduction into an embryonic stem cell deficient in the hprt gene, the embryonic stem cell is cultured in a medium containing aminopterin, hypoxanthine and thymidine, and aminobuterin-resistant. Thus, positive selection for selecting a homologous recombinant containing the hprt gene can be performed.
- a target vector containing the neomycin resistance gene embryo-derived stem cells into which the vector has been introduced are cultured in a G418-containing medium, and G418-resistant strains are selected to select homologous recombinants containing the neomycin resistance gene. Positive selection can be made.
- the embryo-derived stem cells into which the vector has been introduced are cultured, and the growing strain is selected. (Recombinants other than homologous recombination randomly inserted into the chromosome have the DT gene.
- Methods for selecting the desired homologous recombinant from the selected cell lines include the Southern hybridization method (molecular cloning, 2nd edition) for genomic DNA and the PCR method [PCR Protocol (PCR Protocols), Academic Press (1990)] and the like.
- embryonic stem cells When embryonic stem cells are incorporated into a fertilized egg by using the chimeric assembly method, it is generally preferable to use a fertilized egg at a developmental stage before the 8-cell stage. When embryonic stem cells are incorporated into a fertilized egg using the injection chimera method, it is generally preferable to use a fertilized egg from the 8-cell stage to the stage of blastocyst development.
- Pseudopregnant female mice can be obtained by natural mating, but they can be obtained by administering luteinizing hormone-releasing hormone (hereinafter abbreviated as LHRH) or an analog thereof and mating with male mice. Pseudopregnant female mice in which fertility has been induced can also be obtained.
- LHRH luteinizing hormone-releasing hormone
- LHRH As analogs of LHRH, for example, [3,5-Dil-Tyr5] -LHRH, [Gln8] -LHRH, [D-Ala6] -LHRH, des-GlylO- [D-His (Bzl) 6] -LHRH ethylamide And the like.
- the method described in 1. can be used for fertilized egg cells of a target non-human animal, for example, a porcupine, a sheep, a goat, a septum, a poma, a mouse, a rat, a chick, a monkey, a rabbit, etc.
- Fertilized egg cells that are resistant to lectins that recognize glycosylation in which the 6-position of fucose is ⁇ -linked to the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain .
- the resulting fertilized egg cells are transplanted into the oviduct or uterus of pseudopregnant females using the method of embryo transfer described in the manual, Mouse 'Emprio 2nd Edition, etc. to give birth, so that the cells of the whole body are obtained. It is also possible to produce transgenic non-human animals that are resistant to lectins that recognize glycosylation in which the 1-position of fucose is ⁇ -linked to the 6- position of ⁇ ⁇ -acetyldarcosamine at the reducing end of ⁇ -daricoside-linked complex type glycan. it can.
- the target plant virulent cells or cells can be treated with the method described in 1. to place fucose at position 6 of ⁇ -acetylglycosylcosamine at the reducing end of ⁇ -glycosidic complex-type sugar chain.
- fucose at position 6 of ⁇ -acetylglycosylcosamine at the reducing end of ⁇ -glycosidic complex-type sugar chain.
- the prepared callus was transformed into auxin and auxin according to known methods [tissue culture, 20 (1994); tissue culture, 21 (1995); Trends in Biotechnology, 15, 45 (1997)].
- the cells are redifferentiated by culturing in a culture medium containing cytokinin, and recognize the glycosylation in which the 1-position of fucose is linked to the 6-position of N-acetyltyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain. It is possible to produce transgenic plants that are resistant to the relevant lectins.
- Methods for introducing a gene encoding an antibody molecule into cells include molecular 'cloning, 2nd edition, current' protocols ', molekiura' biology,
- a DNA fragment having an appropriate length containing a portion encoding the protein is prepared.
- a recombinant vector is prepared by inserting the DNA fragment or full-length cDNA downstream of a promoter in an appropriate expression vector.
- the transformant of the present invention can be obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- cDNA can be prepared from human or non-human animal tissues or cells using probe primers specific for the antibody molecule of interest.
- any of yeast, animal cells, insect cells, plant cells and the like can be used as long as it can express the desired antibody gene.
- an enzyme involved in the modification of the N-daricoside-linked sugar chain that binds to the Fc region of the antibody molecule is introduced using genetic engineering techniques. It can also be used.
- the host cells used in the production method of the antibody composition of the present invention include the 6-position of N-acetylethyldarcosamine at the reducing end of the N-glycoside-linked complex type sugar chain prepared in step 1 above and the fucose.
- the various host cells described above are resistant to lectins that recognize a sugar chain structure having an ⁇ -linked bond at the 1-position.
- those which can replicate autonomously in the above-mentioned various host cells or can be integrated into a chromosome, and which contain a promoter at a position where the DNA encoding the antibody molecule of interest can be transcribed are used.
- yeast When yeast is used as a host cell, examples of expression vectors include YEP13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419) and the like. Any promoter can be used as long as it can be expressed in yeast strains.
- promoters of glycolytic genes such as hexose kinase, PH05 promoter, PGK promoter, GAP promoter, AD promoter Examples include the H promoter, the gal 1 promoter, the gal 10 promoter, the heat shock protein promoter, the 1 promoter, and the cup 1 promoter.
- any method for introducing a recombinant vector any method can be used as long as it is a method for introducing DNA into yeast.
- an elect-portion method [Methods. Enzymol.], 194, 182 ( 1990)]
- Spheroplast method [Procedures 'ob' the 'National' academy 'ob' science (Proc. Natl. Acad. Sci. US A), 84, 1929 (1978)]
- lithium acetate method Journal of Bacteriology, 153, 163 (1983)], Proceedings' of the National Academy of Sciences, Proc . Natl. Acad. Sci.
- an expression vector When an animal cell is used as a host cell, examples of an expression vector include, for example, pcDNAI, pcDM8 (commercially available from Funakoshi), pAGE107 [Japanese Unexamined Patent Publication No. 3-22979; Cytotechnology, 3, 133, (1990). )], PAS3-3 [Japanese Patent Laid-Open No. 2-227075], PCDM8 [Nature, 329, 840, (1987)], pcDNAI / Amp (Invitrogen), pREP4 (Invitrogen), pAGE103 [Journal J. Biochemistry, 101, 1307 (1987)], pAGE210, and the like.
- Any promoter can be used as long as it can be expressed in animal cells.
- the enhancer of the IE gene of human CMV may be used together with the promoter.
- Host cells include Namalwa cells, human cells, COS cells, monkey cells, CH0 cells, Chinese hamster cells, HBT5637 (Japanese Patent Laid-Open No. 63-299), rat myeloma cells, and mice. Examples include myeloma cells, Syrian hamster kidney-derived cells, embryonic stem cells, and fertilized egg cells.
- any method can be used as long as it is a method for introducing DNA into animal cells.
- Examples thereof include an electroporation method [Cytotechnology, 3, 133 (1990)] and a calcium phosphate method.
- Japanese Unexamined Patent Publication (Kokai) No. 2-227075] Lipofxion method [Proceedings 'ob' the 'nation' aka Natl. Acad. Sci.
- the current protocol can be used for the following: Baculovirus Expression Vectors, A Laboratory Manual, WH Freeman and Company, New York (1992); Proteins can be expressed by the method described in Bio / Technology, 6, 47 (1988).
- a recombinant gene transfer vector and a baculovirus are co-transfected into insect cells to obtain a recombinant virus in an insect cell culture supernatant, and then the recombinant virus is infected into insect cells to express proteins.
- a recombinant gene transfer vector and a baculovirus are co-transfected into insect cells to obtain a recombinant virus in an insect cell culture supernatant, and then the recombinant virus is infected into insect cells to express proteins.
- Examples of the gene transfer vector used in the method include pVL1392, pVL1393, pBlueBacIII (all manufactured by Invitorogen) and the like.
- the baculovirus for example, leaves in burglar Gaka insect is a virus that infects ⁇ ⁇ Togurafa californica force Nuclear Doroshisu-Uinoresu to single-poly (Autographa californica nuclear polyhedrosis virus) and the like 3 ⁇ 4 for Rereru that force s.
- Sf9 and Sf21 which are ovarian cells of Spodopterafrugiperda [current protocologone-les-in-molecular, biology, Baculovirus Expression Vectors, A Laboratory Manual, WH freeman and Company, New York (1992)], High 5 (manufactured by Invitrogen), which is an ovarian cell of Trichoplusia ni, and the like.
- Examples of a method of co-introducing the above-mentioned recombinant gene introduction vector and the above-mentioned paculovirus into insect cells for preparing a recombinant virus include a calcium phosphate method.
- an expression vector examples include a Ti plasmid and a tobacco mosaic virus vector.
- Any promoter can be used as long as it can be expressed in plant cells, and examples thereof include the 35S promoter of cauliflower mosaic virus (CaMV) and the inactin 1 promoter.
- CaMV cauliflower mosaic virus
- Examples of the host cell include plant cells of tobacco, potato, tomato, carrot, soybean, abrana, alfa alfa, rice, wheat, wheat, and the like.
- any method can be used as long as it is a method for introducing DNA into a plant cell.
- a method using Agrobacterium [JP-A-59-140885; Kaisho 60-70080, W094 / 00977], the electoral port method [JP-A-60-251887], a method using a particle gun (gene gun) [Japanese Patent No. 2606856, Japanese Patent No. 2517813], and the like. I can give it.
- the target antibody composition is produced by culturing the transformant obtained as described above in a medium, producing and accumulating the target antibody molecule in the culture, and collecting the target antibody from the culture.
- the method for culturing the transformant in a medium can be performed according to a usual method used for culturing a host.
- a culture medium for culturing a transformant obtained by using a eukaryote such as yeast as a host contains a carbon source, a nitrogen source, inorganic salts, and the like which can be used by the organism to efficiently culture the transformant.
- a eukaryote such as yeast
- a host contains a carbon source, a nitrogen source, inorganic salts, and the like which can be used by the organism to efficiently culture the transformant.
- the medium can be used, either a natural medium or a synthetic medium may be used.
- the carbon source may be any one that can be assimilated by the organism; glucose, fructose, sucrose, molasses containing these, carbohydrates such as starch or starch hydrolysate, organic acids such as acetic acid and propionic acid, Alkonoles such as ethanol and propanol can be used.
- Nitrogen sources include ammonium salts of inorganic or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and the like.
- Other nitrogen-containing compounds peptone, meat extract, yeast extract, cone chip liquor, casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermenting cells and digests thereof can be used.
- potassium potassium phosphate potassium potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, man sulfate, copper sulfate, calcium carbonate and the like can be used.
- the culture is usually performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the cultivation temperature is preferably 15 to 40 ° C, and the cultivation time is usually 16 hours to 7 days.
- the pH is maintained at 3.0 to 9.0.
- the pH is adjusted using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium during the culture.
- an inducer may be added to the medium, if necessary.
- an inducer may be added to the medium.
- cultivating a microorganism transformed with a recombinant vector using a liposome motor is used.
- Indole acrylic acid may be added to the medium.
- a commonly used RPMI1640 medium [The Journal of the American Medica / Le 7 Societies (The Journal of the American Medical Association), 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Darbecco's modified MEM medium [Virology], 8, 396 (1959) ], 199 medium [Proceeding of the Society for the Biological Medicine (Proceeding of the Society for the Biological Medicine), 73, 1 (1950)], Whitten medium [Development Engineering Experiment Manual-Transgenic 'How to Make Mice (Kodansha) Motoya Katsuki (1987)] or a culture medium supplemented with fetal calf serum or the like.
- Culture is carried out usually p H6 ⁇ 8, 30 ⁇ 40 ° C, 5 % C0 2 present 1 to 7 days under conditions such as lower. Using cultivation methods such as Fuedpatch cultivation and holofiber cultivation, cultivation can be performed for several days to several months. If necessary, an antibiotic such as kanamycin or penicillin may be added to the medium during the culture.
- Culture media for transformants obtained using insect cells as hosts include commonly used TNM-FH media (Pharmingen), Sf-900II SFM medium (Life Technologies), ExCell400, ExCell405 (All manufactured by JRH Biosciences), Grace's Insect Medium [Nature, 195, 788 (1962)] and the like can be used.
- the cultivation is usually performed under conditions of pH 6 to 7 and 25 to 30 ° C for 1 to 5 days.
- an antibiotic such as gentamicin may be added to the medium during the culture.
- a transformant obtained using a plant cell as a host cell can be cultured as a cell or after being differentiated into a plant cell or organ.
- a medium for culturing the transformant a commonly used Murashige & Stag (MS) medium, a white (White) medium, or a medium to which a plant hormone such as auxin or cytokinin is added, is used. Can be used.
- Cultivation is usually performed at pH 5 to 9 and 20 to 40 ° C for 3 to 60 days.
- antibiotics such as kanamycin and hygromycin may be added to the medium during the culture.
- a yeast, animal cell, insect cell or plant cell-derived transformant having a recombinant vector into which DNA encoding the antibody molecule of interest has been incorporated is cultured according to a conventional culture method.
- the antibody composition can be produced by producing and accumulating the antibody composition and collecting the antibody composition from the culture.
- Methods for producing the antibody composition include a method of producing the antibody in the host cell, a method of secreting the antibody out of the host cell, and a method of producing the antibody composition on the host cell outer membrane.
- the host cell to be used and the structure of the protein to be produced By changing the value, the method can be selected.
- the antibody composition When the antibody composition is produced in a host cell or on the host cell outer membrane, the method of Paulson et al. [Journal of Biological 'Chemistry. Biol. Chem.), 264, 17619 (1989)], Lowe et al. [Proceedings' ob 'The National' Academy 'ob' Science (Proc. Natl. Acad. Sci. USA), 86, 8227 (1989); Genes Development (Genes Develop.), 4, 1288 (1990)], Alternatively, the antibody composition can be positively secreted out of host cells by applying the methods described in JP-A-05-336963 and JP-A-06-823021 mutatis mutandis.
- DNA encoding an antibody molecule and DNA encoding a signal peptide suitable for the expression of the antibody molecule are inserted into an expression vector using a gene recombination technique, and the expression vector is introduced into host cells. By doing so, the target antibody molecule can be actively secreted outside the host cell.
- the production amount can be increased by using a gene amplification system using a dihydrofolate reductase gene or the like.
- transgenic non-human animal a plant
- transgenic plant a plant
- An antibody composition can also be produced using an individual.
- the transformant is an animal or plant individual
- the animal is bred or cultivated according to a conventional method to produce and accumulate the antibody composition, and the antibody composition is collected from the animal or plant individual.
- the antibody composition can be produced.
- Examples of a method for producing an antibody composition using an animal individual include, for example, a known method [American Journal of Clinical Nutrition], 63, 639S (1996); American 'Genes according to the American Journal of Clinical Nutrition, 63, 627S (1996); Bio / Technology, 9, 830 (1991)] There is a method for producing a target antibody composition in an animal created by introducing the antibody.
- an antibody composition is produced and accumulated in the animal, and the antibody composition is collected from the animal. Thereby, an antibody composition can be produced.
- the place of production and accumulation in the animal include milk (eg, JP-A-63-309192) and eggs of the animal.
- the promoter used in this case any promoter that can be expressed in animals can be used. Examples thereof include ⁇ -casein promoter, which is a mammary cell-specific promoter,] 3 casein promoter, ⁇ ratatoglobulin promoter, and whey.
- An acidic protein promoter or the like is preferably used.
- a transgenic plant into which DNA encoding an antibody molecule has been introduced can be prepared by a known method [tissue culture, ⁇ (1994); tissue culture, 21 (1995)]. Cultivating according to Trends in Biotechnology, 15, 45 (1997)], producing and accumulating an antibody composition in the plant, and collecting the antibody composition from the plant.
- a method for producing an antibody composition can be mentioned.
- the cells are recovered by centrifugation after completion of the culture. After suspension in an aqueous buffer, the cells are disrupted using an ultrasonic disrupter, French press, Mentongaulin homogenizer, Dynomill, etc. to obtain a cell-free extract.
- a normal enzyme isolation and purification method that is, a solvent extraction method, a salting out method using ammonium sulfate, a desalting method, a precipitation method using an organic solvent, Getylaminoethyl (DEAE)-Sepharose, DIAI0N HPA-75 (manufactured by Mitsubishi Chemical), etc.
- Anion exchange chromatography using resin S-Sepharose FF (Pharmacia), etc., cation exchange Chromatography method, hydrophobic chromatography method using resins such as butyl sepharose, pheninolesepharose, gel filtration method using molecular sieve, affinity mouth chromatography method, chromatofocusing method, isoelectric focusing
- a purified sample can be obtained using techniques such as electrophoresis alone or in combination.
- the cells are similarly collected, crushed, and centrifuged to collect the insoluble substance of the antibody composition as a precipitate fraction.
- the recovered insoluble form of the antibody composition is solubilized with a protein denaturant.
- a purified sample of the antibody composition can be obtained by the same isolation and purification method as described above.
- the antibody composition can be collected in the culture supernatant. That is, a soluble fraction is obtained by treating the culture by a technique such as centrifugation as described above, and the antibody composition is obtained from the soluble fraction by using the same isolation and purification method as described above. A purified sample can be obtained.
- Examples of the antibody composition thus obtained include an antibody, a fragment of the antibody, and a fusion protein having an Fc region of the antibody.
- an antibody composition the acquisition of an antibody composition, the acquisition of a humanized antibody composition and an Fc fusion protein will be described, but other antibody compositions will be described in the above method or in accordance with the method. You can also get it.
- the expression vector for humanized antibody is an expression vector for animal cells into which genes encoding human antibody CH and CL have been incorporated, and the gene encoding human antibody CH and CL has been added to the expression vector for animal cell. It can be constructed by cloning.
- the C region of a human antibody can be CH and CL of any human antibody.
- the C region of the IgGl subclass of the H chain of a human antibody hereinafter referred to as hCT / 1
- human And the C region of the / c class of the L chain of the antibody hereinafter referred to as hC / c).
- genes encoding CH and CL of the human antibody chromosomal DNA consisting of exons and introns can be used, and cDNA can also be used.
- Any expression vector for animal cells can be used as long as it can integrate and express a gene encoding the C region of a human antibody.
- PAGE107 [Cytotechnology, 3, 133 (1990)]
- pAGE103 [Journal of Biochemistry. Biochem.]
- PHSG274 [Gene, 27, 223 (1984)]
- pKCR Proceedings' ob. The National Academy of Sciences ( proc . Natl. Acad. Sci.
- Promoters and enhancers used in animal cell expression vectors include the SV40 early promoter and enhancer [Journal of Biochemistry (J. Biochem.), 101, 1307 (1987)], Moro-I mouse leukemia Virus LTR Radiochemical 'and Biophysical Research. Communications (Biochem. Biophys. Res. Comraun.), 149, 960 (1987)], immunoglobulin heavy chain promoter [Cell, 41, 479] (1985)] and Enhanser [Cell, 33, 717 (1983)].
- Humanized antibody expression vectors are of the type in which the antibody H chain and the L chain are present on separate vectors or of the same vector type (hereinafter referred to as tandem type). Can be used, but the ease of construction of a humanized antibody expression vector, the ease of introduction into animal cells, and the balance of antibody H chain and L chain expression levels in animal cells are balanced. In view of the above, tandem humanized antibody expression vectors are preferred [Journal of Immunological Methods] (J ". Immunol. Methods), 167, 271 (1994)].
- the constructed humanized antibody expression vector can be used for expression of a human chimeric antibody and a human CDR-grafted antibody in animal cells.
- CDNAs encoding non-human animal antibodies for example, mouse antibody VH and VL, can be obtained as follows.
- MRNA is extracted from hybridoma cells bearing the desired mouse antibody, and cDNA is synthesized.
- the synthesized cDNA is cloned into a vector such as a phage or a plasmid to prepare a cDNA library. From the library, using the C region or V region of the existing mouse antibody as a probe, a recombinant phage having a cDNA encoding VH or a recombinant phage having a recombinant plasmid and a cDNA encoding VL Di or recombinant plasmid, respectively.
- the entire nucleotide sequence of VH and VL of the target mouse antibody on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence of VH and VL is deduced from the nucleotide sequence.
- any mouse, rat, hamster, rabbit and the like can be used as long as hybridoma cells can be produced.
- Methods for preparing total RNA from hybridoma cells include guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymol., 154, 3 (1987)], and mRNA from total RNA. Examples of the method of preparation include an oligo (dT) -immobilized cellulose column method [Molecular 'Cloning 2nd edition] and the like. Kits for preparing mRNA from hybridoma cells include Fast Track mRNA Isolation Kit (Invitrogen), Quick Prep mRNA Purification Kit (Pharmacia) and the like.
- a common method for preparing a cDNA library is a conventional method [Molecular Cloning, 2nd Edition; Ryrent, Protocols, Molecular Biology, Current Protocols in Molecular Biology, Supplement 1-34], Some are ⁇ Examples of such kits include a method using a Super Script TM Plasmid System for cDNA Synthesis and Plasraid Cloning (GIBCO BRL) and a ZAP-cDNA Synthesis Kit (Stratagene).
- any vector can be used as a vector for incorporating a cDNA synthesized by converting mRNA extracted from hybridoma cells into type II, as long as the vector can incorporate the cDNA.
- ZAP Express [Strategies, 5, 58 (1992)]
- pBluescript II SK (+) [Nucleic Acids Research, 17, 9494 (1989)]
- ⁇ zap II (Stratagene, Inc.)
- gtlO N ⁇ gtll [Denue 'cloning: ⁇ ' Pura Kutikaru approach (thigh cloning: A Practical approach), I , 49 (1985)]
- Lambda BlueMid (Clontech Co., Ltd.)
- X ExCell pT7T3 18U (Pharmacia)
- pcD2 [Molecular 'and' Cellular Biology (Mol, Cell. Biol.), 3, 280 (1983)]
- pUC18 Gene, 33, 103 (19
- any Escherichia coli can be used as long as it can introduce, express and maintain the cDNA library.
- XL1-Blue MRF ' [Strategies, 5, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088, Y1090 [Science, 222] , 778 (1983)], Marauder 522 [Journal 'ob' Molecular Biology (J. Mol. Biol.), 166, 1 (1983)], K802 [Giananore ob 'Molecular' Biology (J. Mol. Biol.), 16, 118 (1966)] and JM105 [Gene, 38, 275 (1985)].
- Methods for selecting cDNA clones encoding VH and VL of non-human animal antibodies from a cDNA library include colony-no, hybridization or plaque-hybridization methods using isotope or fluorescently labeled probes [ Molecular 'Claw Young 2nd Edition].
- a primer or a cDNA or a cDNA library synthesized from mRNA is prepared as a type III, and the polymerase is referred to as Polymerase Chain Reaction [hereinafter referred to as PCR method; Molecular 'cloning second edition; Current' Protocols 'in' CDNA encoding VH and VL can also be prepared by Molecular Pyology, Supplement 1-34].
- the cDNA selected by the above method is cleaved with an appropriate restriction enzyme or the like, it is cloned into a plasmid such as pBluescript SK (-) (manufactured by Stratagene), and a commonly used nucleotide sequence analysis method, for example, Sanger et al. Reaction, such as the dideoxy method [Procedin Das Ob The National Academy of Sciences (Proc. Natl. Acad. Sci., USA), 74, 5463 (1977)].
- the nucleotide sequence of the cDNA can be determined by analysis using an analyzer, for example, ALF DNA Sequencer (Pharmacia).
- a human-type chimeric antibody expression vector can be constructed.
- the cDNA encoding the VH and VL of the antibody of a non-human animal can be obtained by combining the nucleotide sequence at the 3 'end of the antibody of a non-human animal VH and VL with the 5' end of the CH and CL of the human antibody It is composed of a base sequence and a force, each of which is ligated to a synthetic DNA having a recognition sequence for a suitable restriction enzyme at each end.
- a human chimeric antibody expression vector can be constructed by cloning upstream of the genes encoding the CH and CL of the antibody so that they are expressed in an appropriate form.
- CDNA encoding VH and VL of the human CDR-grafted antibody can be constructed as follows. First, the amino acid sequence of the VH and VL framework (hereinafter referred to as FR) of the human antibody to which the CDRs of the VH and VL of the antibody of the target non-human animal are transplanted is selected. As the amino acid sequence of FR of human antibody VH and VL, any amino acid sequence can be used as long as it is derived from human antibody.
- the amino acid sequences of human antibody VH and VL FR amino acids and the common amino acid sequences of human antibody VH and VL FR subgroups registered in databases such as the Protein Data Bank [Sequences 'ob' protein Among them, in order to produce a human CDR-grafted antibody having sufficient activity, the FR of VH and VL of an antibody of a non-human animal of interest can be obtained. It is desirable to select an amino acid sequence having the highest possible homology (at least 60% or more) with the amino acid sequence of the amino acid.
- the amino acid sequence of the CDRs of the H region and L chain V region of the antibody of the non-human animal of interest is transplanted into the VH and VL FR amino acid sequences of the selected human antibody, and the human CDR-grafted antibody is obtained.
- Design the amino acid sequence of VH ⁇ VL Convert the designed amino acid sequence into a DNA sequence in consideration of the frequency of codons found in the nucleotide sequence of the antibody gene [sequences], "proteins", and / or immunological interest.
- the DNA sequence encoding the amino acid sequence of VH and VL of the antibody is designed. Based on the designed DNA sequence, several synthetic DNAs with a length of around 100 bases are synthesized, and PCR is performed using them. In this case, it is preferable to design six synthetic DNAs for both the H chain and the L chain in view of the reaction efficiency in PCR and the length of the DNA that can be synthesized.
- a human CDR-grafted antibody has the antigen-binding activity of the original non-human animal by simply grafting only the VH and VL CDRs of the target non-human animal antibody to the human antibody VH and VL FR. It is known that it is lower than that of antibodies [Pio / Technology 1 (BI0 / TECH 0L0GY), 9, 266 (1991)]. This is due to the fact that not only the CDRs but also some amino acid residues of FRs are directly or indirectly involved in antigen binding activity in VH and VL of the original non-human animal antibody. It is thought that the amino acid residues are changed to different amino acid residues in the FRs of VH and VL of a human antibody with CDR transplantation.
- human-type CDR-grafted antibodies use amino acid residues involved in direct binding to antigens or amino acid residues in CDRs in the amino acid sequence of FRs of VH and VL of human antibodies. Identify amino acid residues that interact with residues or maintain antibody tertiary structure and indirectly participate in antigen binding, and find them in the original non-human animal antibody It has been modified to amino acid residues to increase the reduced antigen-binding activity (Ray / Technology (BI0 / TECHN0L0GY), 9, 266 (1991)].
- Amino acid residues of FRs of VH and VL of a human antibody can be modified by the PCR method described in 3 (5) of this section using synthetic DNA for modification.
- the nucleotide sequence of the amplified product after PCR is determined by the method described in (2) of this section 3 to confirm that the target modification has been performed. (7) Construction of human CDR-grafted antibody expression vector
- the humanized CDR constructed in ( 5 ) and (6) of this section 3 is located upstream of the human antibody CH and CL coding genes of the humanized antibody expression vector described in (1) of this section 3.
- Cloning of cDNAs encoding VH and VL of the transplanted antibody can be used to construct a human CDR-grafted antibody expression vector.
- an appropriate restriction enzyme at the 5 'end of the synthetic DNA located at both ends By introducing the recognition sequence, the humanized antibody expression vector described in item 3 (1) of this section can be expressed in an appropriate form upstream of the genes encoding CH and CL of the human antibody.
- a human CDR-grafted antibody expression vector can be constructed.
- a human chimeric antibody or a human CDR-grafted antibody (hereinafter, also referred to as a humanized antibody) ) Can be obtained stably.
- Examples of a method for introducing a humanized antibody expression vector into animal cells include the electoral poration method [JP-A-2-257789; Cytotechnology, 3, 133 (1990)] and the like.
- any animal cell that can produce a humanized antibody can be used.
- the cells include Namalba cells, which are human myeloma cells.
- the host cells used in the method for producing the antibody composition of the present invention include the cells prepared in 1. above.
- G418 G418 sulfate
- Animal cell culture media include RPMI1640 medium (Nissui Pharmaceutical), GIT medium (Nippon Pharmaceutical), EX-CELL302 medium (JRH), IMDM medium (GIBCO BRL), Hybridoma-SFM A medium (GIBCO BRL) or a medium obtained by adding various additives such as fetal bovine serum (hereinafter referred to as FBS) to these mediums can be used.
- a humanized antibody By culturing in the medium, a humanized antibody can be produced and accumulated in the culture supernatant.
- the amount of humanized antibody produced in the culture supernatant and the antigen-binding activity were determined by the enzyme immunoassay
- the transformed strain can increase the amount of humanized antibody produced by using a DHFR gene amplification system or the like according to the method disclosed in Japanese Patent Application Laid-Open No. 2-2587891.
- Humanized antibodies can be purified from the culture supernatant of the transformant using a protein A column [Antibodies, Chapter 8, Monoclonal 'Antibodies].
- other purification methods usually used for protein purification can be used.
- a humanized antibody can be purified by performing a combination of gel filtration, ion exchange chromatography, and ultrafiltration.
- the molecular weight of the purified humanized antibody H chain, L chain or the entire antibody molecule can be determined by polyacrylamide gel electrophoresis [hereinafter referred to as SDS-PAGE; Nature, 227, 680 (1970)] or Wes. It can be measured by the tan plotting method [Antibodies, Chapter 12, Monoclonal 'Antebodies].
- the expression vector for Fc fusion protein is an expression vector for animal cells in which a gene encoding human F1 and a protein to be fused with the Fc region of the antibody is incorporated. It can be constructed by cloning the gene encoding the protein to be fused.
- the Fc region of a human antibody includes a region containing the CH2 and CH3 regions, as well as a region containing the hinge region and a part of CH1. Any compound may be used as long as at least one amino acid of CH2 or CH3 is deleted, substituted, added or inserted, and has substantially the activity of binding to an Fcy receptor.
- chromosomal DNA consisting of exons and introns can be used, and cDNA can also be used.
- cDNA can also be used.
- each gene sequence is used as a type II PCR method ( recruiter-I 'cloning 2nd edition; current' Protocols. '' Molequira-I 'biology, Supplement 1-34) It is possible to do.
- the expression vector for animal cells any vector can be used as long as it can integrate and express the gene encoding the c region of the human antibody. For example,
- PHSG274 [Gene, 27, 223 (1984)], pKCR [Proceedings of the world.Nachonanole Academy of Sciences (Proc. Natl. Acad. Sci. USA), 78, 1527 (1981) )], PSGld2-4 [Site Technology (Cytotechnology), 4, 173 (1990)].
- promoters and enhancers used in animal cell expression vectors include the SV40 early promoter and enhancer [Journal of Biochemistry (J. Biochem.), 101, 1307 (1987)], and Moroni murine leukemia virus. LTR [Biochemical and by off-site research 'Research' Communications (Biochem. Biophys. Res. Commun.), 149, 960 (1987)], Promoter of immunoglobulin H chain [Cell, 41, 479 (1985)] and Enhanser [Cell, 33, 717 (1983)].
- DNA encoding a protein to be fused with the Fc region of a human antibody can be obtained as follows.
- MRNA is extracted from cells or tissues that express the protein to be fused with the desired Fc, and cDNA is synthesized.
- the synthesized cDNA is cloned into a vector such as a phage or plasmid to prepare a cDNA library.
- a recombinant phage or recombinant plasmid having a cDNA encoding the target protein is isolated using the gene sequence portion of the target protein as a probe.
- the entire nucleotide sequence of the target protein on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence is estimated from the nucleotide sequence.
- any animal such as a mouse, a rat, a mouse, a muster, a gray heron, and the like can be used as long as cells and tissues can be extracted therefrom.
- Methods for preparing total RNA from cells and tissues include the guanidine thiocyanate-cesium acetate method with triphenylenole [Methods in Enzymol., 154, 3 (1987)], and raRNA from total RNA. Examples of the method for preparing the same include the Oligo (dT) immobilized cellulose column method (Molecular 'Clawing second edition) and the like. Kits for preparing raRNA from cells and tissues include Fast Track mRNA Isolation Kit (Invitrogen), Quick Prep mRNA Purification Kit (Pharmacia) and the like.
- Methods for cDNA synthesis and preparation of cDNA libraries include conventional methods (Molecular Cloning 2nd Edition; Current Protocols in Molecular Kit Biology, Supplement 1-34), or commercially available kits. For example, a method using a Super Script TM Plasmid System for cDNA Synthesis and Plasmid Cloning (GIBCO BRL) or a ZAP-cDNA Synthesis Kit (Stratagene) can be used.
- any vector can be used as a vector for incorporating a cDNA synthesized as a type II mRNA extracted from cells or tissues, as long as the vector can incorporate the cDNA.
- ZAP Express [scan Toratejizu (Strategies), 5, 58 ( 1992)], pBluescript II SK (+) [ Nucleic Ashi''s.
- any Escherichia coli can be used as long as it can introduce, express and maintain the cDNA library.
- XL1-Blue MRF [Strategies, 5, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088, Y1090 [Science, 222, 778] (1983)]
- Marauder 522 Marournal of Molecular Biology (j. Mol. Biol.), 166, 1
- primers can be prepared, and a cDNA or cDNA library synthesized from mRNA can be used as a type III cDNA to prepare a cDNA encoding the target protein by PCR.
- a PCR method can be used as a method for fusing the target protein with the Fc region of a human antibody.
- any synthetic oligo DNA (primer) on the 5 'and 3' sides of the gene sequence of the target protein, and perform PCR to obtain a PCR product.
- an arbitrary primer is set for the gene sequence of the Fc region of the human antibody to be fused, and a PCR product is obtained.
- a primer is set so that the same restriction enzyme site or the same gene sequence exists on the 3 ′ side of the PCR product of the protein to be fused and the 5 ′ side of the PCR product of the Fc region.
- the mutation is introduced by using a primer into which the mutation has been introduced. Both genes are ligated by performing further PCR using the obtained two types of PCR fragments.
- ligation can be performed by performing ligation after treating with the same restriction enzyme.
- the gene sequence ligated by the above method is cleaved with an appropriate restriction enzyme or the like, and then cleaved into a plasmid such as pBluescript SK (-) (manufactured by Stratagene), and a commonly used nucleotide sequence analysis method, for example, Sanger The dideoxy method [Proc. Natl. Acad. Sci. USA], 74, 5463 (1977)] or the ABI PRISM 377 DNA theatre (PE Biosystems).
- the base sequence of the DNA can be determined by performing analysis using a base sequence analyzer such as that manufactured by the company.
- a transformant that stably produces the Fc fusion protein By introducing the Fc fusion protein expression vector described in the above (1) into an appropriate animal cell, a transformant that stably produces the Fc fusion protein can be obtained.
- Examples of a method for introducing an Fc fusion protein expression vector into animal cells include an electroporation method [Japanese Patent Laid-Open No. 2-257891; Cytotechnology, 3, 133 (1990)] and the like.
- any animal cell that can produce the Fc fusion protein can be used. Specifically, it is derived from mouse myeloma cells NS0 cells, SP2 / 0 cells, Chinese hamster ovary cells CHO / dhfr- cells, CH0 / DG44 cells, rat myeloma YB2 / 0 cells, IR983F cells, and Syrian hamster kidney.
- BHK cells human myelo Mamal cells, such as Namalva cells, and preferably, CH0 / DG44 cells, rat myeloma YB2 / 0 cells, which are Chinese hamster ovary cells, and host cells used in the method of the present invention according to the above item 1. And the like.
- a transformant that stably produces the Fc fusion protein can be selected using a medium for culturing animal cells containing a drug such as G418 according to the method disclosed in Japanese Patent Application Laid-Open No. 2-257891.
- a medium for culturing animal cells containing a drug such as G418 As culture media for animal cells, RPMI1640 medium (Nissui Pharmaceutical), GIT medium (Nippon Pharmaceutical), EX-CELL302 medium (JRH), IMDM medium (GIBCO BRL), Hybridoma-SFM medium (Manufactured by GIBCO BRL) or a medium obtained by adding various additives such as fetal bovine serum to these media.
- the Fc fusion protein can be produced and accumulated in the culture supernatant by culturing the obtained transformant in a medium.
- the production amount and antigen-binding activity of the Fc fusion protein in the culture supernatant can be measured by ELISA or the like.
- the transformed strain can increase the production amount of the Fc fusion protein using a dhfr gene amplification system or the like according to the method disclosed in JP-A-2-2577891.
- the Fc fusion protein can be purified from the culture supernatant of the transformant using a protein A column or a protein G column (Antibodies, Chapter 8, Monoclonal Antipodis).
- a protein A column or a protein G column Antibodies, Chapter 8, Monoclonal Antipodis
- other purification methods usually used for protein purification can be used.
- purification can be performed by a combination of gel filtration, ion-exchange chromatography, ultrafiltration, and the like.
- the molecular weight of the entire purified Fc fusion protein molecule can be determined by SDS-PAGE [Nature, 227, 680 (1970)] or Western blotting (Antibodies, Chapter 12, Monoclonal 'Antipodise'). Can be measured.
- the method for producing an antibody using an animal cell as a host cell has been described above. However, as described above, the antibody can be produced in a bacterium, a yeast, an insect cell, a plant cell, or an animal or plant.
- the host cell is transformed into the N-glycoside-linked complex type sugar chain reducing terminal N-terminal using the method described in 1 above. After making the 6th position of acetyltilcosamine and the 1st position of fucose resistant to a lectin recognizing a sugar chain structure having an ⁇ -bond, the cells are cultured, and the desired antibody composition is purified from the culture.
- the antibody composition of the present invention can be produced. 4. Evaluation of activity of antibody composition
- the binding activity to an antigen and the binding activity to an antigen-positive cultured cell line are determined by ELISA method and fluorescent antibody method [Cancer Immunology] (Cancer Immunol). I bandit mother.), 36, 373 (1993)]. Cytotoxic activity against antigen-positive cultured cell lines can be evaluated by measuring CDC activity, ADCC activity, etc. [Cancer Immunol. Immunother., 36, 373 (1993)] .
- the safety and therapeutic effect of the antibody composition in humans can be evaluated using an appropriate model of an animal species relatively close to humans, such as a cynomolgus monkey.
- the sugar chain structure of the antibody molecule expressed in the host cell can be determined according to the analysis of the sugar chain structure of a normal glycoprotein.
- the sugar chains bound to IgG molecules are composed of neutral sugars such as galactose, mannose, and fucose; amino sugars such as N-acetyl danolecosamine; and acidic sugars such as sialic acid. Analysis and sugar chain structure analysis using a two-dimensional sugar chain mapping method can be performed.
- composition analysis of the sugar chain of an antibody molecule neutral sugar or amino sugar is released by acid hydrolysis of the sugar chain with trifluoroacetic acid or the like, and the composition ratio can be analyzed.
- the composition ratio can also be analyzed by a fluorescent labeling method using 2-aminopyridine. Specifically, the acid hydrolysis is carried out according to a known method [Agricultural, And, Biological Chemistry (Agruc. Biol. Chem.), 55 (1), 283-284 (1991)].
- the disassembled sample can be fluorescently labeled with 2-aminopyridylation and analyzed by HPLC to calculate the composition ratio.
- Structural analysis of the sugar chain of the antibody molecule can be performed by two-dimensional sugar chain mapping [Analytical Biochemistry., 171, 73 (1988), Biochemistry Experimental Method 23—Glycoprotein sugar chain research method (Academic Society) Publishing Center) edited by Reiko Takahashi (1989)].
- the X-axis indicates the retention time or elution position of the reverse-phase chromatography monosaccharide
- the Y-axis indicates the retention time or elution position of the sugar chain by normal-phase chromatography. It is a method of estimating the sugar chain structure by plotting and comparing those results with those of known sugar chains.
- the antibody is hydrazinolyzed, the sugar chain is released from the antibody, and the sugar chain is fluorescently labeled with 2-aminopyridine (hereinafter abbreviated as PA) [Journal of Biochemistry (J. Biochem.), 95, 197 (1984)], the sugar chain is separated from excess PA reagent by gel filtration, and reversed-phase chromatography is performed. Next, normal phase chromatography is performed on each peak of the separated sugar chain. Based on these results, it was plotted on a two-dimensional sugar chain map, and the sugar chain standard (TaKaRa), the literature [Analytical 'Biochemistry (Anal. Biochem.), 171, 73 (1988)] The sugar chain structure can be estimated from the comparison of spots.
- PA 2-aminopyridine
- the antibody composition is composed of antibody molecules having different sugar chain structures binding to the Fc region of the antibody.
- the antibody composition of the present invention is characterized in that, among all N-glycoside-linked complex-type sugar chains that bind to the Fc region, the proportion of sugar chains in which fucose is not linked to N-acetyldarcosamine at the sugar chain reducing end is the parent strain.
- This is an antibody composition higher than the antibody composition produced by NS0 cells, which is characterized by high ADCC activity.
- Such an antibody composition can be identified by using the method for analyzing the sugar chain structure of the antibody molecule described in 4. above. It can also be identified by using an immunological quantification method using a lectin.
- a lectin that recognizes the sugar chain structure of the antibody molecule constituting the antibody composition is labeled, and the labeled lectin is allowed to react with the sample antibody composition. Next, the amount of the complex of the labeled lectin and the antibody molecule is measured.
- Lectins used to identify the sugar chain structure of antibody molecules include, for example, WGA (wheat-germ agglutinin from T. vulgaris), ConA (concanavalin A from C ⁇ _ensiformis), and RIC (from R. communis). Toxin), L-PHA (leukoagglutinin from P.
- ACL Amaranthus caudatus Lectin
- BPL Bauhinia purpurea Lectin
- DSL Datura stramonium Lectin
- DBA Dolichos bif lorus Agglutinin
- EBL Elderberry Balk
- ECL Erythrina cristagalli Lectin
- EEL Euonymus europaeus Lectin
- GNL Galanthus nivalis Lectin
- GSL Griffonia simplicifolia Lectin
- HPA Helix pomatia Agglutinin
- HHL Hippeastrum Hybrid Lectin
- LEL Lycopersicon esculentum Lectin; ⁇ MAL (Maackia amurensis Lectin) MPL (Maclura pomifera Lectin), NPL (Narcissus pseudonarcissus Lectin),
- a lectin that specifically recognizes the sugar chain structure in which fucose is bound to N-acetyldarcosamine at the reducing end of N-darcoside-linked complex sugar chains enables detailed sugar chain structure .
- Specific examples thereof include lentil lectin LCA (Lentil Agglutinin from Lens Culinaris) Endome lectin PSA (Pea Lectin from Pi sum sativum), Broad bean lectin VFA (from Vicia faba Agglutinin) ⁇ Hilochawantake lectin L (Lectin derived from Aleuria aurantia).
- the antibody composition obtained according to the present invention has high ADCC activity.
- Antibodies having high ADCC activity are useful in the prevention and treatment of various diseases including cancer, inflammatory diseases, autoimmune diseases, immune diseases such as allergies, cardiovascular diseases, and viral or bacterial infections.
- Cancer cells ie, malignant tumors, have proliferating cancer cells.
- Ordinary anticancer drugs are characterized by inhibiting the growth of cancer cells.
- an antibody having high ADCC activity can treat cancer by damaging cancer cells by a cell-killing effect, and is therefore more effective as a therapeutic agent than ordinary anticancer drugs.
- the antitumor effect of antibody drugs alone is often inadequate at present, and combination therapy with chemotherapy is performed [Science, 280, 1197, 1998]. If a stronger antitumor effect of the antibody composition alone is observed, the dependence on chemotherapy is reduced, and side effects are reduced.
- the in vivo reaction in those diseases is triggered by the release of mediator molecules by the immune cells, so the immune cells are eliminated using antibodies with high ADCC activity Thereby, the energy reaction can be suppressed.
- Cardiovascular diseases include arteriosclerosis. Atherosclerosis is currently treated with a balloon catheter, but cardiovascular disease can be prevented and treated by suppressing the proliferation of arterial cells in post-treatment restenosis using antibodies with high ADCC activity. .
- Antibodies that recognize tumor-associated antigens include anti-GD2 antibody (Anticancer Res., 13, 331-336, 1993), anti-GD3 antibody (Cancer Immunol. Iramunother., 36, 260-266, 1993), anti-GM 2 antibody (Cancer Res., 54, 1511-1516, 1994), anti-HER2 antibody (Proc. Natl. Acad. Sci.
- Antibodies that recognize antigens associated with allergy or inflammation include anti-interleukin-6 antibody (Immunol. Rev., 127, 5-24, 1992) and anti-interleukin-6 receptor antibody (Molecular Immunol., 31, 371- 381, 1994), anti-interleukin 5 antibody (Immunol. Rev., 127, 5-24, 1992), anti-interleukin 5 receptor antibody, anti-interleukin 4 antibody (Cytokine, 3, 562-567, 1991) ), Anti-interleukin 4 receptor antibody (J. Immunol.
- anti-tumor necrosis factor antibody Hybridoma, 13, 183-190, 1994
- anti-tumor necrosis factor Receptor antibody Molecular Pharmacol., 58, 237-245, 2000
- anti-CCR4 antibody Nature, 400, 776-780, 1999
- anti-chemokine antibody J. Immunol. Meth., 174, 249-257, 1994
- an anti-chemokine receptor antibody J. Exp. Med., 186, 1373-1381, 1997.
- Antibodies that recognize antigens related to cardiovascular diseases include anti-GpIIb / IIIa antibodies (J. Immunol., 152, 2968-2976, 1994) and anti-platelet-derived growth factor antibodies (Science, 253, 1129-1132, 1991). ), An anti-platelet-derived growth factor receptor antibody (J. Biol. Chem., 272, 17400-17404, 1997) or an anti-coagulation factor antibody (Circulation, 101> 1158-1164, 2000).
- Antibodies that recognize antigens associated with autoimmune diseases include anti-self DNA antibodies (Immunol. Letters, 72, 61-68, 2000). Antibodies that recognize antigens associated with viral or bacterial infection include anti-gp120 antibodies (Structure, 8, 385-395, 2000), anti-CD4 antibodies (J. Rheumatology, 25, 2065--2076, 1998), anti-CCR4 Antibody or anti-verotoxin antibody (J. Clin. Microbiol., 37, 396-399, 1999).
- the above antibodies can be obtained from public institutions such as ATCC (The American Type Culture Collection), RIKEN Cell Development Bank, Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology, or Dai Nippon Pharmaceutical Co., Ltd., R & D SYSTEMS, PharMingen , Cosmo Bio Inc., Funakoshi Co., Ltd., and other private reagent sales companies.
- ATCC The American Type Culture Collection
- RIKEN Cell Development Bank Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology, or Dai Nippon Pharmaceutical Co., Ltd., R & D SYSTEMS, PharMingen , Cosmo Bio Inc., Funakoshi Co., Ltd., and other private reagent sales companies.
- the medicament containing the antibody composition obtained by the present invention can be administered alone as a therapeutic agent, it is usually mixed with one or more pharmacologically acceptable carriers, and It is desirable to provide it as a pharmaceutical preparation produced by any method well known in the pharmaceutical art.
- intravenous administration is preferred.
- Dosage forms include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes and the like.
- Formulations suitable for oral administration include emulsions, syrups, capsules, tablets, powders, granules and the like.
- Liquid preparations such as emulsion syrups include water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, p -Can be manufactured using preservatives such as hydroxybenzoic acid esters and flavors such as strawberry flavor and peppermint as additives.
- Capsules, tablets, powders, granules, etc. are excipients such as lactose, grape bran, sucrose, mantole, etc., disintegrants such as starch, sodium alginate, lubricating agents such as magnesium stearate, talc, etc. And a binder such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, a surfactant such as fatty acid ester, and a plasticizer such as glycerin as additives.
- Formulations suitable for parenteral administration include injections, suppositories, sprays and the like. Injectables are prepared using a carrier consisting of a salt solution, a pudose solution, or a mixture of both. Alternatively, a powder injection can be prepared by freeze-drying the antibody composition according to a conventional method and adding sodium chloride thereto.
- Suppositories are prepared using carriers such as cocoa butter, hydrogenated fats or carboxylic acids.
- a nebulizer is prepared using the antibody composition itself or a carrier or the like which does not irritate the oral and respiratory mucosa of the recipient and disperses the antibody composition as fine particles to facilitate absorption. .
- the carrier include lactose and glycerin.
- Formulations such as aerosols and dry powders are possible depending on the properties of the antibody composition and the carrier used. Also, in these parenteral preparations, the components exemplified as additives in the oral preparation can be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., but is usually lO ⁇ g / kg Omg / kg per adult per day.
- Methods for examining the antitumor effect of the antibody composition on various tumor cells include CDC activity measurement and ADCC activity measurement in in vitro experiments, and mouse and other experimental animals in in vivo experiments. And antitumor experiments using a tumor system.
- FIG. 1 shows the results showing the antigen-binding activity of anti-CCR4 chimeric antibodies produced by the parent strain NS0 cell line and lectin-resistant NS0 strain.
- the vertical axis of the graph, the absorbance at a wavelength of 4 9 0 nm, the horizontal axis indicates the concentration of the reaction solution of the anti-CCR4 chimeric antibody.
- ⁇ indicates the antigen binding activity of the NS0 / CCR4 antibody
- ⁇ indicates the antigen binding activity of the NS0 / LCA-CCR4 antibody.
- FIG. 2 shows the results of evaluating the ADCC activity of the anti-CCR4 chimera antibody produced by the parent strain NSO cell line and lectin-resistant NS0 strain.
- the vertical axis of the graph shows the cytotoxic activity of the target cells, and the horizontal axis shows the concentration of the anti-CCR4 chimeric antibody in the reaction solution.
- FIG. 3 shows elution diagrams obtained by analyzing the PA-linked sugar chains prepared from the purified anti-CCR4 chimeric antibody by reversed-phase HPLC.
- the vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- FIG. 4 shows the results showing ADCC activity of an anti-CCR4 human chimeric antibody produced by a lectin-resistant strain.
- the vertical axis indicates cytotoxic activity, and the horizontal axis indicates antibody concentration.
- the mouth indicates the activity of the 5-03 strain, the country indicates the activity of the CH0 / CCR4-LCA strain, ⁇ indicates the activity of the antibody produced by the CH0 / CCR4-AAL strain, and ⁇ indicates the activity of the antibody produced by the CH0 / CCR4-PHA strain.
- FIG. 5 shows the results of evaluating the 0-activity activity of the anti-CCR4 human chimeric antibody produced by the lectin-resistant strain.
- the vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- the mouth indicates the YB2 / 0 strain (KM2760 # 58_35-16), the ⁇ indicates the 5-03 strain, and the hata indicates the active individual of the antibody produced by the CH0 / CCR4-LCA strain.
- FIG. 6 is a diagram showing an elution diagram obtained by analyzing the PA-Danigar sugar chain prepared from the purified anti-CCR4 humanized chimeric antibody by reverse-phase HPLC.
- the vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- Figure 6A shows the antibody produced by strain 5-03
- Figure 6B shows the antibody produced by strain CH0 / CCR4-LCA
- Figure 6C shows the antibody produced by strain CH0 / CCR4-AAL
- Figure 6D Shows the results of analysis of the antibody produced by the CH0 / CCR4-PHA strain.
- FIG. 7 is a diagram showing the first step of construction of an expression vector for GMD derived from CH0 cells (total of 6 steps).
- FIG. 8 is a view showing a second step of construction of an expression vector for GMD derived from CH0 cells (a total of 6 steps).
- FIG. 9 is a diagram showing a third step of the construction of a GMD-derived GMD expression vector (6 steps in total).
- FIG. 10 is a view showing the fourth step of the construction of a GMD-derived GMD expression vector (6 steps in total).
- FIG. 11 is a view showing a fifth step of the construction of the expression vector for GMD derived from CH0 cells (six steps).
- FIG. 12 is a view showing a sixth step of the construction of an expression vector for GMD derived from CH0 cells (a total of six steps).
- FIG. 13 is a graph showing the degree of resistance of the CH0 / CCR4-LCA strain expressing GMD to LCA lectin.
- FIG. 3 is a diagram in which the measurement was performed twice with the survival rate of a cell group cultured without adding LCA lectin being 100%.
- 249 is CH0 / CCR4- into which the expression vector pAGE249 has been introduced.
- Fig. 3 shows the survival rate of LCA strains against LCA lectin.
- GMD indicates the degree of resistance to the LCA lectin of the CH0 / CCR4-LCA strain into which the GMD expression vector pAGE249GMD has been introduced.
- FIG. 14 is a view showing ADCC activity of an anti-CCR4 chimeric antibody produced by a cell group of the CH0 / CCR4-LCA strain expressing GMD.
- the vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- Fig. 15 shows the elution diagram obtained by reverse-phase HPLC analysis of the PA-Danigar sugar chain prepared from the anti-CCR4 chimeric antibody purified from the CH0 / CCR4-LCA strain expressing the GMD gene. It is.
- the vertical axis shows the relative fluorescence intensity, and the horizontal axis shows the elution time.
- FIG. 16 shows elution diagrams obtained by analyzing the PA-linked sugar chains prepared from the purified anti-GD3 chimeric antibody by reverse phase HPLC.
- the vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- FIG. 17 shows the results of evaluating the antigen-binding activity of the anti-GD3 chimeric antibody.
- the vertical axis of the graph indicates the absorbance at a wavelength of 490 nm in the ELISA reaction, and the horizontal axis indicates the concentration of the anti-GD3 chimeric antibody in the reaction solution.
- FIG. 18 shows the results of evaluating the ADCC activity of the anti-GD3 chimeric antibody.
- the vertical axis of the graph indicates the degree of target cell cytotoxicity calculated by the formula shown in section 2 of Example 2, and the horizontal axis indicates the concentration of the anti-GD3 chimeric antibody in the reaction solution.
- FIG. 19 is a diagram showing the construction process of plasmid pBS-2B8L.
- FIG. 20 is a diagram showing a construction process of plasmid pBS-2B8Hm.
- FIG. 21 is a diagram showing a construction process of a plasmid pKANTEX2B8P.
- Figure 22 shows the results of measuring the binding activity of the purified anti-CD20 chimeric antibody R92-3-1 antibody and Rituxan TM to human CD20-expressing cells Raji cells by changing the antibody concentration using the fluorescent antibody method. is there.
- the relative fluorescence intensity at each concentration is shown on the vertical axis, and the antibody concentration is shown on the horizontal axis.
- the image shows the Rituxan TM, and the image ⁇ shows the 1 "activity of the R92-3-1 antibody.
- FIG. 23 shows the results of measuring the binding activity of the purified anti-CD20 chimeric antibody R92-3-1 antibody Rituxan TM to human CD20-negative cells CCRF-CEM cells using the fluorescent antibody method.
- FIG. 24 shows ADCC activity of purified anti-CD20 chimeric antibody KM3065 and Rituxan TM on human CD20-expressing cells.
- A is for Raji cells
- B is for Ramos cells
- C is for WIL2-S cells.
- the vertical axis shows the cytotoxic activity
- the horizontal axis shows the antibody concentration.
- ⁇ indicates Rituxan TM activity
- ⁇ indicates R92-3-1 antibody activity.
- FIG. 25 shows an elution diagram obtained by preparing a PA-linked sugar chain from the purified anti-CD20 chimeric antibody R92-3-1 antibody and Rituxan TM and analyzing it by reversed-phase HPLC.
- the vertical axis shows the relative fluorescence intensity
- the horizontal axis shows the elution time.
- FIG. 26 is a diagram showing the construction of plasmid U6_pre_sense.
- FIG. 27 is a diagram showing the construction of a plasmid P BS_BglII.
- FIG. 28 is a diagram showing the construction of plasmid U6_pre_antisense.
- FIG. 29 is a diagram showing construction of plasmid U6-sense_B.
- FIG. 30 is a diagram showing construction of plasmid U6_sense-R.
- FIG. 31 is a diagram showing construction of plasmid U6_antisense_B.
- FIG. 32 is a diagram showing construction of plasmid U6-antisense_R.
- FIG. 33 is a diagram showing construction of plasmid U6_FUT8_B.
- FIG. 34 is a diagram showing construction of plasmid U6_FUT8_R.
- FIG. 35 is a diagram showing construction of plasmid U6-FUT8_B_puro.
- FIG. 36 is a diagram showing construction of plasmid U6-FUT8-R-puro.
- FIG. 37 is a view showing a decrease in the amount of FUT mRNA in the FUT8 siRNA-introduced strain. The ratio of the amount of FUT8mRA expressed in each cell line to the amount of] 3-actin mRNA is shown.
- FIG. 38 shows an elution diagram obtained by analyzing the PA disaccharide sugar chain prepared from six kinds of anti-CCR4 chimeric antibodies by reverse-phase HPLC. The vertical axis shows the relative fluorescence intensity, and the horizontal axis shows the elution time.
- FIG. 39 shows the results obtained by measuring the binding activity to CCR4 of six types of anti-CCR4 chimeric antibodies having no ⁇ 1,6-fucose and different ratios of sugar chain antibody molecules by changing the antibody concentration.
- the vertical axis shows the binding activity to CCR4, and the horizontal axis shows the antibody concentration.
- the country has anti-CCR4 chimeric antibody (46%), the mouth has anti-CCR4 chimeric antibody (39%), has 0-4 chimeric antibody (27%), ⁇ has anti-CCR4 chimeric antibody (18%), Okina has anti-CCR4 chimeric antibody (18%).
- the CCR4 chimeric antibody (9%) shows the activity of the anti-CCR4 chimeric antibody (8%).
- FIG. 40 shows ADCC activity against CCR4 / EL-4 cells of anti-CCR4 chimeric antibodies having different proportions of 1,6-fucose-free glycan antibody molecules using donor ⁇ effector cells. is there.
- the vertical axis shows the cytotoxic activity, and the horizontal axis shows the antibody concentration.
- FIG. 40 shows ADCC activity against CCR4 / EL-4 cells of anti-CCR4 chimeric antibodies having different proportions of 1,6-fucose-free glycan antibody molecules using donor ⁇ effector cells. is there.
- the vertical axis shows the cytotoxic activity,
- FIG. 42 is a diagram showing the steps of preparing a plasmid CH0-GMD in which the 5 ′ end of clone 34-2 was introduced into the 5 ′ end of GMD cDNA clone 22-8 derived from CH0 cells.
- Example 1 Production of lectin-resistant NS0 cells and production of an antibody composition using the cells
- RPMI-FBS (IO) medium fetal calf serum
- the cells were cultured in a flask for culture 75 cm 2 (manufactured by Iwaki Glass Co., Ltd.) and grown to just before confluence.
- N-methyl- ⁇ '-nitro-N-nitrosoguanidin (hereinafter referred to as MNNG, manufactured by Sigma) was added.
- lentil lectin (Lens culinaris agglutinin; hereinafter referred to as LCA, manufactured by Vector) at a final concentration of 1 mg / ml in the medium was added.
- these strains were named NS0-LCA strains.
- tandem expression vector pKANTEX2160 for the anti-CCR4 chimeric antibody described in W001 / 64754 stable cells for producing the anti-CCR4 chimeric antibody were produced as follows.
- 10 ⁇ g of the anti-CCR4 chimeric antibody expression vector pKANTEX2160 was introduced into the parent cell line NS0 or NS0-LCA of 4 ⁇ 10 6 cells by the electroporation method [Cytotechnology, 3, 133, 1990] Then, suspend the cells in 10 ml of RPMI-FBS (10) medium and place them on a 96-well culture plate (manufactured by Sumitomo Bakelite) at 200 ⁇ l / well. Noted. After culturing at 37 ° (:, 24 hours) in a 5% CO 2 incubator, G418 was added to a concentration of 0.5 mg / ml, followed by culturing for 1 to 2 weeks. Appeared, and the culture supernatant was recovered from the wells in which proliferation was observed, and the amount of accumulated anti-CCR4 chimeric antibody in the supernatant was measured by the ELISA method described in Example 1 (3).
- RPMI-FBS (10) medium containing 50 nM The cells were suspended at a concentration of about 2 ⁇ 10 5 cells / ml, and each 2 ml was dispensed into a 24-well plate (manufactured by Greiner). 5 ° /. And 1-2 weeks of culture at 37 ° C for at C0 2 incubator within one induced transformants showing 50 nM MTX resistance.
- the expression level of the anti-CCR4 chimeric antibody in the culture supernatant of the wells in which the transformed strain was found to grow was measured by the ELISA method described in Example 1, (3).
- the MTX concentration was gradually increased to 200 nM and 500 ⁇ in the same manner as above, and finally G418 was 0.5 mg /
- a transformant capable of growing in an RPMI-FBS (IO) medium containing 500 ml of MTX at a concentration of 500 nM and highly producing an anti-CCR4 chimeric antibody was obtained.
- One transformed strain was selected from each of the NS0 strain and the NS0-LCA strain.
- a transformant derived from NS0 strain was named NS0 / CCR4 strain
- a transformant derived from NS0-LCA strain was named NSO / LCA-CCR4 strain.
- the NSO / LCA-CCR4 strain was filed with the Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (AIST, Tsukuba, Ibaraki, Japan) on March 14, 2002 at FERM BP- Deposited as 7964.
- the concentration of the anti-CCR4 antibody in the culture supernatant was measured as follows.
- IgG anti-human immunoglobulin G
- SIGMA serum albumin
- Tween-PBS 0. 05% T W een20 PBS containing (manufactured by Wako Pure Chemical Industries, Ltd.) (hereinafter, referred to as Tween-PBS), 1 ° / .
- the transformed cells expressing the anti-CCR4 chimeric antibody obtained in Example 1 (2) were hybridoma-SFM containing MTX at a final concentration of 500 nM and bovine serum albumin (Invitrogen) at a final concentration of 0.2%.
- the cells were suspended in a medium (manufactured by INVITROGEN) at a concentration of 2 ⁇ 10 5 cells / ml, and seeded in a suspension culture flask (manufactured by Iwaki Glass). 5% C0 by culturing for 7 days at 37 ° C for within 2 incubator culture supernatant was recovered.
- the anti-CCR4 chimeric antibody was purified from each culture supernatant using a Prosep-A (Millipore) column and gel filtration.
- the antibodies obtained were named the NSO / LCA-CCR4 antibody produced by the NS0 / LCA-CCR4 strain and the NS0 / CCR4 antibody produced by the NS0 / CCR4 strain.
- Compound 1 (SEQ ID NO: 1) was selected as a human CCR4 (hCCR4) extracellular domain peptide capable of reacting with the anti-CCR4 chimeric antibody, and synthesized as follows.
- hCCR4 human CCR4
- Glx L-glutamic acid or L-glutamine
- Trt Trityl
- Fmoc-Thr (tBu) _0H NCK-9-Fluorenylmethyloxycarbonyl- 0-t-butyl-L-
- Fmoc-Lys (Boc) -OH ⁇ -9-fluorenylmethyloxycarbonyl- ⁇ --butoxycarbonyl- L-lysine
- Fmoc-Asn (Trt) _0H N a -9 -Fluorenylmethyloxycarpoel- ⁇ -trityl-L-asparagine
- Fmoc-Asp (OtBu) -OH Nct-9-Fluorenylmethinoleoxycarbinole-L-aspartate- ⁇ _t-petit / leestenole
- Fmoc-Glu (OtBu) -OH Na—9-Fluorenylmethyloxycarbonyl-L-glutamic acid- ⁇ -t-butynoleester
- DTT dithiothreitol Compound 1 (SEQ ID NO: 1) (H-Asp-Glu-Ser-Ile-Tyr-Ser-Asn-Tyr-Tyr-Leu-Tyr-Glu- Ser-Ile-Pro-Lys-Pro-Cys -OH)
- step (a) a condensation reaction is carried out using Fraoc-Lys (Boc) -0H.
- H-Lys In step (a), Fmoc_Pro-OH, Fmoc-lie-OH, Fmoc-Ser (tBu) -OH, and Fmoc-Glu (OtBu)- (A) to (d) were repeated using OH, Fmoc-Tyr (tBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, and Fmoc-Tyr (tBu) _0H in this order.
- step (a) a condensation reaction was performed using Fmoc-Asn (Trt) -0H, and after the washing step of (b), the Fmoc-Asn (Trt) -OH of step (a) was used again. After repeating the condensation reaction and the washing step of (b), the deprotection steps of (and (d) were performed.
- This crude product was dissolved in 2 ml of DMF in the presence of 60 mg of DTT, and then purified by HPLC using a reversed-phase column (manufactured by Shiseido, CAPCELL PAK C18 30 Maraud I.D.X 25 mm). Elution was performed by a linear concentration gradient method in which a 90% aqueous solution of acetonitrile containing 0.1% of TFA was added to a 0.1% aqueous solution of TFA, and the mixture was detected at 220 nm to obtain a fraction containing compound 1. This fraction was lyophilized to give 2.5 mg of compound 1.
- reaction solution was dialyzed overnight against PBS at 4 ° C, sodium azide was added to a final concentration of 0.05%, and the mixture was filtered through a 0.22 mm filter. One solution was used.
- Tween-PBS PBS containing 0.05% Tween20
- each gel was washed with Tween-PBS, and a peroxidase-labeled goat anti-human IgG (v) antibody solution (American Qualex) diluted 6000-fold with 1% BSA-PBS was used as a secondary antibody solution.
- v peroxidase-labeled goat anti-human IgG
- BSA-PBS 1% BSA-PBS
- Each was added at 50 ⁇ 1 ⁇ l, and reacted at room temperature for 1 hour.
- the plate was washed with Tween-PBS, and the color was developed by adding an ABTS substrate solution at 50 / z L / well, and after 20 minutes, the reaction was stopped by adding a 5% SDS solution to L / water. Thereafter, 0D415 was measured.
- FIG. 1 shows the results of examining the binding activity by changing the concentration of the added anti-CCR4 chimeric antibody. As shown in FIG. 1, the two types of anti-CCR4 chimeric antibodies exhibited the same binding activity to CCR4 peptide.
- the ADCC activity of the anti-CCR4 chimeric antibody was measured as follows using CCR4 / EL-4 (W001 / 64754), a human CCR4 high-expressing cell line, as target cells. (2-2-1) Preparation of target cell solution
- the amount of spontaneously dissociated 51 Cr was determined by performing the same operation as above using only the medium instead of the effector cell solution and the antibody solution, and measuring the amount of 51 Cr in the supernatant.
- the total amount of dissociated 51 Cr can be determined by adding only the medium instead of the antibody solution and adding 1 N hydrochloric acid instead of the effector-cell solution, and performing the same operation as above, and measuring the amount of 51 Cr in the supernatant. I asked.
- ADCC activity was determined by the following equation (1). 51 Cr amount one natural dissociation 51 of the specimen supernatant
- ADCC activity (%) X 100 (1 ) total dissociated 51 Cr amount one natural dissociation 51 Cr amount The results are shown in FIG. It was confirmed that the activity of the NSO / LCA-CCR4 antibody was significantly improved as compared with the NS0 / CCR4 antibody.
- Example 3 Carbohydrate analysis of anti-CCR4 chimeric antibody
- the sugar chain analysis of the anti-CCR4 chimeric antibody purified in (1) of Example 2 was performed. Purified antibody was replaced with solution 10 mM KH 2 P0 4 with Ultrafree 0. 5-10K (Millipore). The replacement magnification was 80 times or more. The concentration of the solution-substituted antibody was measured using UV-1600 (manufactured by Shimadzu Corporation). From the amino acid sequence of the antibody, the molar absorption constant was calculated using the formula (2) [Advances in Protein Chemistry, 12, 303, 1962], and the absorbance at 280 nm was changed to 1.0. The concentration was determined as 38 mg / ml.
- ⁇ 1 ⁇ , ⁇ 1 / 1 ⁇ X nl + BX n2 + CX n3
- nl Number of tributophan per antibody molecule
- n2 Number of tyrosine per antibody molecule
- n3 Number of cystine per antibody molecule
- MW Antibody molecular weight (g / mol) 100 ⁇ g of the antibody was put into a test tube for Hydraclub S-204, and dried by a centrifugal concentrator.
- the test tube in which the sample was dried was subjected to hydrazine decomposition using a hydra club manufactured by Honen. Hydrazine was reacted at 110 ° C. for 1 hour using a hydrazine decomposition reagent manufactured by Honen [Method of Enzymology, 83, 263 (1982)]. After the reaction, hydrazine was distilled off under reduced pressure, and the reaction vessel was left for 30 minutes to return to room temperature.
- a 2-aminopyridine solution was prepared by adding 760 ⁇ l of HC1 to lg of 2-aminopyridine (1 XPA solution) and diluting the solution 10-fold with reverse osmosis purified water (10-fold dilution ⁇ solution).
- a sodium borohydride solution was prepared by adding 20 ⁇ l of 1 ⁇ PA solution and 430 ⁇ l of reverse osmosis purified water to 10 mg of sodium borohydride.
- the column was equilibrated with a buffer solution (pH 3.8) and eluted with a linear gradient of 0.5% 1-butanol for 80 minutes.
- Source Decomposition MALDI-TOF-MS analysis
- MALDI-TOF-MS analysis analysis of the peaks of the protein by post-source decay analysis (MALDI-TOF-MS analysis), comparison of elution positions with TaKaRa's PA-Dani sugar chain standard, and After digestion of each PA glycan using various enzymes, the analysis was performed by reversed-phase HPLC analysis, and the HPLC analysis chart is shown in Fig. 3.
- buffer A lOmM sodium phosphate buffer (pH 3.8) was used.
- buffer B 10 mM sodium phosphate buffer (pH 3.8) + 0.5% 1-butanol was used, and the analysis was carried out using the following Dalgent.
- Buffer B (%) 0 60 60 0 0
- peaks 1 to 8 indicate the following structures (1) to (8), respectively.
- GlcNAc indicates N-acetyldarcosamine
- Gal indicates galactose
- Man indicates mannose
- Fuc indicates fucose
- PA indicates pyridylamino group.
- the sugar chain content was calculated from the peak area of each PA ligament in reverse phase HPLC analysis.
- PA-glycans whose reducing ends are not N-acetyldarcosamine were excluded from peak area calculations because they were derived from impurities or were by-products during the preparation of PA-glycans.
- N- Darikoshido binding complex type sugar chain of N- Asechirudarukosa sugar group in which fucose is not bound to 6-position of the Min (hereinafter, alpha 1, 6 - and carbohydrate groups have a no fucose Abbreviated ratio) is the area occupied by peaks (1) to (4) out of the peaks (1) to (4), and the sugar with fucose bound to the 6-position of ⁇ -acetyldarcosamine at the reducing end of ⁇ -daricoside-linked complex type sugar chain.
- the ratio of the chain group (hereinafter abbreviated as “sugar chain with 1,6-fucose”) was calculated from the area occupied by peaks 1 to 8 among 1 to 8. Table 1 shows the results. Table 1
- Transformed cell clone KM-871 (FERM BP-3512) of mouse myeloma SP2 / 0 cell (ATCC CRL-1581) producing an anti-GD3 chimeric antibody described in JP-A-5-304989 calf serum (PAA Laboratories, Inc.) added with RPMI1640 medium (vitro Rozhen Co.) (hereinafter, RPMI-FBS (IO) medium hereinafter) cultured in suspension culture flask 75 cm 2 (manufactured by Iwaki Glass) using And grown to just before confluence.
- RPMI1640 medium vitro Rozhen Co.
- RPMI-FBS (IO) medium is added to the cells in the main culture solution to a density of 1 ⁇ 10 5 cells / ml, suspended, and then 0.1 ⁇ g / ml of alkylating agent N- Methyl-N'-nitro-N-nitrosoguanidin (MNNG, manufactured by Sigma) was added.
- C0 2 incubator (NATIONAL APPLIANCE manufactured COMPANY) within 3 days after standing at 37 ° C, and seeded at a density of 1000 cells / Ueru in suspension culture for 96-well plate (manufactured by Iwaki Glass).
- the anti-GD3 chimeric antibody was purified from the culture supernatant using Prosep-A (manufactured by Bioprocessing) column according to the attached instructions.
- the antibody produced by the SP2 / 0 / GD3-LCA strain was named SP2 / 0 / GD3-LCA antibody
- the antibody produced by clone KM-871 was named SP2 / 0 / GD3 antibody.
- the binding activity to GD3 of the purified anti-ganglioside GD3 antibody obtained in the second section of Example 4 was measured according to the method described below.
- ganglioside GD3 (Snow Brand Milk Products) was dissolved in 2 ml of ethanol solution containing 10 jug of dipalmitoylphosphatidylcholine (SIGMA) and 5 ⁇ ⁇ of cholesterol (SIGMA). 20 / l (40 pmol / l) of this solution is dispensed into each well of a 96-well ELISA plate (manufactured by Greiner), air-dried, and 1% bovine serum albumin (hereinafter referred to as BSA). PBS (hereinafter, referred to as 1% BSA-PBS) was added at 100 1 / mL and reacted at room temperature for 1 hour to block the remaining active groups.
- BSA bovine serum albumin
- the 1% BSA-PBS was discarded, and the culture supernatant of the transformant or various dilutions of the purified chimeric antibody were added at 50 ⁇ l / well, and the mixture was reacted at room temperature for 1 hour. After the reaction, each well was washed with PBS containing 0.05% TVeen20 (manufactured by Wako Pure Chemical Industries, Ltd.) (hereinafter referred to as “Tween-PBS”), and then diluted with 1% BSA_PBS to 3000-fold. A IgG (H & L) antibody solution (American Qualex) was added as a secondary antibody solution at 50 1 / well, and reacted at room temperature for 1 hour.
- PBS containing 0.05% TVeen20 manufactured by Wako Pure Chemical Industries, Ltd.
- the in vitro cytotoxic activity of the purified anti-GD3 antibody obtained in the second section of Example 4 was measured according to the method described below.
- RPMI1640 medium 1 ⁇ 10 6 cells of human melanoma cell line G-361 (ATCC CRL1424) cultured in RPMI1640 medium containing 10% by volume of FBS (indicated as RPMI1640-FBS (10) medium) are radioactive substances.
- the Na 2 51 Cr0 4 3. 7MBq Toryoka ⁇ Ete reacted at 37 ° C, radiolabeled cells.
- the cells were suspended and washed three times by RPMI1640-FBS (10) medium by centrifugation, resuspended in the medium, and left on ice at 4 ° C for 30 minutes to allow the radioactive substances to dissociate spontaneously. After centrifugation, 5 ml of RPMI1640_FBS (10) medium was added to adjust to 2 ⁇ 10 5 cells / ml and used as a target cell solution.
- the amount of naturally dissociated 51 Cr was determined by performing the same operation as above using only the medium instead of the effector cell solution and the antibody solution, and measuring the amount of 51 Cr in the supernatant.
- Total dissociation 51 Cr The amount was determined by adding only the medium instead of the antibody solution and adding 1N hydrochloric acid instead of the effecta one-cell solution, performing the same operation as above, and measuring the amount of 51 Cr in the supernatant.
- ADCC activity was determined by the above equation (1).
- the SP2 / 0 / GD3-LCA antibody was found to have higher activity than the SP2 / 0 / GD3 antibody.
- Example 5 the sugar chain structure analysis of the purified anti-GD3 antibody obtained in Example 4.2 was performed according to the method described in Example 3. As a result, it was found that the ratio of sugar chains to which 1,6-fucose was bound was significantly reduced in the SP2 / 0 / GD3-LCA antibody compared to the SP2 / 0 / GD3 antibody.
- Example 5 Preparation of lectin-resistant CH0 / DG44 cells and production of antibodies using the cells
- CH0 / DG44 cells were cultured in an IMDM-FBS (IO) medium [IMDM medium containing 10% fetal bovine serum (FBS) and 1-fold HT supplement (GIBCO BRL)] in an adhesion culture flask 75 cm 2 ( (Grainer Co., Ltd.) and grown to just before confluence. After washing the cells with 5 ml of Dulbecco's PBS (manufactured by Invitrogen), add 1.5 ml 'of 0.05% trypsin (manufactured by Invitrogen) diluted with Dulbecco's PBS, and leave at 37 ° C for 5 minutes. Was peeled from the bottom of the incubator.
- IO IMDM medium containing 10% fetal bovine serum (FBS) and 1-fold HT supplement
- the were detached cells were recovered by centrifugation operation performed in a normal cell culture were suspended 1 X 10 5 IMDM-FBS ( 10) so that the density of cells / ml medium was added, non-hydrogenated Kakun or MNNG (manufactured by Sigma) as an alkylating agent at 0.1 ⁇ g / ml was added.
- the CHO-LCA strain was also resistant to AAL, and the CH0-AAL strain was also resistant to LCA. Furthermore, the CHO-LCA strain and the CH0-AAL strain are lectins that recognize the same sugar chain structure as those recognized by LCA and ML, that is, N-acetyldarco at the N-glycoside-linked sugar chain reducing terminal. It also showed resistance to a lectin that recognizes a sugar chain structure in which the 6th position of the samin residue and the 1st position of fucose are added by ⁇ - linkage.
- the CHO-LCA strain and the CH0-AAL strain are resistant even in a medium supplemented with a bean lectin (Pisum sativum Agglutinin; hereinafter, referred to as PSA, manufactured by Vector) at a final concentration of lmg / ml. And survived. In addition, it was possible to obtain a lectin-resistant strain even without the addition of the alkylating agent MNNG.
- a bean lectin Pisum sativum Agglutinin; hereinafter, referred to as PSA, manufactured by Vector
- the anti-CCR4 human chimeric antibody expression plasmid PKANTEX2160 was introduced into the three types of lectin-resistant strains obtained in (1) by the method described in Reference Example 1, and the gene was amplified with the drug MTX to obtain anti-CCR4 human Type chimeric antibody producing strain was prepared.
- the antibody expression level was measured using the ELISA method described in Reference Example 1-2, and transformants expressing the antibody were obtained from the CH0-LCA strain, the CHO-AAL strain, and the CHO-PHA strain, respectively.
- the transformant derived from the CHO-LCA strain was derived from the CH0 / CCR4-LCA strain, and the transformant derived from the CHO-AAL strain was derived from the CH0 / CCR4-AAL strain and the CHO-PHA strain.
- CH0 / CCR4-PHA strain was named CH0 / CCR4-PHA strain.
- the CH0 / CCR4-LCA strain is the name of Nega-13, which was established on September 26, 2001 by the National Institute of Advanced Industrial Science and Technology (AIST) at 1-chome, Tsukuba-Higashi, Ibaraki, Japan. No. 6) has been deposited as FERM BP-7756.
- purified antibodies were obtained by the method described in Reference Example 1-3.
- the antigen-binding activity of each anti-CCR4 human chimeric antibody purified sample was evaluated using the ELISA method described in Reference Examples 1-2.
- the antibody produced by the transformed strain also has the same antigen binding activity as the antibody produced by the recombinant cell line (strain 5-03) using the normal CH0 / DG44 cells prepared in Reference Example 1 as a host. Indicated.
- the ADCC activity of each purified anti-CCR4 human chimeric antibody was evaluated in accordance with the method described in Reference Example 1-7. The results are shown in FIG.
- the antibody produced by the CH0 / CCR4-LCA strain and the CH0 / CCR4-ML strain showed an approximately 100-fold increase in ADCC activity.
- antibodies produced by the CH0 / CCR4-PHA strain showed significant ADCC activity. No increase in gender was observed.
- the ADCC activities of the antibodies produced by the CH0 / CCR4-LCA strain and the YB2 / 0 strain were compared according to the method described in Reference Example 1-7, the antibody produced by the CH0 / CCR4-LCA strain was found in Reference Example 1.
- the antibody KM2760-1 produced by the YB2 / 0 cell line prepared in 1) it was revealed that the antibody exhibited higher ADCC activity than the antibody produced by the 5-03 strain (FIG. 5).
- the sugar chain analysis of the anti-CCR4 human chimeric antibody purified in (3) above was analyzed in the same manner as in Example 3.
- the results of the reverse phase HPLC analysis are shown in FIG.
- the sugar chain content was calculated from the peak area of each PA-linked sugar chain in reverse phase HPLC analysis.
- PA-glycans whose reducing ends are not N-acetyldarcosamine were excluded from peak area calculations because they were derived from impurities or were by-products during the preparation of PA-glycans.
- Table 2 shows the percentage (%) of the sugar chain having no 1,6-fucose, which was analyzed by the method described in Example 3 and calculated from the peak area.
- Antibody-producing cells Complex double-stranded sugar chains without ⁇ -1,6-fucose (%)
- the ratio of the sugar chains without 1,6-fucose was calculated for the antibody produced by the CH0 / CCR4-LCA strain, based on the area of the peak in the analysis chart. It increased from 9% to 48%.
- the proportion of sugar chains having no a1,6-fucose increased from 9% to 27%.
- the PHA resistant strain showed almost no change in the sugar chain analysis chart and the proportion of sugar chains without 1,6-fucose.
- a 24-mer synthetic DNA primer having the nucleotide sequence shown by SEQ ID NO: 2 and the nucleotide sequence shown by SEQ ID NO: 3 from the CH0 cell-derived GMD cDNA sequence shown in 1 of Reference Example 3 A 26-mer synthetic DNA primer having Subsequently, a reaction mixture containing 20 ⁇ l of single-stranded cDNA from each cell line prepared in this section (1) as type II [1 XEX Taq Buffer (Takara Shuzo), 0.2 mM dNTP's, 0.5 units of EX Taq polymerase (Takara Shuzo Co., Ltd.) and 0.5 ⁇ M of synthetic DNA primers of SEQ ID NOs: 2 and 3] were prepared, and DNA Thermal Cycler 480 (Perkin Elmer) was prepared.
- DNA Thermal Cycler 480 Perkin Elmer
- a 27-mer synthetic DNA primer having the nucleotide sequence shown in SEQ ID NO: 4 and SEQ ID NO: 5 based on the cDNA sequence of GFPP derived from CH0 cells obtained in Reference Example 2-2 A 23-mer synthetic DNA primer having the nucleotide sequence shown by was prepared.
- a 20 il reaction solution containing 0.5 ⁇ l of single-stranded cDNA from each cell line prepared in this section (1) as type I [1 X EX Taq Buffer (Takara Shuzo), 0.2 mM DNTP's, 0.5 units of EX Taq polymerase (manufactured by Takara Shuzo Co., Ltd.), and 0.5 ⁇ M of synthetic DNA primers of SEQ ID NOS: 4 and 5] were prepared.
- a 28-mer synthetic DNA primer having the nucleotide sequence shown in SEQ ID NO: 6 and the SEQ ID NO: 7 based on the cDNA sequence of FX derived from CH0 cells obtained in Reference Example 1 A 28-mer synthetic DNA primer having the indicated base sequence was prepared.
- a 20 ⁇ l reaction solution containing 1 [5 single-stranded cDNA from each cell line prepared in this section (1) as type I [1X EX Taq Buffer (Takara Shuzo), 0.2 mM DNTP's, 0.5 units of EX Taq polymerase (Takara Shuzo Co., Ltd.) and 0.5 ⁇ M of synthetic DNA primers of SEQ ID NOs: 6 and 7] were prepared, and DNA Thermal Cycler 480 (Perkin Elmer Inc.) was prepared. The product was heated at 94 ° C for 5 minutes, and 22 cycles of 1 minute at 94 ° C and 2 minutes at 68 ° C were performed.
- a 20 ⁇ l reaction mixture containing 0.5 ⁇ l of single-stranded cDNA from each cell line prepared in this section (1) as type [[1 X EX Taq Buffer (Takara Shuzo), 0.2 raM dNTP, s, 0.5 units of EX Taq polymerase (Takara Shuzo), 0.5 synthetic DNA primers of SEQ ID NOs: 44 and 45] were prepared. After heating at 94 ° C for 5 minutes using 1-480 (manufactured by PerkinElmer), 14 cycles of 1 minute at 94 ° C and 2 minutes at 68 ° C were performed.
- the value of the PCR-amplified fragment derived from GMD, GFPP, FX, and FUT cDNA in each cell line measured in (2) to (5) in this section is calculated using the PCR-amplified fragment derived from -actin cDNA in each cell line in this section (6).
- the expression level of the GMD gene in the CH0 / CCR4-LCA strain was reduced to about 1/10 compared to other cell lines. This experiment was performed twice independently, and the average value was used.
- the PCR reaction solution was fractionated by agarose electrophoresis, and a DNA fragment of about 600 bp was recovered using a Gene Clean II kit (manufactured by BI0101) according to the attached manual.
- the recovered DNA fragment was linked to the pT7Blue (R) vector (Novagen) using a DNA Ligation kit (Takara Shuzo).
- the resulting recombinant plasmid DNA was used to transform Escherichia coli DH5 strain (manufactured by Toyobo Co., Ltd.) to obtain plasmid mt-C (see FIG. 7).
- the PCR reaction solution was fractionated by agarose electrophoresis, and a DNA fragment of about 150 p was recovered using a Gene Clean II kit (manufactured by BIOIOI) according to the attached manual.
- the recovered DNA fragment was ligated to pT7Blue (R) vector (Novagen) using a DNA Ligation kit (Takara Shuzo), and Escherichia coli DH5 ⁇ strain (Toyobo) was obtained using the obtained recombinant plasmid DNA.
- Toyobo Escherichia coli DH5 ⁇ strain
- the plasmid WT-N (-) was reacted with 5 ⁇ of restriction enzyme (Takara Shuzo) at 37 ° C for 16 hours, and DNA was recovered by phenol / cuff-form extraction and ethanol precipitation.
- restriction enzyme i ⁇ RI (Takara Shuzo) at 37 ° C for 16 hours, fractionating by agarose gel electrophoresis, the DNA fragment of about Ikbp was purified using Gene Clean II kit (BIOIOI). Collected according to the attached manual. 3 / _t g of plasmid pBluescriptSK (-) (Stratagene) was reacted with restriction enzyme No.
- the plasmid PAGE249 was reacted with restriction enzymes Hindlll and BamHI (both from Takara Shuzo) for 16 hours at 37 ° C, fractionated by agarose gel electrophoresis, and a DNA fragment of about 6.5 kbp was purified with Gene Clean II kit. (Manufactured by BI0101) according to the attached manual. 2 xg of plasmid WT in pBS was reacted with restriction enzymes Hindlll and BamHI (both from Takara Shuzo) at 37 ° C for 16 hours, fractionated by agarose gel electrophoresis, and a DNA fragment of about 1.2 kbp was purified with Gene Clean II kit.
- the pAGE249 vector was introduced into the CH0 / CCR4-LCA strain in the same manner as described above to obtain a Koguchi-U group of transformants showing a resistance to neuroglomycin.
- the transformed cells expressing GMD obtained in this section (2) were transformed using IMDM-dFBS (10) medium containing MTX (manufactured by SUGMA) at 200 nM and hygromycin at a concentration of 0.5 mg / ml.
- the cells were cultured in an 18 cm 2 flask (manufactured by Greiner) in a 5% CO 2 incubator at 37 ° C. Several days later, when the cell density reached confluence, the culture supernatant was removed, the cells were washed with 25 ml of PBS buffer (GIBCO BRL), and then 35 ml of EXCELL301 medium (JRH) was injected.
- the culture supernatant was collected.
- the anti-CCR4 chimeric antibody was purified from the culture supernatant using a Prosep-A (Millipore) column according to the attached instructions.
- the transformed cells into which the PAGE249 vector had been introduced were cultured in the same manner as described above, and the anti-CCR4 chimeric antibody was recovered from the culture supernatant and purified.
- the transformed cells expressing the GMD gene obtained in this section (2) were transferred to IMDM-dFBS (10) medium containing 200 nM of MTX (SIGMA) and 0.5 mg / ml of hygromycin.
- the cells were suspended at a concentration of 6 ⁇ 10 4 cells / ml and dispensed into 96-well culture plates (Iwaki Glass Co., Ltd.) at 50 1 / well.
- IMDM_dFBS 10
- MTX manufactured by SIGMA
- dygromycin at a concentration of 0.5 mg / ml.
- LCA LENS CULINARIS AGGLUTININ: Vector at a concentration of / ml
- the medium in which Laboratories was suspended was added in an amount of 50 ⁇ l each, and the cells were cultured in a 37 ° C 5% 0) 2 incubator for 96 hours.
- the CH0 / CCR4-LCA strain expressing GMD showed a decrease in LCA resistance, and the cell viability in the presence of 0.2 mg / ml LCA was about 40%. The cell viability in the presence of 0.8 mg / ml LCA was about 20%.
- the CH0 / CCR4-LCA strain into which the pAGE249 vector was introduced the cell viability in the presence of 0.2 mg / ml LCA was 100%, and the cell viability in the presence of 0.8 mg / ml LCA was 80%. %. From the above results, it was suggested that the CH0 / CCR4-LCA strain had a reduced expression level of the GMD gene, and as a result, acquired resistance to LCA.
- ADCC activity was measured according to the method described below. i) Preparation of target cell solution
- RPMI1640-1 ⁇ 10 6 cells of the CCR4-EL4 strain (see Reference Example 1, 7) cultured in a medium supplemented with G418 sulfate (manufactured by Nacalai Tester) at a concentration of 500 ⁇ g / ml in FBS (10) medium prepared, the Na 2 51 Cr0 4 is a radioactive substance 3. 7MBq reacted eq addition 37 for 90 min, and rays labeled release cell. After the reaction, the suspension was washed with RPMI1640-FBS (10) medium three times by centrifugation, resuspended in the medium, and left on ice at 4 ° C for 30 minutes to allow the radioactive substances to dissociate spontaneously. . After centrifugation, 5 ml of RPMI1640-FBS (10) medium was added to adjust to 2.5 ⁇ 10 5 cells / ml and used as a target cell solution. ii) Preparation of effector cell solution
- ADCC activity measurement 50 ml of vein blood of a healthy person was collected, and 0.5 ml of heparin sodium (manufactured by Takeda Pharmaceutical Co., Ltd.) was added and mixed gently. This was centrifuged using Lymphoprep (manufactured by Nycomed Pharma AS) according to the instruction manual to separate a mononuclear cell layer. After washing by centrifugation three times with RPMI1640-FBS (10) medium, the cells were resuspended at 2 ⁇ 10 6 cells / ml using the medium to obtain an effector cell solution. iii) ADCC activity measurement
- the plate was centrifuged, and the amount of 51 Cr in the supernatant was measured using a T-counter.
- the amount of spontaneously dissociated 51 Cr was determined by performing the same operation as above using only the medium instead of the effector cell solution and the antibody solution, and measuring the amount of 51 Cr in the supernatant.
- the total amount of 51 Cr dissociated was determined by adding the medium alone instead of the antibody solution and adding 1N hydrochloric acid instead of the effector cell solution, performing the same operation as above, and measuring the amount of 51 Cr in the supernatant.
- ADCC activity was determined by the above formula (I).
- the ADCC activity of the purified anti-CCR4 chimeric antibody obtained from the CH0 / CCR4-LCA strain expressing GMD was reduced to about the same level as KM3060 obtained in Reference Example 1.
- the ADCC activity of the purified anti-CCR4 chimeric antibody obtained from the CH0 / CCR4-LCA strain into which the pAGE249 vector was introduced has the same ADCC activity as the purified anti-CCR4 chimeric antibody obtained from the CH0 / CCR4-LCA strain.
- the CH0 / CCR4-LCA strain had a reduced expression level of the GMD gene, and as a result, it could produce an antibody with high ADCC activity.
- the sugar chain analysis of the purified anti-CCR4 chimeric antibody obtained in (3) of this section was performed according to the method described in Example 5 (4), and the analysis results are shown in FIG.
- the ratio of glycans without 1,6-fucose was reduced to 9% as calculated from the area of the analytical peak.
- anti-GD3 chimeric antibody L-chain expression vector pChi641LGM4 of anti-gandarioside GD3 human chimeric antibody (hereinafter also referred to as anti-GD3 chimeric antibody) [Journal of Immunol'Methods (J. Immunol.
- the plasmid P Chi641LGM40 constructed above was digested with the restriction enzyme Clal (Takara Shuzo), blunt-ended using the DNA Blunting Kit (Takara Shuzo), and further cut with Mlul (Takara Shuzo).
- An approximately 5.68 kb fragment containing the obtained L chain cDNA and the H chain expression vector of the anti-GD3 chimeric antibody pChi641HGM4 [Journal of Immunological Methods (J. Immunol.
- Example 4 ⁇ g of the anti-GD3 chimeric antibody expression vector pChi641LHGM4 prepared in the first section of Example 7 was prepared in 1.6 ⁇ 10 6 cells of the CH0 / DG44 strain, and (1) in Example 5. Introduced into the isolated CH0-LCA strain by the electroporation method [Cytotechnology, 3, 133 (1990)], and then IMDM medium (Invitrogen) containing 10% by volume of dialyzed fetal bovine serum (Invitrogen) was used. Company Ltd., IMDM- dFBS (10) medium hereinafter) suspended in 10ml Nigoshi, aliquoted 2 00 ⁇ ⁇ / Ueru min 96 Ueru culture plate (manufactured by Iwaki Glass).
- the cells were cultured in a 5% 2 incubator for 2 weeks. A transformant showing growth independent of the nucleic acid component in the culture medium appeared, and the culture supernatant was recovered from the well where growth was observed.
- the antigen-binding activity of the anti-GD3 chimeric antibody in the supernatant was measured by the ELISA method described in Example 4, section 3 (1).
- methotrexate (Sigma, ⁇ ) was used to increase the amount of antibody production using the DHFR gene amplification system.
- the MTX concentration was increased to 200 nM and cultured at 37 ° C for 2 weeks to induce a transformed strain showing 200 nM MTX resistance by the same method as described above.
- the MTX concentration was increased to 500 nM and cultured at 37 ° C. for 2 weeks to induce a transformant showing 500 nM MTX resistance in the same manner as described above.
- a stable transformant capable of growing on an IM DM-dFBS (10) medium containing MTX at a concentration of 500 nM and highly producing an anti-GD3 chimeric antibody was obtained.
- the obtained transformant was transformed into a single cell (cloned) by the limiting dilution method to obtain a cloned strain.
- the cloned strains obtained using the CH0-LCA strain as a host cell for gene transfer were named CH0 / GD3-LCA-1 strain and CH0 / GD3-LCA-2 strain.
- the cloned strain obtained as the CH0 / DG44 strain host cell was designated as CH0 / GD3 strain.
- the CH0 / GD3-LCA-1 strain was transferred to the National Institute of Advanced Industrial Science and Technology (AIST) Patent Organism Depositary (November 1-1, Tsukuba, Ibaraki, Japan, Chuo No. 6) on November 11, 2002 by FERM BP- Deposited as 8236. 3. Purification of anti-GD3 chimeric antibody
- the purified anti-GD3 chimeric antibody is produced by using the CH0 / GD3-LCA-1 strain-producing antibody for the CH0 / GD3-LCA-1 antibody and the CH0 / GD3-LCA-2 strain-producing antibody for the CH0 / GD3-LCA-2 antibody. I named it.
- Example 7 Each of the three types of anti-GD3 chimeric antibodies produced and purified in Section 3 was subjected to SDS-PAGE (polyacrylamide gel electrophoresis) according to a known method [Nature, 227, 680, 1970]. The molecular weight and degree of purification were analyzed. As a result, each purified anti-GD3 chimeric antibody showed a single band with a molecular weight of approximately 150 kilodaltons (Kd) under non-reducing conditions, and approximately 50Kd and approximately 25Kd under reducing conditions. Two bands were found.
- Kd kilodaltons
- Antibodies of the type have a molecular weight of approximately 150 Kd under non-reducing conditions, and under reducing conditions, disulfide bonds (hereinafter referred to as S-S bonds) in the molecule are cleaved, resulting in an H chain having a molecular weight of approximately 50 Kd.
- S-S bonds disulfide bonds
- FIG. 16 shows an elution diagram obtained by analyzing the PA-glycan prepared from the purified anti-GD3 chimeric antibody by reverse phase HPLC.
- peaks 1 to 8 indicate the structures (1) to (8) described in Example 3, respectively.
- Table 4 shows the percentage (%) of complex double-stranded sugar chains without ⁇ , 6-fucose, calculated from the peak area of the analysis chart.
- Table 4 Carbohydrate analysis of anti-GD3 chimeric antibody
- CH0 / GD3-LCA-2 antibody 80 As shown in Table 4, the CH0 / GD3-LCA-1 antibody has a complex duplex with no al, 6-fucose compared to the normal CH0 / GD3 antibody. The percentage of type sugar chains increased from 9% to 42%. In the case of the CH0 / GD3-LCA-2 antibody, the ratio of complex double-stranded sugar chains without a1,6-fucose increased from 9% to 80%.
- Example 8 Evaluation of activity of anti-GD3 chimeric antibody
- FIG. 17 shows the results of examining the binding activity by changing the concentration of the added anti-GD3 chimeric antibody.
- the three types of anti-GD3 chimeric antibodies exhibited almost the same binding activity to gandriside GD3. This result indicates that the antigen-binding activity of the antibody produced by LCA lectin-resistant CH0 / DG44 cells is equivalent to the antibody produced by normal CH0 / DG44 cells.
- ADCC activity In vitro cytotoxic activity of anti-GD3 chimeric antibody
- ADCC activity 1 was determined according to the method described in Section 3 (2) of Example 4. Raw was measured.
- VL L chain V region
- SEQ ID NO: 46 The cDNA encoding the amino acid sequence of the L chain V region (hereinafter referred to as VL) of the anti-CD20 mouse monoclonal antibody 2B8 described in TO94 / 11026 (described in SEQ ID NO: 46) was subjected to PCR using the following method. Was built.
- the nucleotide sequence of the VL described in W094 / 11026 at the 5, 5, and 3 ends is the binding nucleotide sequence of the amplification primer during the PCR reaction (including the restriction enzyme recognition sequence for cloning into a humanized antibody expression vector). ) was added. Divide the designed base sequence into a total of 6 base sequences (approximately 100 bases from the 5 'end) (adjacent base sequences should have an overlapping sequence of about 20 bases at their ends) and use them as sense strands. In fact, six synthesiss 0 of SEQ ID NOs: 48, 49, 50, 51, 52, and 53 were prepared in the alternate order of the antisense strand, and were commissioned to be manufactured by £ ⁇ £ 1 ").
- Each oligonucleotide was adjusted to a final concentration of 0.1 liM in a 50 L reaction mixture [PCR Buffer # 1 with KOD DNA Polymerase (Toyobo), 0.2 mM dNTPs, ImM magnesium chloride, 0.1 mM. 5 ⁇ M13 primer M4 (Takara Shuzo) and 0.5 ⁇ M13 primer RV (Takara Shuzo)], and the DNA thermal cycler GeneAmp PCR System 9600 (Perkin Elmer) was used at 94 ° C.
- a cDNA encoding the amino acid sequence of VH of the anti-CD20 mouse monoclonal antibody 2B8 described in W094 / 11026 (described in SEQ ID NO: 47) was constructed by PCR using the following method.
- the 5'-end and 3'-end of the VH nucleotide sequence described in W094 / 11026, the binding nucleotide sequence of the amplification primer during the PCR reaction (including the restriction enzyme recognition sequence for cloning into a humanized antibody expression vector) ) was added.
- six synthetic DNAs of SEQ ID NOs: 54, 55, 56, 57, 58, and 59 were prepared (consigned to GENSET) in the alternate order of the antisense strand.
- the 1 minute cycle was performed for 25 cycles, and the reaction was further performed at 72 ° C for 10 minutes. After agarose gel electrophoresis of the reaction solution at 25 / z L, a PCR product of about 0.49 kb of VH was recovered using a QIAquick Gel Extraction Kit (manufactured by QIAGEN).
- DNAO.l Atg obtained by restriction enzyme Sma I (Takara Shuzo) using plasmid pBluescriptll SK (-) (Stratagene) and about 0.1 l ⁇ ag of the PCR product obtained above And add 7.5 ⁇ l of TAKARA ligation kit ver. 2 solution I (Takara Shuzo Co., Ltd.) restriction enzyme Sma I (Takara Shuzo Co., Ltd.) and react at 22 ° C overnight. I let it. Escherichia coli DH5a strain (manufactured by Toyobo Co., Ltd.) was transformed using the recombinant plasmid DNA solution thus obtained.
- Each plasmid DNA was prepared from the clone of the transformant, and reacted using BigDye Terminator Cycling Ready Reaction Kit v2.0 (Applied Biosystems) according to the attached instructions.
- the nucleotide sequence was analyzed by PRISM 377.
- the plasmid pBS-2B8H having the target nucleotide sequence shown in FIG. 20 was obtained.
- a synthetic DNA shown in SEQ ID NO: 60 was designed, and PCR was performed using LA PCR in vitro Mutagenesis Primer Set for pBluescriptll (Takara Shuzo). Resulted in the substitution of bases as follows.
- a PCR product of about 0.44 kb was recovered using a QIAquick Gel Extraction Kit (manufactured by QIAGEN) to prepare a 30 L aqueous solution.
- a 50 iL reaction solution containing 1 ng of the above plasmid pBS-2B8H [LA PCR Buffer II (Takara Shuzo), 2.5 units of TaKaRa LA Taq, 0.4 mM dNTPs, 2.5 mM chloride PCR was performed using magnesium, 50 nM T7 BcaBEST Sequencing primer (Takara Shuzo) and 50 nM MUT Bl primer (Takara Shuzo).
- a PCR product of about 0.63 kb was recovered using a QIAquick Gel Extraction Kit (manufactured by QIAGEN) to obtain a 30 // L aqueous solution. Subsequently, 0.45 kb of the PCR product obtained above and 0.63 kb of the PCR product were added in 0.5 ⁇ L each to 47.5 ⁇ L of a reaction solution [LA PCR Buffer II (Takara Shuzo), 0.5 ⁇ L.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002481837A CA2481837A1 (en) | 2002-04-09 | 2003-04-09 | Production process for antibody composition |
EP03723096A EP1498490A4 (en) | 2002-04-09 | 2003-04-09 | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
JP2003582296A JPWO2003085118A1 (ja) | 2002-04-09 | 2003-04-09 | 抗体組成物の製造方法 |
AU2003236015A AU2003236015A1 (en) | 2002-04-09 | 2003-04-09 | Process for producing antibody composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-106820 | 2002-04-09 | ||
JP2002106820 | 2002-04-09 | ||
JP2003-24685 | 2003-01-31 | ||
JP2003024685 | 2003-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003085118A1 true WO2003085118A1 (fr) | 2003-10-16 |
Family
ID=28793555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/004502 WO2003085118A1 (fr) | 2002-04-09 | 2003-04-09 | Procede de production de composition anticorps |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040132140A1 (ja) |
EP (1) | EP1498490A4 (ja) |
JP (1) | JPWO2003085118A1 (ja) |
AU (1) | AU2003236015A1 (ja) |
CA (1) | CA2481837A1 (ja) |
WO (1) | WO2003085118A1 (ja) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005017155A1 (ja) * | 2003-06-18 | 2005-02-24 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーター |
WO2005035778A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
WO2005035563A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | アンチトロンビンⅲ組成物の製造方法 |
WO2005035581A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ヒトVEGF受容体Flt-1に特異的に結合する抗体組成物 |
WO2005035582A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Ccr4に特異的に結合する抗体組成物 |
WO2005035586A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
WO2005035583A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Il-5受容体に特異的に結合する抗体組成物 |
WO2005035577A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドgd3に特異的に結合する抗体組成物 |
WO2005035740A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 無血清馴化したゲノム改変細胞 |
WO2005035741A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ゲノムが改変された細胞 |
WO2005035578A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドgm2に特異的に結合する抗体組成物 |
WO2005053742A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
WO2005053741A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
WO2006013964A1 (ja) * | 2004-08-05 | 2006-02-09 | Kyowa Hakko Kogyo Co., Ltd. | 糖蛋白質組成物の製造法 |
WO2006067913A1 (ja) * | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
EP1500400A4 (en) * | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
WO2007100091A1 (ja) * | 2006-03-03 | 2007-09-07 | Osaka University | フコシルトランスフェラーゼの発現を抑制するための組成物 |
US7541029B2 (en) | 2000-04-12 | 2009-06-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anti-rhesus D monoclonal antibodies |
JP2010512765A (ja) * | 2006-12-22 | 2010-04-30 | エフ.ホフマン−ラ ロシュ アーゲー | 選択方法 |
WO2014027656A1 (ja) * | 2012-08-13 | 2014-02-20 | 協和発酵キリン株式会社 | 補体C3bによる細菌の菌体表面への沈着および貪食細胞による貪食活性を増加させる方法、並びに細菌感染症の治療方法および治療剤 |
US8895266B2 (en) | 2000-10-06 | 2014-11-25 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
KR20210047892A (ko) * | 2018-08-29 | 2021-04-30 | 유나이티드 바이오파마, 인크. | 비푸코실화된 항체 및 그의 제조법 |
Families Citing this family (658)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US20060021071A1 (en) * | 2003-10-09 | 2006-01-26 | Kyowa Hakko Kogyo Co., Ltd. | Cell in which genome is modified |
MXPA06014069A (es) | 2004-06-04 | 2007-04-25 | Genentech Inc | Metodo para tratar esclerosis multiple. |
CA2580271A1 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
ES2755976T3 (es) | 2005-02-07 | 2020-04-24 | Roche Glycart Ag | Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas |
PT1851250E (pt) * | 2005-02-18 | 2012-08-27 | Medarex Inc | Anticorpo monoclonal humano para o antigénio membranar específico da próstata (psma) |
NZ560414A (en) * | 2005-02-18 | 2011-04-29 | Medarex Inc | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
TW200720439A (en) * | 2005-03-25 | 2007-06-01 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
BRPI0611445A2 (pt) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
US20090208500A1 (en) * | 2005-06-03 | 2009-08-20 | Genentech, Inc. | Method of producing antibodies with improved function |
US20090214528A1 (en) | 2005-08-31 | 2009-08-27 | Haimanti Dorai | Host cell lines for production of antibody constant region with enhanced effector function |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
ES2547689T3 (es) | 2005-12-02 | 2015-10-08 | Genentech, Inc. | Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R |
ES2526204T3 (es) | 2006-01-05 | 2015-01-08 | Genentech, Inc. | Anticuerpos anti-EphB4 y métodos para usar los mismos |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
JP2009539384A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗dll4抗体および抗dll4抗体使用の方法 |
AR061245A1 (es) * | 2006-06-06 | 2008-08-13 | Genentech Inc | Composiciones y metodos para la modulacion del desarrollo vascular |
WO2008010101A2 (en) | 2006-07-18 | 2008-01-24 | Sanofi-Aventis | Antagonist antibody against epha2 for the treatment of cancer |
JP2009543579A (ja) | 2006-07-19 | 2009-12-10 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗炎症反応のための標的としてのWSX−1/p28 |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
SG10201510384UA (en) | 2006-09-13 | 2016-01-28 | Abbvie Inc | Cell culture improvements |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
NZ576032A (en) | 2006-10-12 | 2012-03-30 | Genentech Inc | Antibodies to lymphotoxin-alpha |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CA2667019C (en) | 2006-10-27 | 2016-03-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
AR063975A1 (es) * | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
BRPI0722060A2 (pt) * | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase |
JP2010517944A (ja) * | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Dll4シグナリング阻害薬およびその使用 |
WO2008100805A2 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
WO2008137915A2 (en) | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20100291073A1 (en) | 2007-05-14 | 2010-11-18 | Medimmune, Llc | Methods of reducing eosinophil levels |
SI2586788T1 (en) | 2007-07-09 | 2018-07-31 | Genentech, Inc. | Prevention of the reduction of the disulfide bond during the recombinant production of polypeptides |
CA2978687C (en) | 2007-09-26 | 2020-02-18 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP2205258B1 (en) | 2007-09-28 | 2017-05-24 | Janssen Biotech, Inc. | Methods and structural conformations of antibody preparations with increased resistance to proteases |
KR101867606B1 (ko) | 2007-11-07 | 2018-06-18 | 제넨테크, 인크. | 미생물 질환의 치료를 위한 조성물 및 방법 |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
AU2009223054A1 (en) * | 2008-03-11 | 2009-09-17 | Genentech, Inc. | Antibodies with enhanced ADCC function |
BRPI0906261A2 (pt) * | 2008-03-31 | 2015-07-07 | Genentech Inc | "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" |
CN102076865B (zh) * | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
RU2536937C2 (ru) | 2008-10-14 | 2014-12-27 | Дженентек, Инк. | Варианты иммуноглобулина и их применения |
JP5808249B2 (ja) | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
CN102257005A (zh) | 2008-10-20 | 2011-11-23 | 雅培制药有限公司 | 在抗体纯化过程中的病毒灭活 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
KR101812811B1 (ko) | 2008-12-23 | 2017-12-27 | 제넨테크, 인크. | 단백질 a에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체 |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
SG174515A1 (en) | 2009-03-25 | 2011-10-28 | Genentech Inc | NOVEL ANTI-a5ß1 ANTIBODIES AND USES THEREOF |
KR101822663B1 (ko) | 2009-03-25 | 2018-01-29 | 제넨테크, 인크. | 항-fgfr3 항체 및 그의 사용 방법 |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
ES2513292T3 (es) | 2009-07-31 | 2014-10-24 | Genentech, Inc. | Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF |
WO2011019619A1 (en) | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
BR112012003983A2 (pt) | 2009-08-31 | 2021-09-14 | Roche Glycart Ag | Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção |
ES2599076T3 (es) | 2009-09-02 | 2017-01-31 | Genentech, Inc. | Smoothened mutante y métodos de utilización del mismo |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
NZ599337A (en) | 2009-10-22 | 2013-05-31 | Genentech Inc | Anti-hepsin antibodies and methods using same |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
JP2013509415A (ja) | 2009-10-29 | 2013-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 抗体グリコシル化変異型 |
JP6007420B2 (ja) | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | 親和性成熟に基づく抗体最適化方法 |
NZ598901A (en) | 2009-11-05 | 2014-08-29 | Genentech Inc | Methods and composition for secretion of heterologous polypeptides |
JP5818805B2 (ja) | 2009-12-11 | 2015-11-18 | ジェネンテック, インコーポレイテッド | 抗vegf−c抗体及びその使用方法 |
PL2516465T3 (pl) | 2009-12-23 | 2016-11-30 | Przeciwciała anty-bv8 i ich zastosowania | |
US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
TW201138823A (en) | 2010-03-24 | 2011-11-16 | Genentech Inc | Anti-LRP6 antibodies |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
MX336109B (es) | 2010-06-03 | 2016-01-08 | Genentech Inc | Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo. |
EP2582729A4 (en) | 2010-06-18 | 2014-05-28 | Hoffmann La Roche | ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
KR20130120439A (ko) | 2010-07-09 | 2013-11-04 | 제넨테크, 인크. | 항-뉴로필린 항체 및 사용 방법 |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
JP2013541501A (ja) | 2010-08-03 | 2013-11-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 慢性リンパ性白血病(cll)のバイオマーカー |
SI2608796T1 (sl) | 2010-08-05 | 2019-03-29 | Seattle Genetics, Inc. | Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov |
JP2013541937A (ja) | 2010-08-05 | 2013-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質 |
EP2603529A1 (en) | 2010-08-13 | 2013-06-19 | Roche Glycart AG | Anti-tenascin-c a2 antibodies and methods of use |
WO2012020006A2 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
US20120089541A1 (en) | 2010-08-31 | 2012-04-12 | Genentech, Inc. | Biomarkers and methods of treatment |
US8481680B2 (en) | 2010-10-05 | 2013-07-09 | Genentech, Inc. | Mutant smoothened and methods of using the same |
JP6163429B2 (ja) | 2010-11-10 | 2017-07-12 | ジェネンテック, インコーポレイテッド | 神経疾患免疫治療のための方法及び組成物 |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
NZ610976A (en) | 2010-12-20 | 2015-07-31 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
US20120195910A1 (en) | 2010-12-22 | 2012-08-02 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
CA2825081A1 (en) | 2011-02-28 | 2012-09-07 | Birgit Bossenmaier | Antigen binding proteins |
WO2012116927A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
HUE036229T2 (hu) | 2011-03-02 | 2018-06-28 | Roche Glycart Ag | CEA antitestek |
KR20140021589A (ko) | 2011-04-07 | 2014-02-20 | 제넨테크, 인크. | 항-fgfr4 항체 및 사용 방법 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
RU2638806C2 (ru) | 2011-05-12 | 2017-12-15 | Дженентек, Инк. | Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов |
HUE033584T2 (hu) | 2011-05-16 | 2017-12-28 | Hoffmann La Roche | FGFR1 agonisták és alkalmazási eljárások |
CN103596984B (zh) | 2011-06-15 | 2016-04-13 | 霍夫曼-拉罗奇有限公司 | 抗-人epo受体的抗体及使用方法 |
EA201400046A1 (ru) | 2011-06-22 | 2014-07-30 | Ф. Хоффманн-Ля Рош Аг | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов |
EP2726098A1 (en) | 2011-06-30 | 2014-05-07 | F.Hoffmann-La Roche Ag | Anti-c-met antibody formulations |
CN103890007A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 神经调节蛋白抗体及其用途 |
CA2842481A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
BR112014003999A2 (pt) | 2011-08-23 | 2017-06-13 | Roche Glycart Ag | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp |
WO2013026831A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antigen binding molecules |
KR20140068062A (ko) | 2011-09-15 | 2014-06-05 | 제넨테크, 인크. | 분화의 촉진 방법 |
EP2758055A1 (en) | 2011-09-19 | 2014-07-30 | F.Hoffmann-La Roche Ag | Combination treatments comprising c-met antagonists and b-raf antagonists |
CA2849011A1 (en) | 2011-10-05 | 2013-04-11 | Genentech, Inc. | Methods of treating liver conditions using notch2 antagonists |
CA2850032C (en) | 2011-10-14 | 2022-06-07 | Genentech, Inc. | Anti-htra1 antibodies and methods of use |
CA2850836A1 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
EA201490879A1 (ru) | 2011-10-28 | 2014-08-29 | Дженентек, Инк. | Терапевтические комбинации и способы лечения меланомы |
BR112014012005A2 (pt) | 2011-11-21 | 2017-12-19 | Genentech Inc | composições, métodos, formulação farmacêutica e artigo |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
RU2639519C2 (ru) | 2011-12-22 | 2017-12-21 | Ф.Хоффманн-Ля Рош Аг | Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
US9963511B2 (en) | 2011-12-22 | 2018-05-08 | Hoffmann-La Roche Inc. | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
BR112014017518A2 (pt) | 2012-01-18 | 2018-09-04 | Genentech Inc | anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo |
EP2804630B1 (en) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Methods of using fgf19 modulators |
AU2013215332A1 (en) | 2012-01-31 | 2014-09-04 | Genentech, Inc. | Anti-Ig-E M1' antibodies and methods using same |
AU2013216753B2 (en) | 2012-02-11 | 2017-09-21 | Genentech, Inc. | R-spondin translocations and methods using the same |
CN104125852B9 (zh) | 2012-02-15 | 2017-05-17 | 弗·哈夫曼-拉罗切有限公司 | 基于Fc‑受体的亲和色谱 |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013165940A1 (en) | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
MX2014014086A (es) | 2012-05-23 | 2015-01-26 | Genentech Inc | Metodo de seleccion para agentes terapeuticos. |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
CA2875096A1 (en) | 2012-06-15 | 2013-12-19 | Genentech, Inc. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
CN104394886B (zh) | 2012-07-04 | 2017-05-24 | 弗·哈夫曼-拉罗切有限公司 | 抗茶碱抗体及使用方法 |
BR112014030844A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo |
EP3138580B1 (en) | 2012-07-04 | 2021-03-03 | F. Hoffmann-La Roche AG | Covalently linked antigen-antibody conjugates |
US9803191B2 (en) | 2012-07-05 | 2017-10-31 | Genentech, Inc. | Expression and secretion system |
EA201590171A1 (ru) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b |
US20140030279A1 (en) | 2012-07-09 | 2014-01-30 | Spirogen Sarl | Anti-cd22 antibodies and immunoconjugates |
BR112015000439A2 (pt) | 2012-07-09 | 2017-12-19 | Genentech Inc | imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação |
CN104411337A (zh) | 2012-07-09 | 2015-03-11 | 基因泰克公司 | 包含抗cd79b抗体的免疫偶联物 |
ES2848732T3 (es) | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
CA2882725C (en) | 2012-08-23 | 2021-03-09 | Regents Of The University Of Minnesota | Treatment of sickle cell disease and inflammatory conditions |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
EP3461501A1 (en) | 2012-11-13 | 2019-04-03 | F. Hoffmann-La Roche AG | Anti-hemagglutinin antibodies and methods of use |
AU2013360775B2 (en) | 2012-12-21 | 2018-04-12 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
MX2015010791A (es) | 2013-02-22 | 2015-11-26 | Hoffmann La Roche | Metodos para tratar el cancer y prevenir la resistencia a farmacos. |
CA2896259A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
JP2016510751A (ja) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | 抗がん剤耐性を治療及び予防する方法 |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
RU2015139054A (ru) | 2013-03-14 | 2017-04-19 | Дженентек, Инк. | Способы лечения рака и профилактики лекарственной резистентности рака |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
KR20150127203A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법 |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
EP3299391B1 (en) | 2013-03-14 | 2019-12-04 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
MX2015012872A (es) | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anticuerpos anti-tau y metodos de uso. |
EA035645B1 (ru) | 2013-03-15 | 2020-07-21 | Дженентек, Инк. | ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ |
KR20150128707A (ko) | 2013-03-15 | 2015-11-18 | 제넨테크, 인크. | 간암의 진단 및 치료를 위한 조성물 및 방법 |
KR20150131177A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | 항-CRTh2 항체 및 그의 용도 |
CN118547067A (zh) | 2013-03-15 | 2024-08-27 | 豪夫迈·罗氏有限公司 | 治疗pd-1和pd-l1相关疾患的生物标志物和方法 |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
PE20151925A1 (es) | 2013-04-29 | 2015-12-26 | Hoffmann La Roche | Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares |
SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
US9708406B2 (en) | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
BR112015029838A2 (pt) | 2013-05-31 | 2017-09-26 | Genentech Inc | anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus |
RU2687044C2 (ru) | 2013-05-31 | 2019-05-06 | Дженентек, Инк. | Антитела против стеночной тейхоевой кислоты и их конъюгаты |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
PE20210949A1 (es) | 2013-08-01 | 2021-05-24 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
KR20160042438A (ko) | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
CN105518027A (zh) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | 使用抗lgr5抗体的方法 |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
KR20160068855A (ko) | 2013-10-11 | 2016-06-15 | 제넨테크, 인크. | Nsp4 억제제 및 사용 방법 |
EP3620470B1 (en) | 2013-10-11 | 2023-07-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
MX2016004802A (es) | 2013-10-18 | 2016-07-18 | Genentech Inc | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
CN105849280B (zh) | 2013-10-23 | 2020-11-06 | 豪夫迈·罗氏有限公司 | 诊断和治疗嗜酸性粒细胞紊乱的方法 |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
ES2758508T3 (es) | 2013-12-09 | 2020-05-05 | Allakos Inc | Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos |
AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
EP3083689B1 (en) | 2013-12-17 | 2020-05-27 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
BR112016012666A2 (pt) | 2014-01-03 | 2017-09-26 | Hoffmann La Roche | conjugado, anticorpos, formulação farmacêutica e usos de conjugado |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
EP3089996B1 (en) | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
JP6521464B2 (ja) | 2014-01-03 | 2019-05-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 共有結合で連結されたポリペプチド毒素−抗体コンジュゲート |
PL3092251T3 (pl) | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
CN106413756A (zh) | 2014-01-24 | 2017-02-15 | 豪夫迈·罗氏有限公司 | 使用抗steap1抗体和免疫缀合物的方法 |
DK3102197T3 (en) | 2014-02-04 | 2018-11-19 | Genentech Inc | Smoothened mutant and methods for its use |
SG10201901076WA (en) | 2014-02-08 | 2019-03-28 | Genentech Inc | Methods of treating alzheimer's disease |
SG11201606316XA (en) | 2014-02-08 | 2016-08-30 | Genentech Inc | Methods of treating alzheimer's disease |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
WO2015127405A2 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
WO2015131155A1 (en) | 2014-02-28 | 2015-09-03 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
JP6644717B2 (ja) | 2014-03-14 | 2020-02-12 | ジェネンテック, インコーポレイテッド | 異種ポリペプチドを分泌させるための方法及び組成物 |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
BR112016022345A2 (pt) | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
MX2016015162A (es) | 2014-05-22 | 2017-03-03 | Genentech Inc | Anticuerpos anti - gpc3 e inmunoconjugados. |
RU2016144405A (ru) | 2014-05-23 | 2018-06-26 | Дженентек, Инк. | MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
RU2016148616A (ru) | 2014-06-11 | 2018-07-18 | Дженентек, Инк. | Анти-lgr5 антитела и их применение |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CA2947504A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Anti-brdu antibodies and methods of use |
BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
KR20230172625A (ko) | 2014-08-28 | 2023-12-22 | 바이오아트라, 인코퍼레이티드 | 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체 |
ES2830385T3 (es) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anticuerpos e inmunoconjugados anti-HER2 |
CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
JP6730261B2 (ja) | 2014-09-17 | 2020-07-29 | ジェネンテック, インコーポレイテッド | 抗her2抗体を含む免疫複合体 |
RS60349B8 (sr) | 2014-09-23 | 2022-10-31 | Hoffmann La Roche | Postupak upotrebe anti-cd79b imunokonjugata |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
WO2016070001A1 (en) | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
CN114381521A (zh) | 2014-11-03 | 2022-04-22 | 豪夫迈·罗氏有限公司 | 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物 |
US20160161485A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
KR20170080675A (ko) | 2014-11-05 | 2017-07-10 | 제넨테크, 인크. | 항-fgfr2/3 항체 및 이의 이용 방법 |
MX2017005150A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a. |
MX2017005148A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
US10160795B2 (en) | 2014-11-14 | 2018-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Ebola virus glycoprotein and their use |
SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US10882920B2 (en) | 2014-11-19 | 2021-01-05 | Genentech, Inc. | Antibodies against BACE1 and use thereof for neural disease immunotherapy |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
PL3221355T3 (pl) | 2014-11-20 | 2021-03-08 | F. Hoffmann-La Roche Ag | Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1 |
MX2017007231A (es) | 2014-12-03 | 2017-11-08 | Genentech Inc | Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. |
EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
RU2731055C2 (ru) | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение |
LT3227336T (lt) | 2014-12-05 | 2019-09-25 | F. Hoffmann-La Roche Ag | Anti-cd79b antikūnai ir jų naudojimo būdai |
RU2017120039A (ru) | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | Антитела к рецепторам гематоэнцефалического барьера и способы их применения |
CN107108726A (zh) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
KR20170128234A (ko) | 2015-01-16 | 2017-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1에 특이적인 항체 및 키메라 항원 수용체 |
JP2018511557A (ja) | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | 2種以上の抗c5抗体の組み合わせおよび使用方法 |
JP2018512597A (ja) | 2015-02-04 | 2018-05-17 | ジェネンテック, インコーポレイテッド | 突然変異体スムースンド及びその使用方法 |
SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
EP3261665A1 (en) | 2015-02-24 | 2018-01-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
AU2016233398A1 (en) | 2015-03-16 | 2017-09-07 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
EP3271389B8 (en) | 2015-03-20 | 2020-04-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
PL3273992T3 (pl) | 2015-03-23 | 2020-11-16 | Jounce Therapeutics, Inc. | Przeciwciała przeciwko icos |
WO2016153572A1 (en) | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
US20180208658A1 (en) | 2015-04-03 | 2018-07-26 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
DK3280441T3 (da) | 2015-04-07 | 2021-11-15 | Alector Llc | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf |
JP7044553B2 (ja) | 2015-04-24 | 2022-03-30 | ジェネンテック, インコーポレイテッド | 結合ポリペプチドを含む細菌を特定する方法 |
CN107709363A (zh) | 2015-05-01 | 2018-02-16 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
EP4238994A3 (en) | 2015-05-11 | 2024-02-07 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
CN107667119A (zh) | 2015-05-12 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
CN107771182A (zh) | 2015-05-29 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 人源化抗埃博拉病毒糖蛋白抗体和使用方法 |
EP3708681A1 (en) | 2015-05-29 | 2020-09-16 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
CN107810012A (zh) | 2015-06-02 | 2018-03-16 | 豪夫迈·罗氏有限公司 | 使用抗il‑34抗体治疗神经疾病的组合物和方法 |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
TWI827405B (zh) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
WO2016200835A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
TW201709934A (zh) | 2015-06-15 | 2017-03-16 | 建南德克公司 | 抗體及免疫結合物 |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
SI3310814T1 (sl) | 2015-06-16 | 2023-11-30 | F. Hoffmann - La Roche Ag | HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO |
JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | 抗cll-1抗体及び使用方法 |
CN107787331B (zh) | 2015-06-17 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 抗her2抗体和使用方法 |
EP3310385A4 (en) | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
EP3310815A1 (en) | 2015-06-17 | 2018-04-25 | F. Hoffmann-La Roche AG | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
CA3162816A1 (en) | 2015-06-29 | 2017-01-05 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
KR20180021864A (ko) | 2015-06-29 | 2018-03-05 | 제넨테크, 인크. | 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체 |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
JP6914919B2 (ja) | 2015-08-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 抗ヒプシン抗体及びその使用 |
AU2016328357B2 (en) | 2015-09-22 | 2023-03-02 | Ventana Medical Systems, Inc. | Anti-OX40 antibodies and diagnostic uses thereof |
BR112018005737A2 (pt) | 2015-09-23 | 2018-10-09 | Genentech Inc | anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína |
RU2757135C2 (ru) | 2015-09-24 | 2021-10-11 | АБВИТРО ЭлЭлСи | Композиции антител к вич и способы их применения |
IL298355A (en) | 2015-09-25 | 2023-01-01 | Genentech Inc | Anti-tigit antibodies and methods of use |
MA43023A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
WO2017062682A2 (en) | 2015-10-06 | 2017-04-13 | Genentech, Inc. | Method for treating multiple sclerosis |
WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
EP3368568B1 (en) | 2015-10-29 | 2022-04-06 | F. Hoffmann-La Roche AG | Anti-variant fc-region antibodies and methods of use |
BR112018007703A2 (pt) | 2015-10-30 | 2018-11-06 | Genentech Inc | anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
WO2017091577A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
IL257696B1 (en) | 2015-12-09 | 2024-07-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
JP6088703B1 (ja) | 2015-12-18 | 2017-03-01 | 中外製薬株式会社 | 抗c5抗体および使用方法 |
BR112018010945A2 (pt) | 2015-12-30 | 2018-12-04 | Genentech Inc | formulações com degradação de polissorbato reduzida |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
WO2017127764A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
MX2018010546A (es) | 2016-03-15 | 2019-02-20 | Chugai Pharmaceutical Co Ltd | Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3). |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
JP6735355B2 (ja) | 2016-04-15 | 2020-08-05 | バイオアトラ、エルエルシー | 抗Axl抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用 |
EP3443350B1 (en) | 2016-04-15 | 2020-12-09 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
KR20190003957A (ko) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | 암 모니터링 및 치료 방법 |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
EP3889175A1 (en) | 2016-05-02 | 2021-10-06 | F. Hoffmann-La Roche AG | The contorsbody - a single chain target binder |
EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
AU2017263568B2 (en) | 2016-05-13 | 2024-01-18 | Bioatla, Llc | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017223405A1 (en) | 2016-06-24 | 2017-12-28 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
AU2017303205B2 (en) | 2016-07-29 | 2024-08-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
KR102553195B1 (ko) | 2016-07-29 | 2023-07-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | 항-cd19 항체에 대한 항-이디오타입 항체 |
CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
JP7250674B2 (ja) | 2016-08-08 | 2023-04-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
CA3035081A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018050878A1 (en) | 2016-09-19 | 2018-03-22 | F. Hoffmann-La Roche Ag | Complement factor based affinity chromatography |
DK3528838T3 (da) | 2016-09-23 | 2023-08-28 | Hoffmann La Roche | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis |
MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
WO2018085358A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
AU2017361887B2 (en) | 2016-11-21 | 2019-08-15 | Cureab Gmbh | Anti-GP73 antibodies and immunoconjugates |
EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
CN118165104A (zh) | 2016-12-07 | 2024-06-11 | 基因泰克公司 | 抗tau抗体和使用方法 |
KR20190095921A (ko) | 2016-12-12 | 2019-08-16 | 제넨테크, 인크. | 항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법 |
JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met抗體以及其免疫結合物及用途 |
US11274157B2 (en) | 2017-01-12 | 2022-03-15 | Eureka Therapeutics, Inc. | Constructs targeting histone H3 peptide/MHC complexes and uses thereof |
MY197534A (en) | 2017-02-10 | 2023-06-21 | Genentech Inc | Anti-tryptase antibodies, compositions thereof, and uses thereof |
US11021535B2 (en) | 2017-02-10 | 2021-06-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
TWI839327B (zh) | 2017-03-22 | 2024-04-21 | 美商建南德克公司 | 用於治療眼部病症之最佳化之抗體組合物 |
CN110494446A (zh) | 2017-03-28 | 2019-11-22 | 基因泰克公司 | 治疗神经退行性疾病的方法 |
JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
BR112019018767A2 (pt) | 2017-04-03 | 2020-05-05 | Hoffmann La Roche | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção |
KR102294136B1 (ko) | 2017-04-05 | 2021-08-26 | 에프. 호프만-라 로슈 아게 | 항-lag3 항체 |
KR20200005540A (ko) | 2017-04-14 | 2020-01-15 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
PE20200150A1 (es) | 2017-04-21 | 2020-01-17 | Genentech Inc | Uso de antagonistas de klk5 para el tratamiento de una enfermedad |
AU2018258049A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
US20220135670A1 (en) | 2017-04-27 | 2022-05-05 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
CN110831628A (zh) | 2017-05-05 | 2020-02-21 | 爱乐科斯公司 | 用于治疗过敏性眼病的方法和组合物 |
WO2018209125A1 (en) | 2017-05-10 | 2018-11-15 | Fred Hutchinson Cancer Research Center | Epstein barr virus antibodies, vaccines, and uses of the same |
CA3062177A1 (en) | 2017-05-16 | 2018-11-22 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
MX2020000604A (es) | 2017-07-21 | 2020-09-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
AU2018308364C1 (en) | 2017-07-26 | 2023-02-16 | Forty Seven, Inc. | Anti-SIRP-alpha antibodies and related methods |
US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
EP4215543A3 (en) | 2017-10-03 | 2023-10-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
CN111372950A (zh) | 2017-10-12 | 2020-07-03 | 免疫苏醒公司 | Vegfr-抗体轻链融合蛋白 |
EP3703688A2 (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
EP3707510B1 (en) | 2017-11-06 | 2024-06-26 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
SG11202003930YA (en) | 2017-12-01 | 2020-05-28 | Pfizer | Anti-cxcr5 antibodies and compositions and uses thereof |
US12006356B2 (en) | 2017-12-15 | 2024-06-11 | Juno Therapeutics, Inc. | Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same |
AR114001A1 (es) | 2017-12-21 | 2020-07-08 | Hoffmann La Roche | Anticuerpos que se unen a hla- a2 / wt1 |
WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
US10723798B2 (en) | 2017-12-22 | 2020-07-28 | Jounce Therapeutics, Inc. | Antibodies to LILRB2 |
AU2018396970A1 (en) | 2017-12-28 | 2020-08-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
SG11202005273XA (en) | 2017-12-28 | 2020-07-29 | Nanjing Legend Biotech Co Ltd | Antibodies and variants thereof against pd-l1 |
US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
EP3731865A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019134981A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Pd-1に対する単一ドメイン抗体及びその変異体 |
CA3088649A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
TWI835772B (zh) | 2018-01-26 | 2024-03-21 | 美商建南德克公司 | Il-22fc融合蛋白及使用方法 |
BR112020015016A2 (pt) | 2018-01-26 | 2020-12-29 | Genentech, Inc. | Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas |
JP7268038B2 (ja) | 2018-01-31 | 2023-05-02 | アレクトル エルエルシー | 抗ms4a4a抗体及びその使用方法 |
TW202330621A (zh) | 2018-02-01 | 2023-08-01 | 大陸商信達生物製藥(蘇州)有限公司 | 全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用 |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
EP3749362A1 (en) | 2018-02-09 | 2020-12-16 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
WO2019158645A1 (en) | 2018-02-14 | 2019-08-22 | Abba Therapeutics Ag | Anti-human pd-l2 antibodies |
EP3755713A1 (en) | 2018-02-21 | 2020-12-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
MX2020008502A (es) | 2018-02-21 | 2020-09-25 | Genentech Inc | Dosis para el tratamiento con proteinas de fusion il-22 fc. |
JP7391027B2 (ja) | 2018-02-26 | 2023-12-04 | ジェネンテック, インコーポレイテッド | 抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬 |
KR20200130831A (ko) | 2018-03-14 | 2020-11-20 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 항-클라우딘 18.2 항체 |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CN116327926A (zh) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
CA3091231A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
US20210230255A1 (en) | 2018-04-27 | 2021-07-29 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
SG11202011082UA (en) | 2018-05-25 | 2020-12-30 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
US11987629B2 (en) | 2018-06-01 | 2024-05-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
EP3802599B1 (en) | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
JP7372237B2 (ja) | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
JP7511308B2 (ja) | 2018-06-18 | 2024-07-05 | ユーリカ セラピューティックス, インコーポレイテッド | 前立腺特異的膜抗原(psma)を標的とする構築物及びその使用 |
CA3103017A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
US12060422B2 (en) | 2018-06-29 | 2024-08-13 | Alector Llc | Anti-SIRP-Beta1 antibodies and methods of use thereof |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
US11396546B2 (en) | 2018-07-13 | 2022-07-26 | Alector Llc | Anti-Sortilin antibodies and methods of use thereof |
TW202011991A (zh) | 2018-07-18 | 2020-04-01 | 美商建南德克公司 | 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法 |
US11279758B2 (en) | 2018-07-20 | 2022-03-22 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
WO2020027330A1 (ja) | 2018-08-03 | 2020-02-06 | 中外製薬株式会社 | 互いに連結された2つの抗原結合ドメインを含む抗原結合分子 |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
US20210324099A1 (en) | 2018-08-10 | 2021-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-cd137 antigen-binding molecule and utilization thereof |
TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | 抗il1rap抗體及其使用方法 |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
WO2020056170A1 (en) | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
JP7475336B2 (ja) | 2018-09-21 | 2024-04-26 | ジェネンテック, インコーポレイテッド | トリプルネガティブ乳癌のための診断方法 |
EP3856764A4 (en) | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
MX2021003766A (es) | 2018-10-05 | 2021-05-27 | Five Prime Therapeutics Inc | Formulaciones de anticuerpos anti-fgfr2. |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
EA202191058A1 (ru) | 2018-11-16 | 2021-10-07 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Антитела против муцина-16 и способы их применения |
CA3121265A1 (en) | 2018-12-05 | 2020-06-11 | Genentech, Inc. | Diagnostic methods and compositions for cancer immunotherapy |
AU2018451747A1 (en) | 2018-12-06 | 2021-06-17 | F. Hoffmann-La Roche Ag | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody |
JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
EP3883609A2 (en) | 2018-12-20 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
CN113227131A (zh) | 2018-12-20 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 经修饰的抗体Fc及其使用方法 |
AU2019406712B2 (en) | 2018-12-21 | 2024-08-22 | F. Hoffmann-La Roche Ag | Antibody that binds to VEGF and IL-1beta and methods of use |
PE20211295A1 (es) | 2018-12-21 | 2021-07-20 | 23Andme Inc | Anticuerpos anti il-36 y procedimientos de uso de estos |
SG10202105788SA (en) | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Antibodies binding to cd3 |
MX2021007768A (es) | 2018-12-26 | 2021-08-24 | Xilio Dev Inc | Anticuerpos anti-ctla4 y metodos de uso de los mismos. |
EP3902830A1 (en) | 2018-12-30 | 2021-11-03 | F. Hoffmann-La Roche AG | Anti-rabbit cd19 antibodies and methods of use |
EP3911678A1 (en) | 2019-01-14 | 2021-11-24 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
CN113329770A (zh) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | 新型癌抗原及所述抗原的抗体 |
AR119683A1 (es) | 2019-01-29 | 2022-01-05 | Juno Therapeutics Inc | Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1) |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
MX2021010313A (es) | 2019-02-27 | 2021-09-23 | Genentech Inc | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. |
TW202101000A (zh) | 2019-03-08 | 2021-01-01 | 美商建南德克公司 | 用於偵測且量化膜相關蛋白之方法 |
KR20210141555A (ko) | 2019-03-14 | 2021-11-23 | 제넨테크, 인크. | Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료 |
KR20220002967A (ko) | 2019-04-19 | 2022-01-07 | 제넨테크, 인크. | 항 mertk 항체 및 이의 사용 방법 |
US20220143094A1 (en) | 2019-04-19 | 2022-05-12 | Chugai Seiyaku Kabushiki Kaisha | Chimeric receptor that recognizes engineered site in antibody |
EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
CN114269376A (zh) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
JP2022532217A (ja) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | 分離部分及びその使用方法 |
EP3968993A1 (en) | 2019-05-14 | 2022-03-23 | F. Hoffmann-La Roche AG | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
JP2022533432A (ja) | 2019-05-23 | 2022-07-22 | エイシー イミューン ソシエテ アノニム | 抗tdp-43結合分子およびその使用 |
KR20220031616A (ko) | 2019-06-11 | 2022-03-11 | 알렉터 엘엘씨 | 치료요법에 사용하기 위한 항-소르틸린 항체 |
KR20220031054A (ko) | 2019-07-02 | 2022-03-11 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Egfrviii에 결합하는 단일클론 항체 및 이의 용도 |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
CN114341187A (zh) | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | 抗突变型fgfr3抗体及其用途 |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
CN114174342B (zh) | 2019-07-31 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
AU2020321969A1 (en) | 2019-07-31 | 2022-03-17 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
CN114641490B (zh) | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | 结合至病理性tau种类的抗体及其用途 |
CN114340675A (zh) | 2019-09-12 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
KR20220064980A (ko) | 2019-09-18 | 2022-05-19 | 제넨테크, 인크. | 항 klk7 항체, 항 klk5 항체, 다중특이적 항 klk5/klk7 항체, 및 사용 방법 |
CN114423454A (zh) | 2019-09-20 | 2022-04-29 | 豪夫迈·罗氏有限公司 | 抗类胰蛋白酶抗体的给药 |
JP2022548978A (ja) | 2019-09-27 | 2022-11-22 | ジェネンテック, インコーポレイテッド | 薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬 |
TW202122114A (zh) | 2019-10-18 | 2021-06-16 | 美商建南德克公司 | 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法 |
MX2022005400A (es) | 2019-11-06 | 2022-05-24 | Genentech Inc | Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos. |
BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
CA3163897A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
TW202136303A (zh) | 2019-12-13 | 2021-10-01 | 美商阿列克特有限責任公司 | 抗mertk抗體及其使用方法 |
WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
CR20220357A (es) | 2019-12-27 | 2022-08-24 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo |
CN113045655A (zh) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
MX2022009391A (es) | 2020-01-31 | 2022-09-26 | Genentech Inc | Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn. |
CA3165319A1 (en) | 2020-01-31 | 2021-08-05 | Vincent K. Tuohy | Anti-mullerian hormone receptor 2 antibodies and methods of use |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
WO2021168292A1 (en) | 2020-02-20 | 2021-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
BR112022016491A2 (pt) | 2020-02-28 | 2022-10-11 | Shanghai Henlius Biotech Inc | Construto anti-cd137 e usos do mesmo |
CN115151573A (zh) | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
PE20230252A1 (es) | 2020-03-13 | 2023-02-07 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos de estos |
CR20220524A (es) | 2020-03-19 | 2022-12-02 | Genentech Inc | Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso |
KR20220157445A (ko) | 2020-03-24 | 2022-11-29 | 제넨테크, 인크. | Tie2-결합제 및 사용방법 |
EP4127153A2 (en) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modified mammalian cells having reduced host cell proteins |
CN116075525A (zh) | 2020-03-31 | 2023-05-05 | 艾莱克特有限责任公司 | 抗mertk抗体及其使用方法 |
CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
JP2023522930A (ja) | 2020-04-24 | 2023-06-01 | ジェネンテック, インコーポレイテッド | 抗CD79b免疫抱合体の使用方法 |
AU2021262744A1 (en) | 2020-04-27 | 2022-10-06 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
CN115885050A (zh) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | 用于非小细胞肺癌免疫疗法的方法和组合物 |
IL297830A (en) | 2020-05-03 | 2023-01-01 | Levena Suzhou Biopharma Co Ltd | Anti-drug compounds (adcs) comprising an anti-trop-2 antibody, compounds comprising such adcs, as well as methods for their production and use |
CN113993900B (zh) | 2020-05-27 | 2023-08-04 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别神经生长因子的抗体及其用途 |
BR112022024339A2 (pt) | 2020-05-29 | 2022-12-27 | 23Andme Inc | Anticorpos anti cd200r1 e métodos de uso dos mesmos |
CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
BR112022024629A2 (pt) | 2020-06-02 | 2023-02-23 | Dynamicure Biotechnology Llc | Construtos anti-cd93 e seus usos |
JP2023527918A (ja) | 2020-06-08 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hbv抗体及び使用方法 |
CN115698719A (zh) | 2020-06-12 | 2023-02-03 | 基因泰克公司 | 用于癌症免疫疗法的方法和组合物 |
KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
US20220010015A1 (en) | 2020-06-19 | 2022-01-13 | Hoffmann-La Roche Inc. | Antibodies binding to cd3 |
AU2021291005A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and FolR1 |
US11780920B2 (en) | 2020-06-19 | 2023-10-10 | Hoffmann-La Roche Inc. | Antibodies binding to CD3 and CD19 |
US20230235040A1 (en) | 2020-06-22 | 2023-07-27 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
MX2022016453A (es) | 2020-06-24 | 2023-02-01 | Genentech Inc | Lineas celulares resistentes a la apoptosis. |
EP4178985A1 (en) | 2020-07-10 | 2023-05-17 | F. Hoffmann-La Roche AG | Antibodies which bind to cancer cells and target radionuclides to said cells |
KR20230038735A (ko) | 2020-07-17 | 2023-03-21 | 제넨테크, 인크. | 항-notch2 항체 및 이용 방법 |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
US20230322935A1 (en) | 2020-07-29 | 2023-10-12 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
CN116568824A (zh) | 2020-08-03 | 2023-08-08 | 基因泰克公司 | 淋巴瘤的诊断和治疗方法 |
EP4192868A1 (en) | 2020-08-05 | 2023-06-14 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
EP4192854A1 (en) | 2020-08-07 | 2023-06-14 | Genentech, Inc. | Flt3 ligand fusion proteins and methods of use |
JP2023537761A (ja) | 2020-08-14 | 2023-09-05 | エイシー イミューン ソシエテ アノニム | ヒト化抗tdp-43結合分子およびその使用 |
WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
CN116648507A (zh) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
CA3193163A1 (en) | 2020-09-04 | 2022-03-10 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and ang2 and methods of use |
MX2023002901A (es) | 2020-09-14 | 2023-06-01 | Ichnos Sciences SA | Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos. |
CA3197662A1 (en) | 2020-09-30 | 2022-04-07 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
IL301547A (en) | 2020-10-05 | 2023-05-01 | Genentech Inc | Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies |
MX2023004054A (es) | 2020-10-07 | 2023-06-29 | Dren Bio Inc | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. |
JP2023545566A (ja) | 2020-10-20 | 2023-10-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法 |
CA3192306A1 (en) | 2020-10-20 | 2022-04-28 | Burkhard Ludewig | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
KR20230095113A (ko) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약 |
AU2021374590A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
AU2021374592A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
CA3202986A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
JP2024504931A (ja) | 2021-01-12 | 2024-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 |
US20240173442A1 (en) | 2021-01-13 | 2024-05-30 | Hoffmann-La Roche Inc. | Combination therapy |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022162201A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
CN117120084A (zh) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | 用于调节b细胞介导的免疫应答的方法和手段 |
JP2024509695A (ja) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
US20240117011A1 (en) | 2021-02-09 | 2024-04-11 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
CA3208365A1 (en) | 2021-02-15 | 2022-08-18 | Chantal KUHN | Cell therapy compositions and methods for modulating tgf-b signaling |
WO2022187270A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
AU2022230384A1 (en) | 2021-03-01 | 2023-09-07 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
EP4301418A1 (en) | 2021-03-03 | 2024-01-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
WO2022187863A1 (en) | 2021-03-05 | 2022-09-09 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2022192898A2 (en) | 2021-03-10 | 2022-09-15 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
EP4304732A1 (en) | 2021-03-12 | 2024-01-17 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
AU2022238526A1 (en) | 2021-03-15 | 2023-09-07 | F. Hoffmann-La Roche Ag | Compositions and methods of treating lupus nephritis |
US20240174746A1 (en) | 2021-03-18 | 2024-05-30 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗tmem106b抗体 |
TW202300648A (zh) | 2021-03-25 | 2023-01-01 | 美商當康生物科技有限公司 | 抗-igfbp7構築體及其用途 |
AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
EP4326855A1 (en) | 2021-04-19 | 2024-02-28 | Genentech, Inc. | Modified mammalian cells |
JP2024514281A (ja) | 2021-04-23 | 2024-04-01 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Nk細胞係合剤関連の有害作用の防止または軽減 |
CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
CA3218170A1 (en) | 2021-05-12 | 2022-11-17 | Jamie Harue HIRATA | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
BR112023023777A2 (pt) | 2021-05-14 | 2024-01-30 | Genentech Inc | Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo |
JP2024521107A (ja) | 2021-05-21 | 2024-05-28 | ジェネンテック, インコーポレイテッド | 目的の組換え産物を産生するための修飾細胞 |
CN117480184A (zh) | 2021-06-04 | 2024-01-30 | 中外制药株式会社 | 抗ddr2抗体及其用途 |
BR112023025738A2 (pt) | 2021-06-09 | 2024-02-27 | Hoffmann La Roche | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
CN117642426A (zh) | 2021-06-16 | 2024-03-01 | 艾莱克特有限责任公司 | 双特异性抗MerTK和抗PDL1抗体及其使用方法 |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
KR102690141B1 (ko) | 2021-06-25 | 2024-07-30 | 추가이 세이야쿠 가부시키가이샤 | 항ctla-4 항체 |
MX2023014453A (es) | 2021-06-25 | 2024-01-31 | Chugai Pharmaceutical Co Ltd | Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4). |
WO2023283611A1 (en) | 2021-07-08 | 2023-01-12 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
US20230048743A1 (en) | 2021-07-12 | 2023-02-16 | Genentech Inc. | Structures for Reducing Antibody-Lipase Binding |
JP2024525769A (ja) | 2021-07-14 | 2024-07-12 | 舒泰神(北京)生物製薬股フン有限公司 | Cd40を特異的に認識する抗体およびその使用 |
IL309856A (en) | 2021-07-14 | 2024-02-01 | Genentech Inc | Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use |
AU2022315528A1 (en) | 2021-07-22 | 2023-10-19 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
EP4373576A1 (en) | 2021-07-22 | 2024-05-29 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
JP2024528217A (ja) | 2021-08-03 | 2024-07-26 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体および使用方法 |
EP4380978A1 (en) | 2021-08-07 | 2024-06-12 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
CN117897409A (zh) | 2021-08-13 | 2024-04-16 | 基因泰克公司 | 抗类胰蛋白酶抗体的给药 |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
TW202325727A (zh) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | 抗聚泛素多特異性抗體 |
CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
TW202333781A (zh) | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | 抗hla-dq2﹒5抗體製劑 |
EP4419558A1 (en) | 2021-10-19 | 2024-08-28 | Alector LLC | Anti-cd300lb antibodies and methods of use thereof |
KR20240099315A (ko) | 2021-11-05 | 2024-06-28 | 아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) | 암배아성 항원에 대한 단클론성 항체 및 이의 용도 |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
KR20240100369A (ko) | 2021-11-16 | 2024-07-01 | 에이씨 이뮨 에스에이 | 치료 및 진단을 위한 신규한 분자 |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
CN116829179A (zh) | 2021-12-06 | 2023-09-29 | 北京三诺佳邑生物技术有限责任公司 | 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物 |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
AU2022408865A1 (en) | 2021-12-17 | 2024-07-04 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
AU2023206045A1 (en) | 2022-01-07 | 2024-08-22 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
TW202342519A (zh) | 2022-02-16 | 2023-11-01 | 瑞士商Ac 免疫有限公司 | 人源化抗tdp-43結合分子及其用途 |
TW202342520A (zh) | 2022-02-18 | 2023-11-01 | 美商樂天醫藥生技股份有限公司 | 抗計畫性死亡配體1(pd—l1)抗體分子、編碼多核苷酸及使用方法 |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
AU2023238766A1 (en) | 2022-03-23 | 2024-07-25 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023192827A1 (en) | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to hiv-1 env and their use |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
TW202404637A (zh) | 2022-04-13 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法 |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
TW202402810A (zh) | 2022-05-11 | 2024-01-16 | 瑞士商赫孚孟拉羅股份公司 | 與vegf—a及il6結合之抗體及其使用方法 |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
TW202417042A (zh) | 2022-07-13 | 2024-05-01 | 美商建南德克公司 | 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥 |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202417504A (zh) | 2022-07-22 | 2024-05-01 | 美商建南德克公司 | 抗steap1抗原結合分子及其用途 |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
TW202417034A (zh) | 2022-08-19 | 2024-05-01 | 大陸商億一生物醫藥開發(上海)有限公司 | 包含g—csf之調配物及其用途 |
WO2024044779A2 (en) | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024097741A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
WO2024102734A1 (en) | 2022-11-08 | 2024-05-16 | Genentech, Inc. | Compositions and methods of treating childhood onset idiopathic nephrotic syndrome |
WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
US20240226313A1 (en) | 2022-11-17 | 2024-07-11 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
WO2024155807A1 (en) | 2023-01-18 | 2024-07-25 | Genentech, Inc. | Multispecific antibodies and uses thereof |
WO2024156672A1 (en) | 2023-01-25 | 2024-08-02 | F. Hoffmann-La Roche Ag | Antibodies binding to csf1r and cd3 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027303A1 (fr) * | 1996-01-24 | 1997-07-31 | Toyo Boseki Kabushiki Kaisha | Alpha-1-6 fucosyltransferases |
WO2000061739A1 (en) * | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) * | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
-
2003
- 2003-04-09 CA CA002481837A patent/CA2481837A1/en not_active Abandoned
- 2003-04-09 WO PCT/JP2003/004502 patent/WO2003085118A1/ja active Application Filing
- 2003-04-09 AU AU2003236015A patent/AU2003236015A1/en not_active Abandoned
- 2003-04-09 JP JP2003582296A patent/JPWO2003085118A1/ja active Pending
- 2003-04-09 US US10/409,616 patent/US20040132140A1/en not_active Abandoned
- 2003-04-09 EP EP03723096A patent/EP1498490A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027303A1 (fr) * | 1996-01-24 | 1997-07-31 | Toyo Boseki Kabushiki Kaisha | Alpha-1-6 fucosyltransferases |
WO2000061739A1 (en) * | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) * | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
Non-Patent Citations (9)
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
US8409572B2 (en) | 2000-04-12 | 2013-04-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US7541029B2 (en) | 2000-04-12 | 2009-06-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anti-rhesus D monoclonal antibodies |
US8685725B2 (en) | 2000-04-12 | 2014-04-01 | Labortoire Francais du Fractionnement et des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US9718890B2 (en) | 2000-04-12 | 2017-08-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US9718889B2 (en) | 2000-04-12 | 2017-08-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US9708409B2 (en) | 2000-04-12 | 2017-07-18 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US7579170B2 (en) | 2000-04-12 | 2009-08-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII |
US7931895B2 (en) | 2000-04-12 | 2011-04-26 | Lfb Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US10081683B2 (en) | 2000-04-12 | 2018-09-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US8124078B2 (en) | 2000-04-12 | 2012-02-28 | Lfb Biotechnologies | Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies |
US8178093B2 (en) | 2000-04-12 | 2012-05-15 | Lfb Biotechnologies | Method for treating infectious disease using monoclonal antibodies |
US8357370B2 (en) | 2000-04-12 | 2013-01-22 | Lfb Biotechnologies | Anti-D monoclonal antibodies |
US8153124B2 (en) | 2000-04-12 | 2012-04-10 | Lfb Biotechnologies | Method for treating cancer using monoclonal antibodies |
US10233475B2 (en) | 2000-10-06 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US8895266B2 (en) | 2000-10-06 | 2014-11-25 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US9409982B2 (en) | 2000-10-06 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
EP1500400A4 (en) * | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
US7863042B2 (en) | 2003-06-18 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | Fucose transporter |
WO2005017155A1 (ja) * | 2003-06-18 | 2005-02-24 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーター |
JPWO2005035583A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Il−5受容体に特異的に結合する抗体組成物 |
EP1688436A4 (en) * | 2003-10-08 | 2009-12-02 | Kyowa Hakko Kirin Co Ltd | ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY |
WO2005035582A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Ccr4に特異的に結合する抗体組成物 |
JPWO2005035586A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
JPWO2005035577A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドgd3に特異的に結合する抗体組成物 |
WO2005035586A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
JPWO2005035582A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Ccr4に特異的に結合する抗体組成物 |
WO2005035583A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Il-5受容体に特異的に結合する抗体組成物 |
WO2005035577A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドgd3に特異的に結合する抗体組成物 |
EP1688436A1 (en) * | 2003-10-08 | 2006-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Composition of antibody capable of specifically binding ccr4 |
JPWO2005035778A1 (ja) * | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
WO2005035741A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ゲノムが改変された細胞 |
WO2005035778A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
WO2005035563A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | アンチトロンビンⅲ組成物の製造方法 |
WO2005035581A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ヒトVEGF受容体Flt-1に特異的に結合する抗体組成物 |
JPWO2005035581A1 (ja) * | 2003-10-09 | 2007-11-22 | 協和醗酵工業株式会社 | ヒトVEGF受容体Flt−1に特異的に結合する抗体組成物 |
JPWO2005035740A1 (ja) * | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | 無血清馴化したゲノム改変細胞 |
JPWO2005035741A1 (ja) * | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
WO2005035740A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 無血清馴化したゲノム改変細胞 |
WO2005035578A1 (ja) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドgm2に特異的に結合する抗体組成物 |
WO2005053741A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
WO2005053742A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
WO2006013964A1 (ja) * | 2004-08-05 | 2006-02-09 | Kyowa Hakko Kogyo Co., Ltd. | 糖蛋白質組成物の製造法 |
WO2006067847A1 (ja) * | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2006067913A1 (ja) * | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
JPWO2006067847A1 (ja) * | 2004-12-22 | 2008-06-12 | 中外製薬株式会社 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2007100091A1 (ja) * | 2006-03-03 | 2007-09-07 | Osaka University | フコシルトランスフェラーゼの発現を抑制するための組成物 |
JP2010512765A (ja) * | 2006-12-22 | 2010-04-30 | エフ.ホフマン−ラ ロシュ アーゲー | 選択方法 |
WO2014027656A1 (ja) * | 2012-08-13 | 2014-02-20 | 協和発酵キリン株式会社 | 補体C3bによる細菌の菌体表面への沈着および貪食細胞による貪食活性を増加させる方法、並びに細菌感染症の治療方法および治療剤 |
KR20210047892A (ko) * | 2018-08-29 | 2021-04-30 | 유나이티드 바이오파마, 인크. | 비푸코실화된 항체 및 그의 제조법 |
JP2021534800A (ja) * | 2018-08-29 | 2021-12-16 | ユナイテッド バイオファーマ インコーポレイテッド | アフコシル化抗体およびその製造法 |
JP7292377B2 (ja) | 2018-08-29 | 2023-06-16 | ユナイテッド バイオファーマ インコーポレイテッド | アフコシル化抗体およびその製造法 |
KR102651432B1 (ko) | 2018-08-29 | 2024-03-26 | 유나이티드 바이오파마, 인크. | 비푸코실화된 항체 및 그의 제조법 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
Also Published As
Publication number | Publication date |
---|---|
AU2003236015A1 (en) | 2003-10-20 |
US20040132140A1 (en) | 2004-07-08 |
EP1498490A4 (en) | 2006-11-29 |
CA2481837A1 (en) | 2003-10-16 |
JPWO2003085118A1 (ja) | 2005-08-11 |
EP1498490A1 (en) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6523404B2 (ja) | 抗体組成物を生産する細胞 | |
WO2003085118A1 (fr) | Procede de production de composition anticorps | |
ES2362419T3 (es) | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. | |
WO2003084569A1 (fr) | Medicament contenant une composition anticorps | |
JPWO2003055993A1 (ja) | Cd20に特異的に結合する抗体組成物 | |
WO2003085107A1 (fr) | Cellules à génome modifié | |
WO2003085119A1 (fr) | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia | |
WO2005035577A1 (ja) | ガングリオシドgd3に特異的に結合する抗体組成物 | |
WO2005035578A1 (ja) | ガングリオシドgm2に特異的に結合する抗体組成物 | |
WO2005035582A1 (ja) | Ccr4に特異的に結合する抗体組成物 | |
WO2005035583A1 (ja) | Il-5受容体に特異的に結合する抗体組成物 | |
JP2007129903A (ja) | Cd10に特異的に結合する抗体組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003582296 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2481837 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003236015 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003723096 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003723096 Country of ref document: EP |